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ABSTRACT 
The research presented in this thesis endeavours to understand the role of the plakin 
family of cytoskeletal linker proteins in the migration and invasive potential of 
epithelial carcinomas. This study focuses on plectin, a plakin family member that has 
previously been implicated with a role in tissue integrity of the skin and muscle. I 
investigated the complex gene organisation of the alternative first exons in human 
plectin, leading to the discovery of a further novel isoform plectin-lk. A panel of colon 
and breast carcinoma cell lines that vary in their differentiation and metastatic potential 
were used to investigate the expression of the isoforms at the mRNA and protein 
levels, showing plectin to be expressed at higher levels in the more invasive cell types. 
The subcellular localisation of the alternatively spliced plectin isoforms was 
investigated using green fluorescent protein (GFP) and polyclonal antibodies, 
revealing isoform speci fie targeting to different actin structures. Ablation of plectin or 
vim en tin (a major intermediate filament protein of mesenchymal cells that interacts 
with plectin), by small interfering RNAs suggest these proteins are able to modulate 
invasion, migration and attachment of the epithelial carcinoma cells. Further 
investigation into the novel isoform plectin-1 k reveals a role in the formation of 
podosome like adhesion structures in a Rho kinase dependant manner that facilitate 
migration in the SW 480 colon carcinoma cells. The above findings are novel and 
contribute to the understanding of migration and invasion of cancer cells. Furthennore, 
this understanding could provide novel targets of cancer cell metastasis. 
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CHAPTER! 
INTRODUCTION 
1.1. Prologue. 
Plectin, a member of the plakin family of cytolinkers proteins has an integral role in 
skin and tissue integrity by linking the three cytoskeletal networks with each other. 
Furthermore, plectin tethers intermediate filaments to cell junctions and can act as a 
regulator of cytoskeletal dynamics. There is now emerging evidence of plectin as a 
scaffolding protein for a variety of signalling events. This thesis proposes that this 
multifunctional protein has a role to play in the migration, invasion and attachment of 
cells in which alterations in these processes can lead to the progression of cancer. The 
importance of vimentin, an intermediate filament protein that can interact with plectin 
will also be discussed. This chapter will address each of these elements above giving 
an overview of the many roles of plectin and the proteins in which it interacts with. 
Each of the results chapters to follow will then give a focused insight on the subject 
they address. 
1.2. The cytoskeleton, an overview. 
In order to understand the various roles plectin plays as a cytoskeletal linker protein, a 
brief introduction of the cytoskeleton is needed. The mammalian cytoskeleton is made 
up from three networks that all have specific roles in the cell, but increasing evidence 
has highlighted the importance of the interaction of these networks with each other in 
many functions including invasion, migration and metastasis. The cytoskeleton is 
responsible for such diverse functions as the transport and positioning of organelles in 
the cytoplasm, the segregation of the chromosomes during mitosis, cell shape, cell 
movement, and the structural integrity of the membranes (Fuchs and Karakesisoglou, 
2001 ). The three networks, microfilaments, microtubules and intermediate filaments 
will be discussed below. 
1.2.1. Microfilaments (actin cytoskeleton). 
Actin was discovered along with myosin by Kuhne in 1861, but was not isolated until 
1939-1942 by Straub, Bonga and Szent-Gyorgyi (Szent-Gyorgyi, 2004). The actin 
cytoskeleton is paramount to cell motility, contractility, cell remodelling, cytokinesis, 
cell polarity, intracellular transport and phagocytosis (reviewed in Schmidt et al., 
1998). The network consists of polymers of actin (F-actin,) along with a large number 
of actin binding proteins and associated proteins (Stossel, 1993; Winsor et al., 1997). 
Actin filaments are characterised by polarised ends, where the plus (barbed) end grows 
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faster than the minus (pointed) end. Actin can exist as monomers (G-actin) and each 
monomer can bind A TP and hydrolyse to ADP when incorporated into actin filaments. 
The actin monomer, which is highly conserved in evolution (Kron et al., 1992), 
contains 375 amino acids and is a 43 kDa globular monomer with 2 domains. The actin 
cytoskeleton is highly dynamic and filaments can form spontaneously via non-covalent 
interactions, but ATP-bound actin polymerises faster than ADP-bound actin (Engel et 
al., 1977). The organisation of actin filaments is regulated by a large number of 
signalling proteins including Rho, Rae, and Cdc42, which are activated by 
extracellular signals (discussed in Chapter 5). Two alternate forms of actin machinery 
have been shown to exist at the leading edge of motile cells, lamellipodia that exerts a 
persistent protrusion over a surface and filopodia that performs sensory and 
exploratory functions (Mejilano et al., 2004). At the leading edge of the lamellipodia 
actin filaments are driven by activation of the actin-related protein (Arp) 2/3 complex 
and are organised in a branched network with the barbed ends orientated towards the 
membrane. The Arp2/3 complex, which stimulates new filament formation by a 
process termed dendritic nucleation (Mullins et al., 1998), consists of the actin-related 
proteins Arp2 and Arp3 along with five other proteins designated p41-, p34-, P21- and 
p 16-arc (Machesky and Gould., 1999). In contrast at the base of the lamellipodia actin 
filaments are long and un-branched (Small et al., 1995, Svitkina et al., 1999). 
Filopodia consist of elongated parallel filaments and have been implicated in many cell 
processes such as epithelial sheet closure in development, wound healing and cell 
invasion and metastasis of cancer cells (Jacinto et al., 2001, Roth, 2003). Plectin has 
been implicated to play a part in regulation of actin dynamics (Andra et al., 1998) and 
the crystal structure of the murine actin-binding domain of plectin has been elucidated, 
as discussed in section 1.3 (Sevcik et al., 2004). 
1.2.2. Microtubules. 
Microtubules (MT), which were discovered using electron microscopy by Fawcett and 
Porter, 1954 and Manton and Clarke, 1952, are large polar filaments composed of 
heterodimers of a and ~ tubulin that form a cylindrical ring of 13 linear 
protofilaments, 25nm in diameter (reviewed by Brinkley, 1997). Microtubules 
assemble from tbe microtubule organising centre (Tucker, 1992) and undergo rapid 
remodelling with frequent shortening and growth transitions (Waterman-Storer and 
Salmon, 1997). This dynamic instability is important in cell motility and also in the 
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positioning of organelles and movement of vesicles in the cell via dynein and kinesin 
motors (Mitchison et al., 1984; Gross et al., 2007). Microtubules are also essential in 
spindle formation aligning chromosomes and segregation during mitosis (Sawin et al., 
1993; Mcintosh et al., 2002). The microtubule cytoskeleton associates with a variety of 
proteins; Microtubule Associated Proteins (MAPs), which have increasingly been 
found to interact with the other networks, especially actin supporting the idea that the 
networks of the cytoskeleton have interlinking roles (Mandelkow et al., 1995). Also, 
historically microtubules have been shown to form closely associated parallel arrays 
with intermediate filaments throughout the cytoplasm in fibroblasts (Goldman, 1971 ). 
Plakins, especially BP AG 1 have the ability to interact with microtubules (Yang et al., 
1999) and plectin has been shown by immunogold labelling to connect intermediate 
filaments to microtubules (Svitkina et al., 1996). 
1.2.3. Intermediate Filaments. 
Intermediate filaments appeared more recently in evolution compared to the other 
cytoskeleton networks (Rash et al., 1970). The intermediate filament family are 
encoded by one of the largest families of genes in the human genome (Hesse et al., 
2001 ). The family can be classified into six major types (Hermann et al., 2000), and 
specific expression of intermediate filament proteins can be found in different cell 
types (Table 1.1 ). Most intermediate filaments contain a a helical rod domain that is 
usually 310 residues long and is flanked with a non-helical carboxy and amino 
terminal that vary depending on the intermediate filament type (Coulombe et al., 
2001 ). The rod domain contains heptad repeats (subdomains 1 A, 1 B, 2A, 2B) that 
facilities dimerisation between the rod domains (Coulombe et al., 2001 ). Intermediate 
filaments can spontaneously assemble into non-polar tetramer filaments in the absence 
of A TP and GTP (Strelkov et al., 2003 ), with a diameter of 8-9nm, which assemble in 
a rope like array to form the final filament. Free tetramers are rare in the cell, but a cell 
can regulate the assembly by phosphorylation of serine specific residues in the amino 
head domain (lzawa et al., 2006). Intermediate filaments are thought to play a role in 
flexible structural support and are essential to the integrity and organisation of skin and 
muscle (Fuchs et al., 1998). Recent research has shown intem1ediate filaments to be 
more mqtile than once thought. The motile and dynamic propertie_S of each type vary 
due to their various N and C- terminal sequences and binding capacity to other parts of 
the cytoskeleton (see review Helfand et al., 2004). For the considerations of this work 
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the keratins and vimentin intermediate filaments will be discussed due to their 
important interactions with plectin in epithelial cells (Pytela and Wiehe, 1980; Foisner 
et al., 1988; Nikolic et al., 1996). However, plectin can also interact with desmin, glial 
fibrillary acidic protein (OF AP) neurofilaments and lamin-B (Schroder et al., 1999, 
Tian et al., 2006; Errante et al., 1994 and Foisner et al., 1991). 
1.2.3.1. Keratins. 
Keratins are encoded by a large multi-gene family whose 54 members are divided into 
two major groups, type I and type II on the basis of gene structure and sequence 
homology (Gu et al., 2007). They form the main constituents of epithelial cells, which 
contain a variety of keratins that are expressed in a tissue, and differentiation specific 
pattern as illustrated in Table 1.2 (Coulombe et al., 2002; Schweizer et al., 2006). The 
diversity of keratin expression is most pronounced in skin, where each layer has a 
distinct keratin expression (Gu et al., 2007). Keratins display a network that extends 
from the nucleus to the plasma membrane, where they a form attachment at 
desmosomal and hemidesmosomal complexes. They also act as protein scaffolds with 
structural and regulatory functions in a cell-type specific manner (Magin et al., 2007). 
The importance of keratins in skin integrity has been underlined by the large number 
of epidermal diseases found to have keratin mutations (reviewed in Uitto et al., 2007). 
The role of keratins in wound healing and migration has been widely studied recently 
with contrasting results, possibly due to cell specific settings. Specifically, no defects 
were found in embryonic wound healing at mid-gestation of keratin 8 deficient mice. 
However, siRNA ablation of keratin 8 and keratin depletion in hepatocytes from 
keratin null mice was recently shown to inhibit collective sheet migration and 
spreading (Long et al., 2006; Galarneau et al., 2007). Contrasting this, wound healing 
was accelerated in absence of keratin 8 in vimentin positive cells (Long et al., 2006). 
Keratins 8 and 18 are mainly expressed in simple epithelia as found in gastrointestinal 
tract, liver and exocrine pancreas, from which many carcinomas arise (Nishizawa et 
al., 2004). Overexpression of keratins 8 and 18 along with vimentin in melanoma is 
associated with metastasis (Hendrix et al., 1992), and transfection of keratins 8 and 18 
in mouse fibroblasts and melanoma cells increases the invasiveness ofthe cells (Chu et 
al., 1993; Chu et al., 1996). Keratins have been used in the finger printing of 
carcinomas due to their specific expression in different epithelia, as when epithelium 
undergoes malignant transformation its keratin profile usually remains constant. For 
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example, over 90% of colectoral adenocarcinomas express keratin 20 regardless of the 
degree of differentiation or origin of biopsy from either the primary tumour or 
metastatic spread. Also, 90% of colorectoral adenocarcinomas don't express keratin 7; 
this expression of K7-/K20+ is very specific to colon adenocarcinoma and is rarely 
seen in other carcinomas (Chu et al., 2002). 
1.2.3.2. Vimentin. 
Klaus Weber coined the name vimentin for the intermediate filaments that were found 
to decorate mouse 3T3 cells and mesenchymal derived cells but not epithelial derived 
cells (Franke et al., 1978). Later, it was confirmed that vimentin is the major 
intermediate filament expressed in cells of mesenchymal origin such as fibroblasts and 
endothelial cells (Frank et al., 1987). In the same year, it was demonstrated that in 
quail embryo fibroblasts, vimentin intermediate filaments were connected to focal 
contacts (Bershadsky et al., 1987). Vimentin is classed as a type III intermediate 
filament protein (Table 1.1) and can homo-polymerise to form 10 nm filaments in vitro 
and vivo. Few of the other group B proteins can do this and require involvement of 
other group B proteins, often vimentin (Coulombe et al., 2001 ). Vimentin shows a high 
degree of sequence homology between species suggesting important evolutionary 
conserved physiological roles (Herrmann et al., 1989; Schaffield et al., 2001 ). 
Vimentin is often used as a developmental marker of cells and tissues. The protein is 
first expressed in the mouse around E8.5 in the cells of the parietal endoderm and also 
in the cells that delaminate through the primitive streak to become the primary 
mesoderm (Franke et al., 1982; Lane et al., 1983). Later, expression is seen in early 
pre-differentiated cell types during development of the neural and myogenic tissue 
before being replaced by glial fibrillary acidic protein GF AP and desmin (Cochard et 
al., 1984; Furst et al., 1989). In adults, endothelial cells, fibroblasts and cells of the 
haemopoetic lineages, only express vimentin. Vimentin has been used widely in the 
study of intermediate filament dynamics. Using microinjection it was shown that 
filament polymerisation was regulated by subunit exchange (Vikstrom et al., 1989). 
Yoon et al., 1998 demonstrated that filaments were constantly changing their 
configurations in vivo, extending and shortening. Furthennore, Time-lapse imaging of 
GFP-v~mentin in epithelial cells showed short vimentin "squiggles" ~t the cell 
periphery, which then move towards the cell centre. Keratin filaments also display 
these squiggles; however the dynamic properties of keratin short fibrils are 
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dramatically different to those of vi men tin in the same region. This suggests that there 
are different factors regulating the dynamic properties of different types of 
intermediate filaments within the same cytoplasmic regions (Y oon et al., 2001 ). GFP 
tagged vimentin has also been shown to move along microtubules, further supporting 
the interaction of the different cytoskeletal networks (Martys et al., 1999). 
Phosphorylation of the protein has been shown to have a central role in regulating the 
dynamics ofvimentin assembly into polymers (lnagaki et al., 1997) and also regulating 
the connections between intermediate filaments and associated proteins (Ku et al., 
1998). At first inspection, vimentin knockout mice do not show serious differences 
from wild type mice in vivo (Eckes et al., 1998). However, impaired wound healing in 
embryonic and adult mice was visible (Eckes et al., 2000). Furthermore, fibroblasts 
were shown to have impaired mechanical stability and migration and the 
reorganisation of collagen fibrils and contraction of collagen lattices was severely 
impaired (Eckes et al., 1998). 
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Table 1.1. The Intermediate Filament Family. 
,., a.. DJitdbutioa , ...... 
ll'ftP , ....... 
Jd)t 
Keratin (acidic) A I Epithelia 40-60 
Keratin (basic) A II Epithelia 56-68 
Vimentin B ill Heterogenous 55 
Desmin B ill Muscle 53 
GFAP B III Glial cells 50-52 
Peripherin B ill PNS neurons 54 
Syncoillin B III/IV Muscle 54 
NF-L B N CNSneurons 62 
NF-M B N CNSneurons 102 
NF-H B N CNSneurons 110 
a-Intemexin v N CNSneurons 66 
(embryonic) 
Nestin B VI Heterogenous 
progenitor cells & 
mesenchymal cells 
Synemin B VI Muscle 
Desmuslin B VI Muscle 
LaminA/C c v Nuclear 76/62 
Lamin J31 c v Nuclear 6 
Lamin J32 c v Nuclear 78 
Phakinin/CP49 D ? Lens 46 
Filensin D ? Lens 83 
(Adapted from Coulombe et al. , 2001) 
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Table 1.2 Distribution of Keratins in Epithelia. 
Epithelial 'J)pel TypeU W.trliJutlo 
type 
Simple 8 18 Most secretary and parenchymatous cells 
epithelia 
7 19 Ductile epithelia (bile and pancreatic duct, 
renal collecting ducts) and gastrointestinal 
epithelia* 
20 Gastrointestinal epithelia, merkel cells of 
the skin and taste buds of the oral mucosa. 
Stratified 5 14 Basal cells of squamous and glandular 
Squamous epithelia, myoepithelia, mesothelium 
epithelia 
15 Squamous epithelia 
8 18,19 Non-cornifying stratified squamous 
epithelia 
Suprabasal 1 10,11 Epidermis 
cells 
9 Epidermis of palms and feet 
2e High layers of epidermis 
2p Gingival, hard palate 
3 12 Corneal epithelium 
4 13 Non-keratinising stratified squamous 
epithelia of internal organs. 
6 16,17 Hyperproliferative squamous epithelia.** 
*K7 is absent **In addition K17 is most typically expressed in basal cells of 
complex epithelia. (Table from Chu and Weiss, 2002) 
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Table 1.1. The intermediate filament family. 
Intermediate filaments are classified into six major types (1-VI) dependant on genomic 
structure and nucleotide sequence homology. There are four assembly groups (A-D) at 
the protein level dependent on the polymerisation properties. Type I (acidic) and Type 
II (basic) encode the epithelial expressed keratins that co-polymerise to form assembly 
group A. Type III, type IV and type VI assemble into protein group B. Type II and 
Type VI are mostly expressed in muscle except for GFAP, peripherin and nestin. Type 
IV genes encode the neurofilament triplicate proteins which are obligate 
heteropolymers. Type V genes encodes for the nuclear lamins, which form a 
meshwork at the nuclear membrane, lamin proteins cannot co-polymerise with other 
intermediate filament proteins and assemble into group C. Finally, phakinin/CP49 and 
filensin are found in the eye lens and do not conform to any of the above groups and 
form the group D proteins (Reviewed in Coulombe et al., 2001 and Oshima, 2007). 
Table 1.2. Distributions of keratins in epithelia. 
Type I (acidic) and Type II (basic) keratins, co-polymerise in an exclusive obligatory 
fashion that have epithelial tissue specific distributions as shown in the table. Simple 
epithelia generally express the simple epithelial keratins 7, 18, 19, and 20, while 
complex epithelia express complex epithelial keratins 5/6, 10, 14, and 15. 
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1.3. Plectin, a member of the plakin family of proteins. 
In studies of tissues that experience mechanical stress, such as epithelia (Leung et al., 
2002), the cytoskeleton field is becoming increasingly aware, that the three networks 
do not just act alone but are interlinked and together play dynamic roles in cellular 
architecture and integrity. Plectin, along with related proteins termed the plakins, is a 
definite candidate for mediating these interactions (Figure 1.3). The plakins were first 
discovered as linkers tethering the intermediate filament network to cell-cell and cell 
matrix junctions. Uitto et al., 1996 defined the name plakins to encompass a family of 
protein cytolinkers that were all discovered in very different ways. Further studies 
have opened up this family's role, where plakins can link to actin to microtubules in 
the nervous system (Sun et al., 2001) and also act as a scaffold for various signalling 
events (Sonnenberg et al., 2007). 
Plectin was originally isolated as a major intermediate filament-associated protein in 
cultured cells (Pytela and Wiehe, 1980). Additionally, a novel hemidesmosome protein 
named HOI was isolated in bovine corneal epithelial cells, that was later identified as 
plectin (Owaribe et al., 1991; Hieda et al., 1992; Okumura et al., 1999). The protein 
has an estimated molecular weight of >500kDa and is found expressed widely in a 
variety of cell types, including skin and striated muscle. Plectin plays a role in cell and 
tissue integrity by cross-linking between the three cytoskeletal networks and stabilising 
cell-matrix and cell-cell contacts (Wiehe et al., 1998; Leung et al 2002). It has been 
shown that plectin stabilises intermediate filaments to desmoplakin in desmosomes, 
links intermediate filaments directly with ~4-Integrin (Niessen et al., 1997) and is 
present in focal adhesion contacts and distributes with actin stress fibres (Seifert et al., 
1992 and Sanchez-Aparicio et al., 1997). The intermediate filament-binding site has 
been mapped to 50 amino acids at the end of the fifth repeat (Nikolic et al., 1996). 
Interaction of p1ectin with microtubules has been suggested at the C-termini domain of 
plectin (Herrmann et al., 1987; Svitkina et al., 1996). Furthermore, plectin has been 
established as a novel component of focal contact complexes and it has been suggested 
that plectin plays a role as mediator between intermediate filaments and actin filaments 
(Seifert et al., 1992). Extensive analysis of the murine plectin gene shows plectin 
contains over 40 exons on Chromosome 15 and exhibits an unusual 5' transcript 
complexity of plectin isoforms (Fuchs et al., 1999 and Rezniczek et al., 2003). In the 
human gene, plectin spans over 32 exons on 32kb located in the telomeric region (q24) 
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on chromosome 8. When this project commenced; only 4 isoforms in human and rat 
had been identified (Andra et al., 2003; Elliott et al., 1997). However, a subsequent 
bioinformatics search identified eight putative first exons also in the human plectin 
gene (this study and Zhang et al., 2004). 
1.3.1. Role of plectin in cytoskeletal dynamics. 
Plectin has been shown as a regulator of actin filament dynamics beyond its role in 
scaffolding and mechanical stability (Andra et al., 1997). The plectin actin binding 
domain (ABD) is highly conserved consisting of a pair of calponin homology (CH) 
subdomains that had been shown to interact with polymeric actin and also bundle actin 
filaments via dimerisation of the ABD (Fontao, 2001 ). The crystal structure of the 
plectin actin-binding domain shows the domain to adopt a closed conformation with 
intramolecular contacts between the two CH domains (Garcia-Alvarez et al., 2003). 
Plectin has been shown to regulate actin filament dynamics via phosphatidylinositol, 
4,5-bisphosphate (PIP2) (Andra et al., 1998). Stress fibres and focal contacts were 
more prominent in plectin depleted fibroblasts, which display reduced migration and 
increased adhesion (Andra et al., 1998). Contrasting this, plectin deficient 
keratinocytes display a reduced rigidity of the keratin network and fewer 
hemidesmosomal attachments (Osmanagic-Myers et al., 2006). A recent study has also 
identified plectin as an early substrate for caspase 8 suggesting that plectin may also 
play a role in the reorganisation of the actin cytoskeleton during death receptor 
mediated apoptosis (Stegh et al., 2000). 
1.3.2. Role of plectin as a scaffolding protein for signal transduction. 
An emerging role of plectin in controlling signalling pathways is being explored 
(Sonnenberg et al., 2007). Mapping of the protein-protein interactions of plectin has 
identified binding sites for several signalling molecules, such as AMP-activated 
protein kinase (Gregor et al., 2006), RACK-I receptor for activated protein C kinase 1, 
(Osmanagic-Myers and Wiehe, 2004) and Fer kinase (Lunter and Wiehe, 2002). 
Furthermore, the kinase activity of Erkl/2, c-Src and PKC() has been shown to be 
upregulated in plectin deficient keratinocytes (Osamanagic-Myers et al., 2006). These 
data suggest that plectin, along with the role as a cytoskeletal linker protein, may be 
able to effect carcinoma cell migration and invasion via regulation of signalling 
processes. 
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1.3.3. Role of plectin in tissue and cell integrity. 
In stratified epithelia, plectin has been localised at the basal cell surface membranes, in 
peripheral areas of epithelial cells and all cell layers (Wiehe et al., 1983). Plectin, 
present in hemidesmosomes, serves as anchorage sites for intermediate filaments to 
mediate firm adhesion of the basal cells to the basement membrane (Borradori et al., 
1999, Jones et al., 1998). In other studies, plectin has been also been localised to Z-
discs and dense plaques of striated muscle (Wiehe et al., 1983; Wiehe et al., 1984; 
Zemig et al., 1985). At these sites plectin is found associated to desmin peripheral 
myofibrils, to costameres at the sarcolemma and can link adjacent myofibrils to one 
another (Sonnenberg et al., 2007). Furthennore, the predominant expression of plectin 
at pia/glia and endothelia/glia interfaces in the human brain indicates that plectin may 
also have an integral role in the structural organization of the blood-brain barrier and 
the leptomeninges (Lie et al., 1998). 
More evidence for an essential role of plectin in the integrity of muscle and skin 
architecture is demonstrated in plectin null mice. Plectin deficient mice exhibit severe 
skin blistering with a reduction ofhemidesmosomes and abnormalities in skeletal heart 
and muscle (Andra et al., 1997). The role is further supported by human patients with 
plectin abnormalities, who exhibit epidermolysis bullosa simplex (a skin blistering 
disease) with muscular dystrophy (EBS-MD) (McLean et al., 1996). The majority of 
patients have nonsense mutations in the plectin rod-domain, which lead to premature 
termination of translation (Pfender et al., 2003 ). Hemidesmosomes can still be found in 
EBS-MD patients but the anchorage to intermediate filaments is impaired and blisters 
form at the basal layer (McLean et al., 1996 Smith et al., 1996). Plectin mutations at 
the end of the coiled-coiled rod domain have also been found in patients with EB 
simplex of the Ogna type, a rare autosomal disorder. Finally, recent studies have 
shown plectin mutations in patients with EB pyloric ·atresia (EB-P A) an autosomal 
recessive syndrome that is often lethal and causes neonatal blistering with gastric 
abnonnalities (reviewed in Pfender et al., 2003). 
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1.4. Epithelial cell junctions. 
Epithelia, found in multi-cellular organisms, are cohesive sheets of ordered epithelial 
cells (Perez-Moreno et al., 2003). The main types of epithelia are the stratified 
epithelia of the skin layers and simple epithelia, such as those that line the gut (Figure 
1.1 ). The epithelial sheets are anchored to the basement membrane via cell-matrix 
attachments mediated via the integrin family of transmembrane receptors discussed in 
Chapter 5. The basement membrane separates the epidermis from the underlying 
dermis (Marinkovich et al., 1992). Hemidesmosomes (Figure 1.2) are the main 
mediators of adhesion to the basement membrane along with focal contacts. Also 
important for epithelial integrity are the cell-cell adhesions mediated via the calcium 
dependent cadherin family of proteins. There are several types of cell-cell junctions 
found in epithelial layers; tight junctions, adherens junctions, gap junctions and 
desmosomes. Adhesions can be connected through intermediate filaments at 
desmosomes or to microfilaments at adherens junctions and tight junctions (Reviewed 
by Braga, 2002). Tight junctions prevent mixing between apical and baso-lateral 
membranes and render the epithelial sheet impermeable to ions and solutes. Adherense 
junctions in epithelial cells depend on the homophilic, calcium dependent binding of 
the extracellular domain of transmembrane cadherins (Takeichi et al., 1991 ). Gap 
junctions allow the exchange of ions, second messengers and small metabolites 
between adjacent cells formed from connexin and pannexin protein families (reviewed 
in Mese et al., 2007). Cell junctions are also considered highly dynamic complexes 
that integrate signalling processes with the cytoskeletal network. Cell-cell adhesion 
also involves the activation of a number of signalling pathways; Small Rho GTPases, 
Rho, Rae and Cdc42 are members of the rho GTPase subfamily and have been 
implicated in adherens junctions. Other related family members of the super family 
Ras have also been identified as regulators of cell-cell adhesion (Reviewed by Braga, 
2002). 
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A 
B 
-
)( 
Tight junctions 
Hemidesmosomes 
Focal contacts 
Desmosomes 
Adherence junction (e.g. E- Cadherin) 
Gap junctions 
Stratum corneum 
Granular layer 
Spinous layer 
Basal layer 
} Basement membrane 
Figure 1.1. Organisation of simple and stratified epithelia. 
(A) Simple epithelia of one layer thick attaches to the basement membrane (yellow) by focal 
contacts and type II hemidesmosomes. Cell-cell attachments are mediated by adherence 
junctions (blue) and desmosomes. Tight junctions (red) ensure a water tight impermeable barrier 
and cell polarity and gap junctions allow the exchange of ions and metabolites between adjacent 
cells. (B) The stratified squamous epithelia is made up from four layers; stratum corneum, 
granular layer, spinous layer and the basal layer. Hemidesmosomes and focal contacts link the 
basal layer to the basement membrane. Adherens junctions and desmosomes form cell-cell 
junctions. Tight junctions are present in the late spinous layers and throughout the granular 
layers. Connexins present in gap junctions display distinct and overlapping expression patterns 
in the skin. Adapted from Perez-Moreno et al., 2003. 
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1.4.1. Role of plectin in the formation of hemidesmosomes. 
Hemidesmosomes were first identified as electron dense plaques at the plasma 
membrane connecting basement membrane to intermediate filaments (originally 
termed "bobbins" by Weiss and Ferris, 1954). These junctional complexes were found 
to bind epithelial cells to the basement membrane in stratified and complex epithelia 
forming a tight link between the intracellular intermediate filament system and the 
extracellular matrix (Geerts et al., 1999). The hemidesmosomes' main role is providing 
mechanical stability to the layers of the skin as demonstrated with plectin deficient 
mice that exhibit severe skin blistering with a reduction of hemidesmosomes and 
abnormalities in skeletal heart and muscle (Andra et al., 1997). Hemidesmosomes are 
dynamic structures that constantly renew during migration and invasion and division. 
The plakin proteins BPAG-1 (also named BP230) and plectin form the 
hemidesmosomal plaque proteins that bind intermediate filaments to the 
hemidesmosomes (Stanley et al., 1981; Gache et al., 1996; Borradori, 1996; Green et 
al., 1999 and Burgeson, 1997). Along with the hemidesmosomal plaque proteins, the 
transmembrane proteins, integrin a6~4 and BP AG2 (also named BP 180) mediate 
anchorage of the basal epithelial cells to the basement membrane (Jones et al., 1991; 
Sonnenberg et al., 1991; Li et al., 1992). The integrin a6~4 binds particularly to 
laminin-5 (a non-collagenous glycoprotein) that is prominently expressed in the 
basement membrane of epithelial layers (Niessen et al., 1994). The binding of integrin 
a6~4 to plectin is suggested as the first step in hemidesmosomal assembly, as BPAG 1 
or BPAG2 are not recruited efficiently when ~4 cannot bind plectin (Koster et al., 
2004). The tetraspannin protein CD 151 is also an early constitute of the 
hemidesmosomal adhesion structures as it was found strongly associated with laminin-
binding integrin aW 1 in keratinocytes forming pre-hemidesmosomal clusters (Sterk et 
al., 2000). These integrin clusters are speculated to be the nucleation site for assembly 
of a6~4 hemidesmosomes. Furthermore CD 151 binds to a6 and on maturation of the 
complex and then a3 ~I is recruited to focal contacts after hemidesmosomes are 
assembled. However, this interaction is not thought to be essential, as CD 151 null mice 
still form hemidesmosomes (Wright et al., 2004). 
The ~4 subunit of a6~4 integrin is unique to the other integrins in that it possesses a 
I 000 amino acid cytoplasmic domain compared to 59 amino acids in the other ~ 
subunits (Suzuki et al., 1990). The cytoplasmic domain contains two pairs of 
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fibronectin type III repeats separated by a connecting segment (Borradori et al., I999). 
The first and second fibronectin repeats form a complex with plectin (Spinardi et al., 
1993 ). The Ser-I325 in the connecting segment of ~4 was found to be essential for the 
recruitment of plectin into hemidesmosomes in vivo. Furthermore, CHI domain of 
plectin associates with the groove between the two FNIII domains of ~4, inducing a 
conformational change in the cytoplasmic domain in which the additional plectin-
binding site at the C-terminus becomes exposed (Geerts et al., I999). Two proline 
residues in the C terminal of ~4 have been found to be critical for the recruitment of 
plectin to hemidesmosomes (Koster et al., 2004). An additional interaction of the 
plakin domain with the C-terminal tail of ~4 has been suggested to stabilise the 
association and to enable the recruitment of plectin to hemidesmosomes (Koster et al., 
2004; Rezniczek et al., I998). Furthermore, ~4 can adopt a folded conformation 
regulating the binding of plectin (Schaapveld et al., 1998). A recent study has shown 
that plectin ~4 tail interactions may play an important role in connecting a6~4 with 
vimentin (Homan et al., 2002). Interestingly, it has been found that F-actin was not 
present in hemidesmosomes and that plectin associates in a mutually exclusive manner 
with either actin or ~4 as a result of competitive binding (Geerts et al., I999). The third 
fibronectin repeat is essential for binding BPAG2 (Borradori et al., 1997; Aho et al., 
1998; Schaapveld et al., 1998) BPAG2 is a type II transmembrane collagen expressed 
exclusively in epithelial tissues and is suggested as a possible laminin-5 (laminin-332) 
receptor (Nishizawa et al., I993; Aho et al., 1999). Finally the third and fourth 
fibronectin repeats are important in the binding of BP AG I (Hopkinson and Jones, 
2000; Koster et al., 2003). 
1.4.2. Type II hemidesmosomes. 
Hemidesmosomes, found in intestinal epithelial cells do not contain all the proteins 
found in the classical hemidesmosome (Uematsu et al., 1994 and Orion-Rousseau, 
1996). Type II hemidesmosomes, that fonn an adhesion complex lacking BP AG I 
(BP230) and BP AG2 (BP 180) but containing plectin and a6~4 integrin, have been 
described in some cell types and tissues (Jones et al., 199I; Uematsu et al., 1994; 
Orian-Rousseau et al., 1996; Fontao, 1997). Fontao and colleagues characterised a type 
II hemidesmosomes in HT29 cells with electron microscopy showing electron dense 
regions connected to cytokeratin filaments that could be modulated by the extracellular 
matrix. They found that assembly requires actin filaments but not microtubules 
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(Fontao et al., 1999). Further evidence was found in intestinal epithelial cells, where 
plectin and a6~4 associated in type II hemidesmosomes which co-distributes with 
laminin-5 in intestinal mucosa (Simon-Assmann et al., 1994). These studies 
demonstrate that plectin is essential for the integrity of the hemidesmosomal complex 
in both hemidesmosome types. 
1.4.3. Desmosomes. 
Plectin was found to co-immunoprecipitate with plakin family member desmoplakin 
(described below) and was suggested to be involved in the anchorage of intermediate 
filaments to desmosomes and to the sub-membranous skeleton in MDCK cells (Eger et 
al., 1997). Desmosomes are important in tissue architecture as they connect 
intermediate filaments to neighbouring cells providing a continuous network 
throughout tissues (Green et al., 1990). They function as cell-cell attachment sites in 
epithelia, cardiac muscle, and dendritic cells of the lymphoid system. Transmembrane 
members of the cadherins family, desmogleins and desmocollins, form an adhesive 
interface (Garrod et al., 2002) and the cytoplasmic tails interact with armadillo 
proteins, plakoglobin and plakophilins (Schmidt et al., 2005). The plaque proteins then 
interact with desmoplakin which links to the intermediate filaments at the desmosomal 
plaque (reviewed in Godsel et al., 2005). Cell-cell contacts are thought to trigger the 
initiation of desmosomes with recruitment of desmoplakin that is regulated by 
intermediate filament and actin interactions (Godsel et al., 2005). This is supported 
with the recent finding that keratin 8 is involved in the modulation of desmoplakin 
deposition at desmosomes through a phosphoserine dependent process (Loranger et al., 
2006). Although desmoplakin is the main candidate for mediating the intermediate 
filament linkage in stratified cells it is suggested that plectin could possible participate 
in the linkage in simple epithelial cells (Eger et al., 1997). 
18 
Intermediate 
filaments 
BPAG1 
(BP230) 
BPAG2 
(BP180) 
Plectln 
Lamlnin-5 
Hemidesmosome 
Laminin-5 containing 
basement membrane 
Figure 1.2. Composition of a Type 1 hemidesmosome at the basal cell surface of 
epithelia cells. 
Schematic drawing of a hemidesmosome showing plectin as a key component linking 
intermediate filaments to the ~4 integrin. The plakin domain and the actin binding 
domain of plectin are important in the ~4 interaction (see Figure 1.3 for plectin 
domains) and the C-terminal plakin repeat domains mediate linkage to the intermediate 
filament cytoskeleton. BPAG 1 (BP230), BPAG2 (BP180) and tetraspanning CD131 all 
have key roles in the recruitment, assembly or stability of the hemidesmosome along 
with plectin. Adapted from Litjens et al. , 2006. 
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1.5. The plakin family. 
Plectin, BP AG 1 and desmoplakin, that were discussed previously in their role of 
stabilising epithelial junctions, are all members of the mammalian plakin family along 
with microtubule crosslinking factor (MACF7), envoplakin, periplakin and epiplakin 
(Figure 1.3). The mammalian plakins are evolutionary related to the spectraplakins, 
cytoskeletal giants with characteristics of both plakins and spectrins (Roper at al., 
2003, reviewed by Maatta et al., 2004). The spectraplakins were named by Roper and 
colleagues to encompass proteins that have similarities to plakins and spectrin family 
proteins such as shortstop gene in Drosophila and the dystonin/BP AG 1 and MACF 1 
genes in mammals and consist of spectrin repeats that are 38 residues long, connected 
by loops and organised in tandem arrays (Jefferson et al., 2004). Sonnenberg and 
Liem now propose that the plakins are all members of a spectrin superfamily that have 
evolved to encode additional domains and functions (Sonnenberg et al., 2007). The 
plakins are highly conserved through evolution, with plectin-like proteins also being 
found in the green alga, chlamydomonas eugametos, expressed at perinuclear region 
and localized near the cell wall, probably attaching to the cytoplasmic membrane 
(Hendrychova et al., 2002). The invertebrate plakins in Drosophila melanogaster and 
Caenorhabditis elegans were discovered from genetic screens for mutations that 
produced defects in cell adhesion and morphogenesis (reviewed in Jefferson et al., 
2004). The Drosophilia gene, Shortstop and its protein product shot (sometimes 
referred to as Kakapo) was identified in a screen for phenotypes that were similar to 
that produced in the position specific integrins (Walsh et al., 1998; Prout et al., 1997). 
The Caenorhabditis plakins, V AB-1 OA/B were identified in genetic screens for 
embryonic morphological defects, where mutants failed to elongate, the epithelium is 
detached from the cuticle, and the muscles produced irregular body morphologies 
(Bosher et al., 2003 ). 
1.5.1. The plakin family protein domains. 
The plakins proteins are composed of distinct subdomains as shown in Figure 1.1. 
The calponin-homology (CH) domain consists of four a-helices connected by loops 
and a few short helices. Each domain contains ~ 1 0 residues and is present in both 
signalling and cytoskeletal proteins (Stradal et al., 1998; Gimona et al., 2002). 
Calponin-homology domains are sub grouped into CH 1 and CH2 due to functional 
diversity. CHI and CH2 together form an actin-binding domain in some plakins. The 
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CHI domain binds actin alone but with a lower affinity than CH1-CH2 and CH2 has 
an even lower affinity to actin than CH 1 (Winder et al., 1995). The actin-binding 
domains of plakins are also able to homodimerise and heterodimerise with each other, 
contributing to the crosslinking of the actin network (Fontao et al., 2001; Young et al., 
2003). Most of the plakin family harbour a characteristic 'plakin box' domain 
consisting of alpha-helical spectrin repeats and a putative SH3 domain that plays a role 
in protein-protein interactions (Leung et al., 2002; Rezniczek et al., 2004; Jefferson et 
al., 2007). The presence of spectrin repeats in the plakin domain of plectin and BPAG 1 
were recently confirmed by crystallography (Jefferson et al., 2007; Sonnenberg et al., 
2007). The epithelial plakins contain a coiled-coiled rod domain, which is made up 
from heptad repeats that mediate homodimersation, or in some plakins 
heterodimersation. The plakin repeat domains (PRO) are found at the carboxyl termini 
of the epithelial plakins and some spectraplakins. A plakin repeat domain is composed 
of 4.5 copies of a 38 amino acid sequence repeat that adopts a globular structure with a 
unique fold (Choi et al., 2002) and is important in binding plakins to intermediate 
filaments where two or more repeats gives a higher binding affinity. It is also 
suggested that the linker sequence found in some of the plakins may be required to 
allow two domains to simultaneously bind to intermediate filaments (Sonnenberg et 
al., 2007). Finally, there is the gas2 related (GAR) domain that is thought to be 
important in binding to microtubules. The GAR domain is located at the carboxyl 
terminus of some BP AG 1 and MACF isoforms. Plakins without this domain that bind 
to microtubules have been suggested to bind through glycine serine arginine GSR 
repeats (Sun et al., 2001, Yang et al., 1999), which are also present in the GAR 
domains. Preceding the GAR domain are two putative calmodulin-like EF hands. 
Dystrophin and utrophin, members of the spectrin superfamily, connect the actin-based 
cortical cytoskeleton to the laminin in the extracellular matrix through the glycoprotein 
complex (Culligan et al., 1998; Winder et al., 1995). The EF-hand domains in proteins 
of the dystrophin family mediate binding to the transmembrane proteins in the 
complex, linking the cortical actin cytoskeleton to the extracellular matrix through the 
dystrophin (Chung et al., 1999). 
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Figure 1.3. The plakin family members their domain structures. 
Schematic diagram of the mammalian (A) and invertebrate (B) plakin family members. 
All the plakins, except epiplakin, contain a plakin domain that consists of 4-8 spectrin 
repeats with a central SH3 domain. The actin-binding domain is present in plectin, 
BPAGlalb and MACFlalb consisting of two calponin homology domains (CH); 
upstream of this these proteins also contain alternative N-termini. The coiled-coiled 
domain is only present in the epithelial plakins. The spectrin repeat rods are present in 
BPAG, MACF and the invertebrate plakins V AB-1 OA and Shottll. The C-termini of 
these proteins contain a microtubule-binding domain, consisting of EF hands and a 
gas2 related (GAR) domain with a glycine-serine-arginine (GSR) domain. There are 
three plakin repeat domain (PRD) subunits; A, Band C, with incomplete A and B PRO 
labelled a and b. The invertebrate plakins contain plakin repeats that are not organised 
into PRD domains. There is a linker region found in the epithelial plakins at the C-
termini. The C-termini of desmoplakin, plectin, BP AG I e and envoplakin/periplakin 
can interact with intermediate filaments. The key for domains is in the yellow box and 
plectin is highlighted in green. 
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1.5.2. Bullous pemphigoid antigen 1 (BPAG1). 
BPAG1e, a 230 kDa epithelial form ofBPAG1 was discovered along with BPAG2 as 
a target for autoantibodies against hemidesmosomes in patients with the skin blistering 
disease Bullous Pemphigoid (Stanley, et al., 1988). The C-terminus of BPAG 1 was 
found to bind to intermediate filaments in vivo (Leung et al., 1999). BP AG 1 has a 
large number of different isoforms; a b, e (epithelial) and n (neuronal) that result from 
different transcriptional start sites as well as alternative splicing. The isoforms exhibit 
tissue specific expression, primarily BPAG 1 a is expressed throughout the nervous 
system primarily at the pituitary primordia and the dorsal root ganglia (Leung et al., 
2001) and BP AG 1-b is expressed more in heart, skeletal muscles and bone cartilage of 
developing mouse embryos (Leung et al 2001 ). BPAG 1-e (structurally similar to 
desmoplakin Figure 1.3), is expressed in basal epithelial cells localising near 
hemidesmosomes as discussed in Section 1.5.3 (Leung et al., 2002). BPAG 1-n 
expressed in neurons was found to bind actin and neurofilaments (Yang et al., 1999). 
Surprisingly, knock out mice show primary defects in the nervous system rather than 
epithelia (Guo et al., 1995), which can be explained by longer splice variants of 
BPAG 1 found in neurones bind to neuronal filaments, actin and microtubules (Guo et 
al., 1995; Yang et al., 1999). There have been very few reports of BPAG1 defects in 
disease, however recently BP AG 1 had been identified as a component of the disc 1 
interactome, which is disrupted in schizophrenia (Camargo et al., 2007). BPAG 1 that 
has several N-terminal splice variants was also found localised to actin filaments and 
to the nucleus via regulation by the N-terminus similar to the plectin N-terminal 
isoforms (Young et al., 2003) that will be discussed in Chapter 3. 
1.5.3. Desmoplakin. 
Desmoplakin was originally identified in bovine tongue desmosomes (Franke et al., 
1981) and found linked to desmosomes isolated from epithelia (Skerrow et al., 1974). 
Desmoplakin protein was shown to migrate in SDS-page as two bands at 322 kDa 
(DPI) and 295kDa (DPII) (Kowalczyk, 1994), due to alternative splicing within the rod 
domain. The heptad-repeat-containing rod domain mediates parallel dimers so 
desmoplakin II may be present as a monomer (O'Keefe et al., 1989). Desmoplakin I is 
present in all tissues (Angst et al., 1990) and desmoplakin II is found in lower levels in 
non-stratified tissues and absent in the heart (Green et al., 1996). As discussed in 
Section 1.4.3, desmoplakin is targeted to desmosomes though interaction of its N-
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terminal plakin domain with plakoglobin and plakophilins which then interact with the 
desmosomal cadherins. Desmoplakin null mice were found not to survive past E 6.5 
due to impairment of egg cylinder formation, and it was suggested that desmoplakin 
plays a central role not only in establishing intermediate filament cytoskeletal 
architecture, but also in assembly and or stabilisation of the desmosome (Gallicano et 
al., 1998). Intriguingly, a subsequent study revealed that ablation of desmoplakin in 
the developing mouse epidermis had little effect on the structure of desrnosomes, 
however the association to intermediate filaments is disrupted and this leads to skin 
fragility (Vasioukhin et al., 2001 ). Thus, cell type and developmental factors may 
influence the formation and stability of desmosomes (Sonnenberg et al., 2007). 
Mutations in the human desmoplakin gene cause the skin disorder, striate palmoplanter 
keratoderma. The C-terminally truncated desmoplakin causes dilated cardiomyopathy, 
woolly hair and keratodenna in humans (Norgett et al., 2000). The C-terminus of 
desmoplakin may play a role in regulation of interactions between intermediate 
filaments and desmosomes as binding is much weaker when S2849 residue of 
desmoplakin is phosphorylated (Stappenbeck et al., 1994). Desmoplakin has a 
proposed role in the formation of complex adherens junctions that are found only in 
endothelial cells that constitute capillaries and lymph vessels (Schmelz et al., 1994; 
Kowalezyk et al., 1998). This role is demonstrated in desmoplakin siRNA treated 
endothelial cells that failed to form microvasular tubes in Matrigel (Zhou et al., 2004). 
Furthermore, mouse embryos depleted of desmoplakin have leaky and poorly formed 
capillaries (Gallicano et al., 2001 ). Desmoplakin also been recently implicated in the 
rearrangement of microtubules during epidermal differentiation, where loss of 
desmoplakin prevents accumulation of cortical microtubules (Lechler et al., 2007). 
1.5.4. Periplakin and envoplakin. 
Periplakin (195 kDa) was identified along with envoplakin (21 OkDa) as constituents of 
the cornified envelope and desmosomes (Simon and Green, 1984; Ruhrberg et al., 
1996; Ruhrberg et al., 1997). The cornified envelope is a layer of transglutaminase-
crosslinked protein that is below the plasma membrane in terminally differentiating 
keratinocytes (Kalinin at al., 2001 ). Ceramide lipids are found covalently attached to 
these proteins (Marekov et al., 1998) and they have been proposed to act as an 
interdesmosomal scaffold on which the cornified envelope is assembled (Ruhrberg et 
al., 1997). Envoplakin and periplakin have smaller C-terminal domains than the other 
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plakins with periplakin lacking the plakin repeat domain, (Figure 1.3 ). They also have 
the potential to heterodimerise with each other (Ruhrberg et al., 1997). Periplakin has a 
wide tissue expression, but expression is more limited in tissues with envoplakin. 
Envoplakin is expressed in the suprabasal layers of stratified squamous epithelia, but 
not in simple epithelia or non-epithelial tissues. Contrasting this, periplakin is 
expressed in a variety of epithelial and non-epithelial tissues such as brain. Periplakin 
contains an L subdomain that contains a sequence homology to the linker region 
between the plakin repeat domains B and C in desmoplakin; this domain is thought to 
be important in binding to intermediate filaments (Kazerounian et al., 2002; Fontao et 
al., 2003). Supporting original findings by Di Colandrea and colleagues, who found 
periplakin co-localised with intermediate filaments (Di Colandrea et al., 2000). The tail 
of periplakin has been found to specifically bind to keratin 8 and vimentin 
(Kazerounian et al., 2002). Furthermore periplakin was found to participate in the re-
organisation of keratins in migrating cells (Long et al., 2006). Recently, in an attempt 
to further characterise the function of periplakin, a number of novel interactions have 
been identified. Periphilin interacts with perip1akin at the cell-cell junctions and cell 
periphery and is thought to contribute to epidermal integrity and barrier formation 
(Kazerounian et al., 2003). A novel protein kazrin was found to interact with the N-
terminus of periplakin at desmosomes and the interdesmosomal plasma membrane 
(Groot et al., 2004). Additionally periplakin interacts with protein kinase B and can 
relocate the kinase between cellular compartments (Van der Heuvel et al., 2002) and 
also with mannose 6-phosphate receptor, which target newly synthesised lysosomal 
enzymes through their ability to cycle between the trans-golgi network (Le Borgne et 
al., 1998). The diversity of periplakin protein interactions was further demonstrated 
where periplakin was shown to have a direct interaction with FcyRI (CD64) an IgG 
receptor that is upregulated during inflammation with a role in controlling receptor 
endocytosis and ligand binding capacity (Beekman et al., 2004). Interestingly, 
periplakin null mice do not display any abnormal skin defects. Similarly, envoplakin 
knockout mice show only a subtle barrier defect; in both cases the cornified envelope 
was normal (Aho et al., 2004; MiHitHi et al., 2001 ). Of most significance to this study 
was the discovery of plectin as a periplakin interacting protein, where ablation of 
plectin compromised the subcellular distribution of periplakin in HaCaT keratinocytes. 
In addition, ablation of periplakin, plectin or both proteins simultaneously impaired 
migration of MCF7 epithelial sheets (Boczonadi et al., 2007). These finding suggest 
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that different plakin family members can form complexes, thus influence cytoskeletal 
organisation and cell migration. 
1.5.5. Microtubule-actin Crosslinking factor 1 (MACF 1). 
MACF1 belongs to the plakin family due to similarities of theN-terminal actin binding 
to that found in plectin and BPAG 1 (Bernier et al 1996; Byers et al., 1995). It was first 
identified as a partial human eDNA and named by Kunkel and colleagues as ACF7 (it 
also has been named a-trabeculin and macrophin by Sun et al., 1999 and Okuda et al., 
1999 respectively). It is suggested that MACF1 is a hybrid derived from ancestral gene 
for plectin and dystrophin due to the intron positions within the spectrin repeats (Gong 
et al., 2001). There are two major isoforms, MACF1a similar to BPAG1a and 
MACF 1 b similar to BP AG 1 b (Lin et al., 2005). There has been no disease yet linked 
to mutations in MACF1, this may be due to the severity of the phenotype found in 
knockout mice (Chen et al., 2006). The MACF1 knock out mice die at the gastulation 
stage and show a head without a trunk phenotype similar to the Wnt3-/- mice (Chen et 
al., 2006) and in fibroblasts, the microtubules no longer grow along polarised actin-
rich cortical structures but exhibited skewed cytoplasmic trajectories and altered 
dynamic stability (Kodoma et al., 2003). Thus, MACF1 has been proposed to connect 
and coordinate actin and MT cytoskeleton. However, studies on the drosophila 
homologue showing that it plays a significant role in neuronal and muscular 
development indicate that MACFI may be involved in this also (Lin et al., 2005; 
Kodoma et al., 2003). MACF1 protein has a proposed role in signalling; in MACF1 
deficient fibroblasts a constitutively active Rho effector mDia (which is normally 
necessary for the orientation microtubules) could not promote microtubule stability 
(Kodoma et al., 2003). Furthermore, MACFl was found to effect the cortical 
localisation of CLASP2, a microtubule tip binding protein (Drabek et al., 2006). The 
role of MACF1 in signalling suggests that it could be involved in cancer (Sonnenberg 
et al., 2007). Supporting this MACF 1 was found mutated in 12% of breast and colon 
cancers in a recent screen (Sjoblom et al., 2006). 
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1.5.6. Epiplakin. 
Epiplakin, first identified as an autoantigen in a patient suffering from skin blistering 
disease, is unusual in that it contains exclusively plakin repeat domains encoded by a 
single exon (Fujiwara et al., 1992). The human form contains 13 repeats and the mouse 
16 repeats with the final C-terminal six repeats being almost identical (Fujiwara et al., 
2001; Spazierer et al., 2003). Epiplakin is though to have a role in bundling keratin 
intermediate filaments (Fujiwara et al., 1996; Spazierer et al., 2003) where it is widely 
expressed in a variety of tissues with higher amounts in the liver, salivary gland, and 
the digestive tract and in the entire epidermis of the skin (Fujiwara et al., 2001 ). No 
mutations in epiplakin have been reported to cause disease as yet and epiplakin 
knockout mice have no obvious defects. However, epiplakin deficient keratinocytes 
display increased migration further supporting the role that plakins may play in cancer 
progression (Goto et al., 2006; Spazierer et al., 2006). 
1.6. Plakins and cancer. 
The variety of impairments m plakin deficient mtce and in patients with plakin 
mutations underline the versatility and many roles that plakin proteins play in tissue 
and cell integrity, linking at cell-cell and cell-matrix junctions. The plakin proteins 
were found able to link to all three cytoskeletal networks with roles in the regulation 
and dynamics of each network. Furthermore, plakins have been shown to interact with 
a variety of signalling molecules and may impact various signalling processes by 
affecting localisation or the stability of the cytoskeleton (Sonnenberg et al., 2007). 
Commencing this study, there was a lack of knowledge of the role that plakin proteins 
may play in the progression of cancer, prompting our laboratory to investigate this 
field. 
The ability of cancerous cells to metastasise makes it difficult to treat cancer surgically 
or with localised radiation and this contributes to the main cause of death from cancer. 
For a cancer cell to spread to another site in the body it must undergo changes in these 
properties. From a benign tumour in the epithelium a cell undergoes loss of adhesion 
to its neighbours. Eat its way through other tissues, break though the basal lamina, 
invade the blood capillaries, adhere to the capillary wall at its destination invade into 
the tissue and proliferate into the new tissue such as the lung or liver (refer to Chapter 
5). An understanding of the cellular and molecular mechanisms of migration and 
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invasion should lead to the effective design of treatments able to block the process of 
metastasis. Plectin along with the other epithelial plakins have been traditionally 
studied in their role in skin and tissue integrity due to the role these proteins play at 
cell junctions and the severity of blistering diseases found caused by plectin mutations 
(Wiehe, 1998). However, recent studies have implicated other plakin family members 
in the progression of cancer, where there was down regulation of desmoplakin in 
poorly differentiated breast tumours (Davies et al., 1999) and mutations of MACFl in 
breast cancer tumours (Sjoblom et al., 2006). Interacting partners of plectin have been 
previously shown to have roles in cancer progression with integrin a6~4 upregulated in 
many cancers (see review by Mercurio et al., 2001 and Chapter 5). Furthermore, 
laminin-5 has been found to inhibit human keratinocyte migration (O'Toole et al., 
1997) and laminin signalling has been implemented as a key event in tumour invasion 
and metastasis (reviewed by Givant-Horwitz et al., 2004). 
This thesis aims to address if plectin plays a role in cancer cell invasion and if so are 
the plectin isoforms (described in Chapter 3) variably expressed in cancer. Thus, can 
plectin isoform expression lead to a change in the aggressiveness of cancer? 
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CHAPTER2 
MATERIALS AND METHODS 
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2.1. Chemicals and reagents. 
All chemicals and reagents used m this study are of analytical grade and unless 
otherwise stated are supplied from Sigma Aldrich UK or BDH laboratory supplies. 
2.2. Bioinformatic methods used for unravelling the human N-terminal 
alternative first exons of plectin. 
Based on available infonnation on mouse and rat plectin sequences, (Fuchs et al., 
1999; Elliott et al., 1997, respectively) the National Center for Biotechnology 
Information (NCBI) blast tool was used to search the mouse and rat sequences against 
the human genome. Blast, is the abbreviation for Basic Local Alignment Search Tool 
that finds regions of local similarity between sequences and returns significant matches 
of DNA sequences. All assemblies of the genome were selected in the NCBI database 
to date (191h November 2003, Build 34 version 2). Ensemble, a joint project between 
EMBL - EBI and the Sanger Institute, which produces and maintains automatic 
annotation on selected eukaryotic genome, was also used to search the human genome 
against the mouse plectin isoforms to check that the returned results were similar to the 
NCBI sites. The whole genomic plectin DNA sequence was then compared against the 
expressed sequence tag (EST) database (NCBI) using Blast algorithm (NCBI) to 
further identify potential alternative first exons in the human plectin gene. The EST 
database contains partial single pass eDNA sequences (refer to Boguski et al., 1993 
and Boguski, 1995 for in depth explanation) and has been used to identify previously 
unknown gene products for mapping. ExPAsy translate tool (Expeti Protein Analysis 
System proteomics server for the Swiss institute of bioinformatics) was used to 
conveniently convert the DNA sequence to protein sequences for each plectin isoform 
for further use in comparing species. 
2.3. Molecular Biology. 
The following section will contain the methods used for RNA extraction, rt- PCR, real 
time PCR and cloning of the plectin isoforms into GFP constructs. 
2.3.1. Primer design of plectin alternative first exon N-terminal isoforms. 
Oligonucleotide primers were designed for human plectin splice variants 
corresponding to mouse exons 1 - l g and subsequently for the novel ex on 1 k. The 
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primers were identified for each of the exons using, where possible, the following 
considerations; between 18-20bp long, a melting temperature of 54-58°C, GC 
nucleotide content between 40-60%, primers ending on a G, C (to act as a clamp), no 
primer dimers, no repeats, no stretches of polynucleotide G or C. The size of the 
template determines the temperature and annealing time, if the primer is too long then 
inefficient priming annealing can take place and if the sequence is too short then the 
primer may not be specific enough for to prime for the correct sequence of interest. 
The annealing temperature for the forward and reverse primer should be kept similar, 
as miss-priming can occur of the higher temperature primer at the lower temperature. 
The GC nucleotide content of the primer is important as the GC pairs form 3 hydrogen 
bonds, raising the annealing temperature of the PCR, leading to inefficient 
amplification, However, including G or C nucleotides at the 3' end of the primer 
provides a GC clamp that ensures the correct binding due to the strong hydrogen 
bonds. It must be noted that poly G and C stretches can promote non-specific binding 
and stretches of poly A and poly T can open up the template resulting in lower 
amplification efficiency, so should be avoided. The primers should also be designed so 
that they are not self-complimentary and therefore, cannot form hairpin loops (primer 
dimers), which would reduce the amplification efficiency significantly. (Sourced from 
Qiagen critical factors for successful PCR and real time PCR). The reverse primer was 
chosen located in ex on 4 of the plectin gene due to the presence of possible alternative 
2nd and 3rd exons that were also short and GC rich. The program Fast PCR (Kalendar et 
al., 2007) was used as a quick reference to temperatures and presence of primer 
dimers, the actual position was manual selected. Sequences of oligomers, which were 
sent to MWG biotech for synthesis, are shown in Table 2.1. 
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Primer Name Sequence 
Reverse ex on 4 attctgcagcttgtggaacg 
Plec 1 tgcctgctaccaccag 
Plec la tacctggctgtgctcag 
Plec lb agcctgtttccctccctg 
Plec lc cggtcattcgcatcgcag 
Plec ld ccgatgaagatcgtgcc 
Plec le atccagaacgagatcagc 
Plec lf ttcatccaggcctacgagg 
Plec lg tacctctaccagcagctg 
Plec lk catggacaggtacagcatgg 
Table 2.1. Primers used in rtPCR. 
The above table lists the exons and the corresponding pnmers used for reverse 
transcriptase-PCR and real-time PCR of the alternative first exons of plectin. 
2.3.2. RNA extraction and purification of carcinoma cells. 
In order to create an RNase free environment and, therefore, avoid RNA degradation 
the following procedures were used. Sterile techniques were used with disposable 
RNase free plastics and tips, Diethyl pyrocarbonate treated (DEPC) water was used 
(Ambion) and isopropanol, ethanol and chloroform were of molecular grade and 
reserved for RNA work (Sigma). Finally, surfaces were wiped clean with RNase away 
spray (Fisher Scientific) to reduce the chance of contaminating RNA from the 
environment. RNA was isolated from 70% confluent T75 flask (Greiner Bio-one UK) 
cultures of HT29, SW948 SW480, T84, MCF7 and MDA-MB-231 using Tri Reagent 
(Sigma-Aldrich, UK) following the protocol provided by the manufacturer. Briefly, a 
T75 flask of cells was lysed using 2 ml of Tri reagent and the lysate homogenised 
through a lml tip, and allowed to stand for 5 minutes to allow for dissociation of 
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nucleotide complexes. Next, 0.4 ml chloroform (molecular grade, Sigma Aldrich UK) 
was added to the lysate that was transferred to 2 x I.5 ml eppendorfs, shaken 
vigorously, before standing for I5 min at room temperature. This was then centrifuged 
at 12000 x g for I5 min 4°C to separate the phases containing, a red organic protein 
phase, DNA containing inter phase and a colourless RNA containing upper phase. The 
RNA phase was removed, with care to prevent DNA contamination, and I ml 
isopropanol (molecular grade, Sigma Aldrich UK) was added and left to stand for l 0 
minutes at room temperature before centrifuging again at I2000 G I 0 min 4°C, to 
precipitate the RNA, visualised as a white pellet. The isopropanol was removed and 
the pellet washed with 75% ethanol (molecular grade, Sigma Aldrich UK) to remove 
residual salts, then the sample was re-centrifuged 7500 x g 5 min to remove the 
ethanol. The pellet was air dried briefly and then resuspended in DEPC water at 50°C, 
pipetting gently to dissolve the pellet. Residual DNA was removed by treatment with 
DNase I enzyme (Qiagen UK) 6.25 Units with up to 87.5 ~-tl RNA made up to 100 ~-tl 
in suppliers buffer, incubated 10 minutes at room temperature. RNA clean up kit spin 
columns (Qiagen UK) removed any contaminating DNA by only binding strands of 
nucleotides in the silicon membrane that are longer than l 00 bp, hence removing the 
enzyme fragmented DNA and retaining the longer RNA strands in high salt buffers. 
DEPC water (Ambion UK), 2 x 30 ~-tl, was used to elute the RNA. The RNA was 
quantified using Beckman DU-600 spectrophotometer absorbance A read at 260 nm, 
280 nm and 320nm. The RNA was deemed good quality if the ratio A260/280 ratio was 
between 1. 7 and 2.0. The quantity of RNA was measured, as one A260 unit equals 50 
11g of double-stranded RNA/ml. The quality of RNA was further verified by running 
on a denaturing agarose gel. Samples were combined with formaldehyde loading dye 
(1 x MOPS/ 13.5% formaldehyde/ 50% fonnamide) and heated to 65°C for five 
minutes to denature the RNA structures The samples were loaded onto a 2% agarose 
gel, containing MOPS buffer (0.2 M MOPS; pH 7.0 0.08 M NaAc 0.01 M EDTA 
O.OI% bromophenol blue) with I2.3 M formaldehyde and samples were run at 100 V, 
1/3 down the gel (3-4cm). The gel was stained with ethidium bromide solution (2 
mg/ml in MOPS running buffer). Expected bands of the small 18S (~2 kb) and large 
28S (~5 kb) ribosomal RNA were visualised and photographed with UV light using the 
FujiFilm Intelligent Dark Box II. RNA was stored in DEPC treated water at -20°C or -
80°C for long-term storage. The RNA is of good quality if the 28S subunit is twice as 
intense as the 18S subunit band. Figure 2.1 shows a representative RNA extraction 
used in this study and the spectrophotometer reading output showing the quality of the 
RNA used for realtime PCR. 
34 
A 
B 
Sample 
HT29 
SW948 
SW480 
T84 
MCF7 
MDA 
28S 
18S 
260nm 
0.3819 
0.5386 
0.4864 
1.2989 
1.1313 
1.6472 
280nm 
0.2091 
0.2831 
0.2512 
0.7088 
0.6131 
0.8940 
Figure 2.1. RNA extraction. 
Background 260/28 Concentration 
320nm 0 ~g/ml 
0.0190 1.9092 0.5530 
0.0053 1.9200 0.8112 
0.0030 1.9476 0.7316 
0.0159 1.8516 1.9759 
0.0148 1.8660 1.7149 
0.0168 1.8587 2.5076 
(A) Extracted total RNA from carcinoma cell lines were run on a 2% agarose 
electrophoresis gel. Two bands of the more intense 28S subunit and the lower 
18S RNA subunit was visible on the gel. (B) For quantification and indication 
of quality, samples were analysed using a spectrophotometer at 260, 280 and 
320 run. Note the ratio of260/280 is above 1.8 for each of the extractions. 
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2.3.3. eDNA synthesis from RNA extractions. 
SuperScript III RNase H reverse transcriptase (Invitrogen UK) was used to engineer 
eDNA from RNA extracts. For routine PCR and cloning Oligo-dT primers (Invitrogen, 
UK) were used. For real time PCR applications Random hexamers (Invitrogen) were 
used to prime the eDNA synthesis. Oligo-dT primers reverse transcribe from the poly-
A tail at the 3' end whereas random hexamers enable reverse transcription from the 
entire RNA population producing short eDNA this ensures that a representative 
population of the alternative plectin n-terminal isoforms is made. 100 ng of total RNA 
of was used in a 20 111 eDNA reaction with 1111 of 10 mM dNTP mix, 1111 random 
primers 100 ng, 1 111 0.1 M OTT, 1 111 RNase OUT, 4 111 5 x strand buffer (250 mM 
Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCL2) and 1 111 superscript III reverse 
transcriptase (Invitrogen UK). The reaction was heated to 50°C for one hour and then 
the enzyme was inactivated by heating at 70°C for 15 min. The samples were 
incubated for 20 min at 37°C with 1111 per reaction of E. coli RNase H (Invitrogen UK) 
to remove RNA complementary to the eDNA. 
2.3.4. PCR of alternative exons in human cell lines. 
PCR was carried out using Taq polymerase (Promega UK) on Hybaid MBS 2.0 cycler 
using eDNA synthesised from the cell lines. The efficiency of the PCR was optimised 
by altering the concentration of MgCh and the annealing temperature for each isoform 
(Figure 2.2). MgCb is an essential co-factor for Taq polymerase, but the efficiency of 
the PCR is dependent on the concentration, as excess free magnesium can reduce the 
enzymes fidelity and increase non-specific amplification (Eckert and Kunkel, 1990; 
Williams, 1989; Ellsworth et al. 1993). PCR samples were separated on a 2% agarose 
DNA gel in TAE buffer (40 mM Tris-acetate, lmM EDTA pH 8.0). 
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A 
94°C 2min 
{ 94°C 30 sec Cycled Annealing temperature 30 sec for 25 x 72°C 1 minute 
72°C 5 minute 
4°C Hold 
B 
Target MgC12 Annealing 
mM* temperature oc 
Plec-1 12.083 58.8 
Plec-1a 2.083 58.8 
Plec-1b 2.083 58.8 
Plec-lc 1.25 58.8 
Plec-ld 2.5 58.8 
Plec-1e 2.083 54.0 
Plec-lf 2.083 54.0 
Plec-1g 1.25 58.8 
Pleclk N/A** N/A** 
Periplakin 2.5 55.4 
Actin 2.5 65 
Figure 2.2 Optimum conditions for TAQ PCR 
(A) The cycle program that gave the optimum result for PCR product. (B) Table of 
optimum conditions for each forward primer listed in table 2. 1 when paired with 
reverse primer exon 4. *Stock 25mM end concentration in 30J.1l reaction listed. * * 
was optimised using SYBR green kit. 
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2.3.5. Cloning of alternative first ex on plectin isoforms into pGEM-T easy and 
sequencing of constructs. 
PCR samples were run on a 1-2% agarose DNA gel. Correct DNA bands were cut 
from the gel and purified using Qiagen gel Extraction Kit. Purified PCR samples were 
then ligated into pGEM-T Easy Vector System 1 (Promega UK). This vector system is 
useful for easy cloning of PCR products for sequence identification or future sub-
cloning. This vector has 3 '-T overhangs, which allow direct insertion of the PCR 
products generated by Taq DNA Polymerase (generates single base 3' adenine 
overhangs). Purified bands were ligated into the plasmid using T4 DNA ligase 
(Invitrogen UK) 5 Units (I ~-tl) with up to I 0 ~-tl of DNA, at I :3 ratio of plasmid: insert, 
in 2 ~-tl of 10 X ligation buffer (400 m< Tris-HCI, 100 mM MgClz, 100 mM OTT 5 
mM ATP. pH 7.8), made to 20~-tl in DEPC water (Ambion UK). The reaction was 
incubated at room temperature for one hour and enzyme deactivated by heating to 
65°C for 10 minutes. Ligated plasmids were then transformed into competent DH5a 
bacteria cells (refer to Section 2.3.1) by incubating together on ice for fifteen minutes 
then heatshocking ninety seconds at 42°C. Samples were incubated in Luria-Bertani 
Media (LB) for 1 hour 37°C with shaking 250 rpm to induce antibiotic resistance. 
Bacteria was spread onto LB agar and grown overnight at 37°C with ampicillin 
( 1/1000 50 mg/ml) and X-gal selection. When insert is introduced into the vector it 
interrupts the Lac Z gene cassette responsible for synthesising beta-galactosidase, 
which digests the X-gal and produces a blue by-product. White colonies containing the 
vector were picked out and grown in an overnight culture of 5 ml LB. Plasmids were 
then prepared from the bacteria using Gene Elute Plasmid Mini Prep Kit (Sigma 
Aldrich UK), digested with EcoRI restriction enzyme (Invitrogen UK) and run on 2% 
agarose gel to verify presence of an insert and the expected size. Samples were sent to 
be sequenced using M-13 reverse primer (Durham University Sequencing unit UK). 
The sequences were then compared to plectin genome using a BLAST search (NCBI) 
to confirm the correct sequence. 
2.3.6. Generation of competent DHS Bacterial cells for use in transformation. 
DH5a bacteria from glycerol stocks (gift of Professor Quinlan) were spread onto LB 
agar plates and grown overnight 37°C. A single colony was used to inoculate a 5ml 
starter culture incubated overnight 37°C. The stmier culture (I ml) was used to 
inoculate I 00 ml of LB media that was then incubated at 37°C shaking 250 rpm until 
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A600 reached 0.25-0.5 units. The cells were chilled on ice for 10 mm and then 
centrifuged at 2500 rpm for 10 min at 4°C. The supernatant was discarded and the 
pellet resuspend in 20 ml buffer 1 (20ml 1M KCL, 12 ml 1M CaCh, 30ml glycerol, 1.2 
ml 3 M KAcetate, pH 5.8 with 0.2 M acetic acid, filter sterilised) and incubated for 60 
min on ice. Cells were further centrifuged at 3000 rpm for 5min 4°C and the pellet 
resuspended in 4 ml buffer 2 (2 ml 1M KCl 15 ml 1m CaCh, 30 ml glycerol 2ml MOPs 
pH 6.8 1OM NaOH/HCL, filter sterilised) and incubated on ice before being aliquoted 
0.2 ml and stored at -80°C. 
2.3.7. Real time PCR of plectin alternative first exons isoforms. 
Real time PCR is a technique where the amplification and quantification of a specific 
nucleic acid sequence can be detected in real time. This is achieved at each cycle by 
detecting fluorescence of the sample, where the amount of fluorescence is directly 
proportional to the amount of product. In this study I used SYBR Green which is a 
fluorescent dye that binds all double stranded DNA molecules, emitting a wavelength 
of 521 nm on binding. The Fluorescence was detected during the extension step of the 
PCR. Real time PCR was carried out on Rotor-gene 3000 (Corbet Research, UK) using 
Rotor Gene 6 software. Initially, SYBR green (Clonetech Invitrogen UK) 1 :60,000 
stock ( 1 :600 stock 1:100 per reaction) was added to the optimised T AQ (Prom ega UK) 
PCR as above (2.3.1 ). Subsequently, QuantiTech, SYBR Green PCR kit (Qiagen UK) 
was used according to the manufacturer's protocol. This provided an improved 
reliability of product (based on melt curves and agarose gel analysis) and was used for 
the results presented in Chapter 3. The primers were designed manually to generate a 
PCR product of 150-250 bp; this is to enable comparison of different targets and to 
increase amplification efficiency (Table 2.1 ). The reaction total volume was 50 Jll, 
primers were used at a concentration of 0.5 11M and template at 1 111 of eDNA reaction 
(20 111 reaction volume using starting total RNA 100 ng). Omitting enzyme or template 
as a control assessed the possibility of DNA contamination. Data acquisition was 
performed during the extension step and melt curve analysis. Using Rotor-gene 
analysis tools, comparative quantification between the lowest grade and higher grade 
carcinomas was acquired. Based on the Takeoff point and the reaction efficiency, the 
relative concentration of each cell line compared to HT29 for each isoform is 
calculated. The second derivative of the amplification plot produces peaks 
corresponding to the maximum rate of fluorescence increase in the reaction, the take 
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off is the point at which is the point where the second derivative is at 20%, and the 
reaction efficiency is where a value of two is 100% (doubling of product with every 
cycle). Agarose gels (2%) were run to evaluate the product along with GeneRuler 
1 OObp Marker (MBI F ermentas UK Life Sciences) to provide further conformation of 
correct size of products. 
2.3.8. PCR of plectin isoforms for cloning into eGFP constructs. 
Constructs primers (Table 2.2) for the alternative exons were designed to include the 
predicted start codon and to encompass exons 1-8 (i.e. the whole actin-binding 
domain) and restriction sites; BamHI and Hindiii for direct cloning into eGFP-N 
vector (Clonetech Invitrogen UK). Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen, UK) was used to amplify the inserts. The vector and inserts were double 
digested with BamHI and Hind III restriction enzymes at 37°C for 2 hrs and digests 
were run on a 1% agarose gel and purified using Qiagen gel Extraction Kit (Qiagen 
UK). The vector was then treated with shrimp alkaline phosphatase (Fermentas UK), 1 
unit per 50 ng of cut vector, which catalyses the release of 5' and 3' phosphate groups. 
This ensures empty vectors do not ligate after digestion and no false positive colonies 
are selected, the enzyme is inactivated by heating to 65°C for 10 minutes then chilled 
on ice. The vector and inserts were ligated with T4 DNA ligase (Invitrogen UK) 1 :3 
ratio of vector to insert. The ligated vectors were transformed into One Shot TOP10 
competent cells (Invitrogen UK) and selected on kanamycin (50~-tg/ml) LB agar plates. 
Individual colonies were used to inoculate 5 mls LB overnight 37°C. The plasmids 
were purified and eluted in 2 x 30 ).11 of sterile distilled water using Qiagen mini prep 
kit, which used silicon membrane spin technology to purify plasmids from bacterial 
cultures. The correct clones were vetified by sequencing using primers that would 
cover the whole sequence and ligation points (Table 2.3). Correct clones were then 
grown in 200 mls LB and plasmids were purified and resuspended in 150 ~-tl using 
Midi prep kit (Qiagen UK). DNA concentration was measured on Beckman DU-600 
spectrophotometer with absorbance A read at 260 nm, 280 nm and 320 nm 
(background con·ection). Quality was checked ensuring a ratio of 1.8-2.0 at 260/280; 
good preparations yielded ~200 f.lg. The final concentration was adjusted to 1 f.lg/~-tl in 
water and the plasmids were stored at -20 or -80°C. 
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Table 2.2. PCR primers used for amplifying exons 1-k for cloning into 
eGFP vector. 
Primer Name 
Reverse exon 8 GFP 
Plec I GFP 
Plec I a GFP 
Plec I b GFP 
Plec Ic GFP 
Plec Id GFP 
Plec Ie GFP 
Plec IfGFP 
Plec lg GFP 
Plec lk GFP 
Sequence 
GCGGATCCGATCCTGCACGTCCGGCA 
GCCAAGCTTCGGCTCCAGCAGCCATG 
GCCAAGCTTCAGCATGTCTCAGCACCA 
GCCAAGCTTCGGCTATGGAGCCCTCGG 
GCCAAGCTTCCATGTCGGGTGAGGACGC 
GCCAAGCTTCCCGATGAAGATCGTGCCCG 
GCCAAGCTTCAGACATGGACCCCTCG 
GCCAAGCTTCCGGCATGGCCGGCCCGCTG 
GCCAAGCTTGCCGAACCAGGGCTCCGG 
GCCAAGCTTCATGGACAGGTACAGCATG 
Table 2.3. Primers used for sequencing of eGFP inserts. 
Name Sequence 
EGFP826 Rev CGAACGGCCACCACGTCT AC 
EGFP N RevSeQ GTCGCCGTCCAGCTCGACCA 
Exon7 FWDSEQ CAGACCAACCTGGAGAACCTG 
EGF0826 REV TGGTGCAGA TGAACTTCAGG 
4I 
2.4. Cell culture. 
The following sections contain the cell culture methods with Table 2.4 listing the cell 
types used in this study. 
2.4.1. Cell maintenance. 
All cells were cultured in a humidified atmosphere, with 5% C02, all media was 
supplemented with 10% fetal calf serum (Sigma Aldrich UK) and 50 units/ml 
penicillin, 50 11g/ml streptomycin. The McCoy's SA media (Sigma Aldrich UK) and 
Dulbecco's modified Eagle's medium (DMEM) (Gibco, Invitrogen UK) were 
supplemented with 5% glutamine; however DMEM/NUT.Mic F-12 (Gibco, Invitrogen 
UK was pre supplemented with 5% Glutamax. Standard sterile tissue culture 
techniques were used and cells were propagated in T25 or T75 flasks (Griener Bio-one 
UK), where appropriate, and never grown above 70-80 % confluence. When cells 
reached above 80% they tend to differentiate and were discarded. Cells were passaged 
using Trypsin EDT A (Sigma Aldrich UK) and all washes performed with 1 x PBS 
(Sigma Aldrich UK tissue culture grade). Experiments were always conducted up to 7 
passages above starting passage (Table 2.4) to ensure consistency of results as cells 
can change in nature due to selection or differentiation at later passages. For long term 
storage cells were centrifuged at 800 rpm for 5 minute to remove old media and 
resuspended on ice in antibiotic free media containing 10% dimethyl sulphoxide 
(DMSO) and finally transferred to -140°C freezer or liquid nitrogen cell bank. 
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Table 2.4. Cell lines used in this study. 
Cell line Type Media Passage Origin Reference 
conditions * 
HT29** Human McCoy's P149 ATCC Fogh, 
(Caucasian) colon 5A HTB-38 1975 
adenocarcinoma modified J Fogh 
(grade II) medium 
(Sigma) 
SW948 Human colon DMEM/N P65 ATCC Leibovitz 
epithelial UT.MixF- CCL-237 et al., 1976 
carcmoma 12 (Gibco) A Leibovitz 
(grade 11-111) 
SW480 Human colon DMEM/N P116 ATCC Fogh et al., 
epithelial UT.MixF- CCL-228 1977. 
carcmoma 12 (Gibco) A Leibovitz 
(grade III-IV) 
T84** Human lung DMEM/N P66 ATCC Murakami 
metastasis from UT.MixF- CCL-248 et al., 1980 
colon epithelial 12 (Gibco) H Masui 
MCF7** Human Caucasian DMEM P24 HTB-22 Soule et 
breast (Gibco) ATCCCM al., 1973 
adenocarcinoma McGrath 
(grade II) 
MDA- Human Caucasian DMEM/N P17 ATCC Cailleau et 
MB- breast UT.MixF- HTB-26 al., 1974 
231** adenocarcinoma 12 (Gibco) R Cailleau 
(grade III- IV) 
THP1 Human acute RPMI- P25 ATCC Tsuchiya 
monocyte 1640 TIB-202 et al., 1980 
leukaemia (Sigma) S Tsuchiya 
* Passage refers to the number of times the cells have been split and is a rough indicator of 
the age of the culture. 
** Cells were obtained through the European collection of cell cultures (ECACC), although 
HT29, T84, MCF7 and MDA cells originate from the A TTCC. 
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2.4.2. Differentiation of THPl cells into macrophage like cells. 
THP 1 cells grow in suspension culture and are monocytic in origin. The cells, upon 
phorbol 12-myristate 13-acetate (PMA) treatment can be stimulated to differentiate 
into macrophage like cells (Auwerx et al., 1988 and Schwende et al., 1996). PMA is a 
potent tumour promoter, which activates protein kinase. Cells were plated at a density 
of 1x105 cells per well with media containing 12.5 ng/ml PMA (Sigma Aldrich UK) 
for 48 hours (adapted from Tsuboi, 2007). After 48 hours adherent macrophages were 
fixed with 4% paraformaldehyde and processed for immunofluorescence (Section 
2.8.1). 
2.4.3. Transfection of plectin-GFP vectors into carcinoma cells. 
The constructs were transfected using GeneJuice (Merck Biosciences, UK). Cells were 
counted to 1x105 cells per 6 x well plate (Griener Bio-one UK) using a 
haemocytometer. Cells were put into suspension in media using Trypsin EDT A (Sigma 
Aldrich UK) and diluted 1:1 with Trypan Blue (Sigma Aldrich UK), which checks for 
cell viability as dead cells take up the blue dye. 10 ~-tl of the Trypan blue cell 
suspension was loaded into the haemocytometer, ten fields consisting of 16 small 
squares were counted, then the average of these was multiplied by 20,000 to find cells 
per ml, this was repeated twice. Cells were then transfected with 1 11g of plasmid and 3 
~-tl of GeneJuice for 48 hours and then the media was changed. The transfection reagent 
uses a non-toxic cellular protein and a polyamine to introduce plasmids inside the 
cells, which form a complex with the reagent. Once inside the cell, the plasmid can 
then express the gene of interest from the internal plasmid promoter using the cells 
machinery. Cells were then used for protein extraction (2. 7.1 ), staining with 
fluorescent antibodies (2.8.1 ), or used to generate stable cell lines (2.4.4). 
2.4.4. Establishing stable plectin GFP stable cell lines in SW480 cells. 
After a 48 hour transfection (refer to Section 2.4.3) with eGFP vectors, cells were 
selected using antibiotic 0418, Geneticin (Invitrogen) at 600 11g/ml. The media was 
changed every two days for 3 weeks until isolated colonies appeared. Stable clones 
were frozen down for use as a mixed stable cell line or single cell clones were selected 
by serial dilution to a concentration of 0.25 cells per well in a 96 well plate, to increase 
the chance of single cell clones. Clones were grown up to larger flasks and analysed by 
immunofluorescence and immunoblotting, those expressing the correct GFP vector at 
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an intennediate level were passaged and frozen for future use. High expressing clones 
could potentially effect the results due to the GFP and not the insert and low 
expressing clones may not provide a strong dominant negative effect or be hard to 
Image. 
2.5. siRNA interference as method of protein depletion in cells. 
Short interfering RNA can be used to knockdown a protein of interest and therefore 
determine a proteins function in a negative manner. The siRNAs act via formation of a 
RNA-induced silencing complex (RISC), which is a multi-protein complex that 
cleaves double, stranded RNA (Figure 2.3). After unwinding into single strands, the 
siRNA recruits RISC complex to the complementary RNA molecules, where it cleaves 
the native complementary RNA or stops ribosome translation of the RNA and 
therefore stops translation of the protein (first described in mammalian cells by 
Elbashire et al., 2001 ). 
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Figure 2.3. Overview of the siRNA pathway. 
Short interfering RNA is introduced into the cell via transfection (A), which then 
binds to a multidomain complex to form the RNA-induced silencing complex 
(RISC) (B). One of the main proteins of the RISC is the argonaute protein, which 
cleaves and discards the passenger (sense) strand of the siRNA duplex leading to 
activation of the RISC complex (C). The antisense strand of the siRNA then guides 
the RISC complex to its homologous mRNA (D), resulting in the endonucleolytic 
cleavage of the target mRNA (E). Reviewed in Bantounas et al. , 2004. 
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2.5.1. siRNA sequences in this study. 
Using the online siRNA database from Ambion non-validated pre-designed siRNA 
oligos standard purity were purchased for human plectin and vimentin (Table 2.5). The 
plectin siRNAs target to exons 5, 23 and 32 which are common to all plectin isoforms 
including the rodless isoform lacking exon 31 ensuring total knockdown of all 
isoforms. Vimentin siRNAs are targeted to exons 4, 8 and 9. 
Table 2.5. siRNA sequences used in this study. 
Name Sequence 5'-3' Target exon Level 
of knock 
down 
Silence 19bp scrambled sequence 3 dt overhangs None No 
negative Sequence withheld interference 
control no 1 observed 
Plectin 1 Sense: GGAAUGAUGACAUCGCUGAtt Exon 5 High 
Id144451 Antisense: UCAGCGAUGUCAUCAUUCCtg 
Plectin1 Sense: GGCACUGCGUAGGAAAUACtt Exon 23 Medium 
ID 144452 Antisense: GUAUUUCCUACGCAGUGCCtc 
Plectinl Sense: GGGCAGAACACUAACCUGAtt Exon 32 Low 
ID 144453 Antisense: UCAGGUUAGUGUUCUGCCCtt 
Vimentin Sense: GCAUGUCCAAAUCGAUGUGtt Exon 4 High 
ID 138993 Antisense: CACAUCGAUUUGGACAUGCtg 
Vimentin not available Exon 8 Low 
ID 138994 
Vimentin Sense: GCAAGUAUCCAACCAACUUtt Exon 9 High 
Id 138995 Antisense: AAGUUGGUUGGAUACUUGCtg 
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2.5.2. Transfection of siRNA into carcinoma cells. 
Oligofectamine (Invitrogen, UK) was used to transfect the SW480 and MDA-MB-231 
cell lines with 60 pmol siRNA per 24 well, 240 pmol per 6 well and 1.920 nmol per 10 
em dish. Since starting this project several new recommended siRNA transfection 
reagents, such as lipofectamine 2000 (Invitrogen UK) have become available that use 
only 20 pmol per 24 well, I decided not to change method since the previous was 
producing excellent knockdowns. Transfections were carried out in antibiotic free 
media that was changed 48 hours after transfection. Cells were processed for 
immunofluorescence, immunoblotting or assaying at 72-96 hours after transfection, 
2.6. Generation of plectin isoform specific polyclonal antibodies. 
Polyclonal antibodies were raised against the first exons of plec 1, 1 b, 1 f and 1 k 
peptide (Table 2.6). The peptides were chosen as the most hydrophilic (antigenic) sites 
and a cysteine residue was added to the start of the peptide sequence for conjugation to 
the carrier protein keyhole limpet hemocyanin (KLH). Carrier proteins, once coupled 
to the peptides, provide additional motifs required for association with Class II 
molecules and T -cell receptors and in tum generate a stronger antibody response. Two 
rabbits were inoculated with each peptide to increase positive results. The peptide 
synthesis, raising of antibodies and collection of the serum was conducted by 
Cambridge Research Biochemicals, Billingham, UK. 
Table 2.6. Peptide sequences for generation of polyclonal antibodies. 
Name Isoform Peptide sequence Properties 
target 
LMl/2 Plec 1 SPPKRGPLPTEEQRVYRRK Amide 
LM3/4 Plec 1 b RRGRRWAQDEQ Acid 
LM5/6 Plec 1 f QDFIQA YEEVREKYK Acid 
LM7/8 Plec lk DRYSMEELIQ Amide 
2.7.1. Total cell protein extraction from carcinoma cell lines. 
For extraction of total cell protein, media was removed from the adherent cells and the 
cells then washed in lx phosphate buffered saline (PBS) (135 mM NaCl, 2.7 mM KCl, 
10 mM Na2HP04, 2 mM KH2P04 pH 7.4). Cells were lysed on ice in 2x Laemmli 
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sample buffer (50 mM trishydroxymethylaminomethane-hydrochloric acid (Tris-HCl) 
pH 6.8, 20% v/v glycerol, 1 mM ethylenedinitrilotetraacetic acid (EDT A) 1% Sodium 
dodecyl sulphate (SDS)) supplemented with protease inhibitor cocktail, 1 tablet per 10 
ml sample buffer (Roche, UK). Using a low temperature and the protease inhibitors 
during protein extraction is an important step to stop degradation of the proteins. 
Samples were boiled for 5 min and then homogenised through a 250 needle to shear 
DNA. Finally, samples were used fresh or aliquoted and stored for 1 month at -20°C or 
for longer at -80°C (Laemmli et al., 1970). 
2.7.2. Colorimetric protein quantification using spectroscopy. 
Extracted proteins were quantified using bicinchoninic acid, BCA protein assay 
reagent kit (Pierce UK), which is a colorimetric assay where the samples are read at 
562 nm. Standards were made using bovine album serum BSA (Sigma Aldrich UK) 
diluted in the exact sample buffer that the protein samples were stored in. Standard 
concentrations were; 0, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.5 mg/ml, and the protein samples 
were used at dilutions of 1:5 in the assay. Samples were read on Beckman DU-600 
spectrophotometer, which produces a standard curve at which the absorbance of 
unknown samples can be correlated to the concentration. 
2.7.3. !-dimensional gel electrophoresis (20-200 MW proteins) and 
immunoblotting. 
Protein samples were separated under reducing conditions using the Thermo Electron 
mini gel system. Sodium dodecyl sulphate (SDS) is an anionic detergent which 
denatures proteins by "wrapping around" the polypeptide backbone. Samples were 
mixed with equal volumes of loading buffer dye (sample buffer supplemented with 
0.2% bromophenol blue and 1% P-mercaptoethanol) and resolved on SDS-Page gels, 
at 1 OOV through the stacking and 200 V in the resolving gel in 1 X SDS-Page buffer 
(25 mM Tris, 250 mM Glycine, 0.1% SDS). Depending on the size of the proteins of 
interest, resolving gels of 4% to 12% were used for higher resolution in the upper and 
lower part of the gel, respectively (Table 2.7). 
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Table 2.7. SDS-Page gel preparation. 
A 
Component Stacking gel4% 
dH20 ml 6.1 
1.5M Tris 2.1 
pH 6. 8 ml 
10% SDS pl 100 
Acrylamide 1. 35 
30% ml 
10% APS pl 5 
TEMED pl 10 
Total ml 10 
B 
Resolving Gel 
Component 
4% 7.5% 10 % 12 % 
dH20 ml 6.0 4.85 4.01 3.34 
1.5M Tris pH 2.5 2.5 2.5 2.5 
6.8 ml 
10% SDS pl 100 100 100 100 
Acrylamide 1. 35 2.5 3.33 4 
30% ml 
10% APS pl 50 50 50 50 
TMed pl 5 5 5 5 
Total -ml 10 10 10 10 
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2. 7 .4. Coomassie Blue staining of SDS Page gels. 
To visualise proteins separated in the gel, coomassie blue solution ( 40% methanol 10% 
acetic acid 0.1% Coomassie Blue G-250 (Sigma Aldrich UK) ) was used to stain the 
gels for 1 hour after which they were destained at room temperature with a solution of 
40% methanol, 10% acetic acid in dH20, for up to a day changing the solutions 
frequently. 
2. 7 .5. Immunoblotting of whole cell protein extractions. 
Proteins from the gel were transferred to Hybond nitrocellulose membranes 
(Amersham Pharmacia Biotech UK) in IX Towbin buffer (25mM Tris pH 8.3 20 % 
methanol 0.1% SDS) (Towbin et al., 1979), using the Thermo Mini Blot module at 15 
V for 1.5 hours. This method uses semi-wet blotting, where the membrane and gel are 
sandwiched between filter paper and then sponges which are contained in a closed 
cassette filled with buffer. This method is unlike wet blotting, where the whole tank is 
filled with buffer or semi-dry blotting, where only the filter papers are soaked in 
buffer. The membranes were then rinsed in lx TTBS (10 mM Tris pH 7.4, 137 mM 
NaCl, 2.68 mM KCl, 0.2% Tween 20) and stained with Ponceau-S red (Sigma Aldrich 
UK) to check transfer efficiency. Ponceau-S solution stains total protein and this 
method can be used as a visual to check equal protein loading levels and transfer. 
Membranes were blocked for 2 hrs or ovemight in 5% milk 1 x TTBS, probed with 
primary antibody (listed in table 2.8) for 2 hours followed with, 1 hour incubation with 
horseradish-peroxidase conjugated secondary antibody (Dako UK). Washes and 
antibody incubation was performed with 2.5% Milk 1 x TTBS with 5 x 5 min washes 
between incubations. Bound antibodies were visualised usmg Enhanced 
Chemiluminescence (Amersham Pharmacia Biotech UK) and FujiFilm Intelligent 
Dark Box II. When analysis of the intensity of bands obtained during immunoblotting 
was carried out, Image 1 software was used to calculate area and pixel value statistics 
of each band, which was then compared to a control band (on the same blot) to give a 
percentage change ofband intensity. 
2.7.6. 1-dimensional gel electrophoresis and immunoblotting (for high molecular 
weight protein~). 
Plectin has an estimated MW of 500 KDa, although 4% SDS PAGE gels can be used, 
more consistent results were obtained using the NuP AGE Mini-Cell system 
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{Invitrogen UK). Furthermore, using gradient gels allowed a check of proteins at lower 
molecular weights simultaneously. Proteins were resolved on NuP AGE 3-8% Tris-
acetate Gradient gels (Invitrogen) using 1 X NuPAGE Tris-acetate running buffer. Tris 
acetate gels have a lower pH than traditional SDS PAGE gels and have improved 
separation of high molecular weight proteins due to clearer bands and increased gel 
stability. Proteins from the gel were transferred to Hybond nitrocellulose membranes 
(Amersham Pharmacia Biotech), using NuP AGE transfer buffer (Invitrogen UK) and 
20% methanol, at 30 V constant for 1.5 hours using the XCell II Blot Module 
(Invitrogen UK). Membranes were then treated as above in section 2.7.5. 
2. 7. 7. Immunofluorescence of carcinoma cells. 
For fluorescent microscopy, cells were grown on 13 mm glass coverslips that were 
non-coated unless specified. Cells were then fixed with 4% paraformaldehyde in PBS 
using a 16% paraformaldehyde solution stock (Agar Scientific UK) for 10 minutes and 
permeabilised in 0.02% Triton X-1 00 (Sigma Aldrich UK). Alternatively, cells were 
fixed with chilled 1:1 methanol: acetone for 15 minutes. Methanol: acetone fixation 
can be useful when looking at the cytoskeleton because the cell membranes are broken 
and unbound lipids and proteins are released allowing clearer visualisation of the 
filaments. Cells were blocked for 40 minutes using 0.2% fish skin gelatin (Sigma 
Aldrich UK). The primary antibodies used are listed in the Table 2.8. Filamentous (F) 
actin was stained with TRITC labelled phalloidin (Sigma Aldrich UK). Primary 
antibodies were incubated for 1 hour and detected using Alexa 488 or 594-labelled 
secondary antibodies (Invitrogen UK). At each step the cells were washed tlu·ee times 
with cell wash buffer (lx PBS 0.02% NaAz 0.02% BSA). The cells nucleus was 
visualised using 4', 6-Diamidino-2-phenylindole (DAPI) 1 OOng/ml {Invitrogen UK), 
which binds to double stranded DNA. The coverslips were positioned cell-side down 
onto glass slides using Immunomount (Thermo UK), dried overnight and then stored 
in the dark at 4°C. 
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Table 2.8. List of antibodies used in this study. 
Antibody Antibody type Dilution Source 
IF m 
Actin AC-40 Mouse monoclonal NA 1/1000 Sigma 
Cytokeratin 8/18 Mouse monoclonal 1:1000 1:1000 
Cortactin Mouse monoclonal 1:100 Abeam 
Desmoplakin DP1/2 Mouse Monoclonal 1:100 1:1000 ICN 
Desmoplakin AMP320 Rabbit polyclonal 1:100 1:1000 Serotech 
Dynamin Mouse monoclonal 11100 N/A BD Biosciences 
GFP Mouse Monoclonal N/A 1:500 Clonetech 
Periplakin TD2 Rabbit polyclonal 1:100 1:200 Di Coleandra et 
al., 2000 
a3 Integrin F35 177-1 Mouse Monoclonal 11100 N/A Abeam 
a6 Integrin MP 4F10 Mouse monoclonal 11100 CRUK 
~1 Integrin 4B7 Mouse monoclonal 1/100 N/A CRUK 
~4 Integrin 439-9B Rat Monoclonal 1/200 N/A Abeam 
LM1 Rabbit polyclonal 1:200 1:500 This study 
LM2 Rabbit polyclonal 1:200 1:500 This study 
LM3 Rabbit polyclonal 1:200 1:500 This study 
LM4 Rabbit polyclonal 1:200 1:500 This study 
LM5 Rabbit polyclonal 1:200 1:500 This study 
LM6 Rabbit polyclonal 1:200 1:500 This study 
LM7 Rabbit polyclonal 1:200 1:500 This study 
LM8 Rabbit polyclonal 1:200 1:500 This study 
N-Wasp Rat Monoclonal 11100 N/A Michael Way 
Plectin c-20 Goat polyclonal 1:200 1:500 Santa Cruz 
Talin-NCL Mouse monoclonal 1:200 1:500 Nova Castra 
T-Plastin ( c-15) Goat polyclonal 1:50 1:200 Santa Cruz 
Vinculin clone V-11-5 Mouse monoclonal 1:500 1:100 Sigma 
3052 Vimentin Rabbit polyclonal N/A 1:2000 Dundee 
Vimentin clone V9 Cy3 conjugated 1:1000 N/A Sigma 
mouse monoclonal 
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2.8. Microscopy. 
Specimens were viewed using a Zeiss fluorescence Axioplan microscope fitted with a 
40-x/1.30-oil immersion plan-NEOFLUAR lens. Confocal images were obtained with 
Zeiss LSM 510 Confocal microscope using 40x N/ A 1.3 or 60 X/1.1 0 oil immersion 
objectives. The pinhole on the confocal was adjusted so that it matches the diameter of 
the airy disc; the inner light circle of the diffraction pattern of a point light source, this 
gives the best signal to noise ratio. The images were collected at a scan speed of 12.8 
11s per pixel and a resolution of 1024 x 1044. Composite panels were generated using 
Adobe Photoshop CS (Adobe Systems) and LSM510 image browser software (Carl 
Zeiss) and only linear adjustments to brightness and contrast were made. 
2.9. Verification of specificity and optimisation of plectin isoform antibodies. 
The polyclonal antibodies received from Cambridge Biosciences (section 2.6) were 
checked for specificity to the protein product by immunoblotting as below. Prior to 
use, the antibodies were purified from the serum to reduce background noise. Further 
purification of the specific antibody could be carried out using affinity-binding 
chromatography, but this was not necessary as antibodies gave a good result without 
this procedure. 
2.9.1. Purification of antibodies from serum. 
Plectin LM antibodies were purified using saturated ammonium sulphate. Polyclonal 
serum was diluted with 1: 1 1 xPBS and centrifuged to remove any precipitate. 
Saturated ammonium was prepared (70 g in 1 ml of 1 M NaOH and 75 ml dH20) and 
0.67 ml was added slowly in aliquots per ml of diluted antibody vortexing each time. 
Samples were incubated at 4°C for 30 minutes and then centrifuged at 4°C, 30 minutes, 
3000 rpm decanting the supernatant. The pellet was then resuspended in water and 
ammonium sulphate removed using a PD-10 desalting column (GE healthcare UK). 
Reading at 280 nm and using the extinction coefficient of 1.4 mg/mllcm measured the 
yield obtained from extraction. The antibody was diluted to 1 mg/ml in PBS and stored 
at -20°C. 
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2.9.2. Peptide competition assay. 
To ensure that the antibody is specific for the peptide raised the following assay was 
used. Protein extract from SW480 cells, which express the plectin isoforms, was used. 
Immunoblotting of the sample was carried out as Section 2.7.3, except at the primary 
incubation stage the membranes were incubated with; antibody alone, antibody pre 
blocked with peptide overnight (1 IJ.g of antibody incubated with 50 IJ.g of peptide in 
PBS), antibody pre blocked with control peptide overnight and pre immunised serum, 
with the lowest dilution to produce a positive band used. The antibody is shown to be 
specific if there is no band produced in the peptide blocked incubated membrane. 
2.9.3. Conformation of polyclonal antibody specificity by siRNA. 
Another method to further confirm the specificity of the antibodies is to immunoblot 
the antibodies against plectin siRNA protein samples. A knockdown of the band 
should be seen if the antibody is specific to the protein. This method was considered as 
the most convincing and was used to confirm all the antibodies. Furthermore, the 
bands produced were visualised at the expected sizes using HiMark (Invitrogen UK) 
protein ladder, which contains a 500-kDa band. In this study, this was the most 
convincing method and is presented in Chapter four. 
2.10. Cell survival assay after siRNA transfection. 
Equal numbers of cells were transfected in triplicates with siRNA as described in 
section 2.5.3 onto 12 well plates, (Cells were counted using a haemocytometer and 
were plated at 50% confluency prior to transfection). CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega UK) was modified to asses the cell 
survival after 3 days transfection in 12 well plates. After 72 hour of transfection, cells 
were incubated with 1 00~-tl of solution added to 800 f .. tl of cell media and incubated for 
2 hours, 3 x 1 00~-tl from each well was read at 490nm with a spectrophotometric plate 
reader (Anthoslucy1). 
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2.11. Migration and Invasion. 
To study the ability of the cancer cell lines to migrate and invade the methods 
described below were used. 
2.11.1. Collagen insert Migration assay. 
Cells were serum starved for 24 hrs and subsequently seeded at I xI 05 cells onto 24 
well cell culture inserts with 8 Jlm pore size, Thincerts, (Greiner Bio-one UK) coated 
with I 00 Jll of I 00 mg/ml type I collagen (First Link Birmingham Ltd UK) overnight. 
Lower chambers contained I 0% Fetal Calf Serum in media as a chemoattractant. 
Invasion was stopped at indicated time-points by removing non-invaded cells in the 
upper chamber using swabs and washing with PBS. Invaded cells were fixed with ice-
cold methanol and stained with Dapi (Molecular Probes Invitrogen UK). It was 
observed that invaded cells always attached to the bottom of the membrane and did not 
attach to the bottom of the plate. Membranes were removed from the cell culture 
inserts with a scalpel and mounted onto slides where 3 fields of triplicate membranes 
were counted. In order to produce an unbiased result blind counting was used where 
sample identity was unknown. Mean of invaded cells and standard deviation are shown 
in the graphs. 
2.11.2. Gel insert invasion assay. 
Cells and inserts were prepared as above with the exception that the wells were coated 
instead with a collagen gel or with a basement membrane mix gel; Matrigel (BD 
Biosciences). The collagen gels were made by adding 50 f.ll of collagen (2.1 mg/ml 
type I) (First Link Birmingham Ltd UK) I :3 in PBS to the top of the insert and 
allowing gelling 4 hours at 3 7°C. The Matrigel was prepared on ice diluting 8 mg/ml 
I :3 and adding 30 f.ll to the top of each well. Ice and use of ice-cold pipette tips are 
necessary to ensure even coating, as Matrigel gels at temperatures above 4°C. The 
Matrigel layers were then gelled for 4 hours at 37°C following rinsing with PBS, with 
care taken not to disturb the gel layer. In this assay MDA-MB-231 were seeded at a 
lower density (0.5 x 105 cells), due to increased cell size. The cells were allowed to 
invade for 6-8 hours into the collagen gels and 24 hours for Matrigel. These were 
detem1ined as the optimum time points when most cells had invaded. 
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2.11.3. Scratch wound assay. 
Cells were grown to monolayers on 13 mm (VWR) coverslips in 24 well dishes 
(Greiner Bio-one UK). A 10 111 pipette tip (Star Lab UK) was used to scratch a line 
through the cell layers. Cells were then fixed with 4% paraformaldehyde (section 
2.8.1) after wounding at the following time points 0, 30 min, 1 hr, 2hr, 4 hr, 6 hr, I2 hr, 
and 24 hr after to allow for immunofluorescence staining for observing the changes at 
the wound edge. Alternatively for real time wound closure measurements, the glass 
just above the centre of the wound was marked to ensure consistency and 
photographed at the time points using xI 0 objective lense. It was observed that the 
main steps of initiating wound closure initiation occurred between 0 and 2 hours. 
Therefore, future immunofluorescence experiments used these parameters. 
2.11.4. Rho kinase inhibitor assay. 
For the Rho kinase inhibitor assay confluent layers of SW480 cells were pre-incubated 
with inhibitors (Calbiochem UK): H-1152, 300nm and/or Y-27632, 3 11m 
(concentrations from Xie et al., 2005) for 2 hours. Mono layers were then scratched at 
intervals then fixed and processed for immunofluorescence, as in section 2.8.I. 
2.12. Cell attachment assays. 
Twelve well plates (Greiner) were coated with collagen, 2.I mg/ml (First link 
Birmingham Ltd UK) for two hours at 3 7°C. The excess collagen was removed and the 
plates washed in PBS, it was observed that if the collagen was allowed to dry uneven 
coating could occur. The cells, suspended by trypsin treatment, were washed 3x to 
remove trypsin and resuspend to give 500,000 cells per well. Cells in suspension were 
allowed to recover with frequent agitation for I hour. Cells were seeded onto of the 
collagen coating, and after 5 min, I 0 min, 20 min and 40 min, the wells were then 
washed gently three times with PBS to remove non adhering cells. The wells were 
replaced with 800 111 of media and the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega UK) was modified to asses the attachment in 12 well 
plates. Then, 60 111 of dye solution was added to each well and incubated for up to 2-3 
hours (when colour starts to change). A volume of 3 x I 00 111 from each well was read 
at 490 nm with a spectrophotometric plate reader (Anthoslucyl ). For 
immunofluorescence, 13 mm coverslips (VWR UK) were coated as above with 
collagen in 24 well plates. Cells were seeded at 50 000 cells per well and were washed 
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and gently three times with PBS and fixed immediately with 4% paraformaldehyde at 
each time point. Finally, immunofluorescence staining was performed as in section 
2.8.1. 
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CHAPTER3 
MAPPING OF THE ALTERNATIVELY 
SPLICED HUMAN PLECTIN ][SOFORMS. 
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3.1. Introduction. 
The aim of this study was to investigate the role of the cytolinker protein, plectin in the 
migration and invasion of cancer cells. I decided to start this study by looking at the 
human plectin gene and its expression at transcriptional level in human cells and tissue 
to see if there were changes in expression levels between higher grade and lower grade 
cancer cells and different tissue types that could lead to an invasive or migratory 
phenotype. 
The complex organisation of the plectin gene has the potential to generate large 
number of alternatively spiced transcripts. Alternative splicing is viewed as a major 
mechanism in the multiplicity of protein forms in higher eukaryotes (Black, 2003). In a 
genome wide search a large number of mammalian genes that contained multiple 
variable first exons were identified along with plectin, which in all cases are spliced 
into a common downstream exon (Zang et al., 2003). Plectin is not the only member of 
the plakin family to demonstrate a complex alternative splicing arrangement as both 
BPAGl (Jefferson et al., 2006) and MACF (Bernier et al 1996, Gong et al., 2001, Lin 
et al., 2005) also display several alternative spliced N-termini. BPAG 1 has three 
alternative spliced isoforms: BPAG 1 e, which is found in skin and has a characteristic 
structure of the plakins; BP AG 1 a, a predominantly neuronal isoform that differs from 
BP AG 1 e by containing a spectrin repeat rod domain and MT binding domain at the C-
terminus; and BPAG 1 b, predominantly expressed in muscle and structurally similar to 
BP AG 1 a except for the presence of additional p1akin repeats. Within the above 
isoforms further splicing takes place at the N-terminus resulting in three alternative 
first exons for BPAG1a and BPAG1b while BPAG1e has only one possible N-
terminus (Jefferson et al., 2006). In 2001, Gong et al., identified a fourth isoform of the 
MACF 1 gene. MACF 1 isoforms 1 and 2 have identical ABO but differ in the upstream 
N-terminal sequences (Bernier et al., 1996 and Leung et al., 1999); isoform 3 contains 
a unique 5'UTR, a longer N-terminal sequence and just the second half of the actin 
binding domain (Bernier et al., 1996); and isoform 4 is distinct from the others by 
containing plectin repeats at theN-terminus (Gong et al., 2001). 
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Analysis of the mouse plectin gene shows that it contains over 40 exons on 
chromosome 15 and exhibits an unusual 5' transcript complexity (Fuchs et al., 1999; 
Rezniczek et al., 2003 ). At the time this study commenced, 16 mouse plectin isoforms 
had been identified, of which 11 (l-1j) are spliced into a common exon two. In 
addition, two short alternative exons were found for both 2nd and 3rd exons (named 2a 
and 3a), increasing diversity in the region of the gene that encodes the calponin 
homology actin-binding domain (exons 2-8). Finally, three non coding exons (named 
exons -1 ,Oa and 0) that are located 5' to the first coding ex on, 1 c, were identified 
(Fuchs et al., 1999). The 8 alternative protein-coding first exons of the mouse plectin 
gene all differ in length and have no sequence similarity to each other (Fuchs et al., 
1999; Zang et al., 2004). The alternative plectin transcripts were found to exhibit 
distinct tissue specific expression patterns (Fuchs et al., 1999). Furthermore, the 
likelihood that there is multiple promoters in the 5' end of the mouse plectin gene was 
suggested by the presence of CpG islands upstream of alternative 1st exons, leading to 
a hypothesis that tissue specific expression patterns are determined by differential 
promoter activation and alternative cis splicing (Zang et al., 2004). The human plectin 
gene spans over 32 exons on 32kb located in the telomeric region (q24) on 
chromosome 8 (Lui et al., 1996; McLean et al., 1996). At the start of this project only 
four alternative N-terminal first exon splice variants had been identified in the human 
and rat plectin genes (Andra et al., 2003; Elliott et al., 1997), while in rat additional 
transcripts were identified that lacked the C-terminal exon 31 encoding for the rod 
domain (Elliott et al., 1997). A subsequent bioinformatics search that was published 
after this project had started, identified eight putative first exons also in the human 
plectin gene corresponding to the previously identified mouse exons (Zhang et al., 
2004). Notably, all of the plectin isoforms discovered so far have been found to 
contain alternative exons at the 5' end of the gene with only the rodless form being an 
exception. The previously published work on mouse and rat plectin isoforms had lead 
to unanswered questions on the characterisation of the human plectin gene. This 
chapter reports on the gene organisation of the human alternative first exons, with the 
subsequent identification of a novel isoform plectin-1 k. The mRNA expression levels 
of theN-terminal isoforms are also investigated using quantitative real-time PCR in a 
panel of breast and colon carcinoma cells and human tissues showing changes in 
expression levels between the cell lines and also revealing that several of the human 
plectin isoforms have unique tissue specific expression patterns. 
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3.2. Results. 
3.2.1. Human plectin gene contains a similar diversity of alternative N-terminal 
isoforms to mouse and rat genes. 
The published mouse first exon sequences (Fuchs et al., 1999) were compared to the 
human genome to find related sequences. Using BLAST algorithm set to search for 
highly similar sequences across genomes, sequences of over 81% similarity were 
found in the human for eight of the alternative mouse coding first exons ( exons 1, 1 b, 
1 a, 1 c, 1 d, 1 e, 1 e, 1 f, 1 g). Furthermore, when the human exons were compared to the 
rat genome highly similar (>81 %) sequences were also found for the exons 1d, 1e, 1f, 
1 g in addition to the previously identified rat exons 1, 1 a, 1 b, 1 c (Elliot et al., 1997). 
Table 3.1 summarises the alignments of human alternative N-terminal exons with 
corresponding rat or mouse sequences using BLAST2 algorithm tool (NCBI). Exons 
1 a, 1 b, 1 d, 1 e and 1 k were identical in length in all three species. However, even 
though the exons 1, 1 c, 1 f and 1 g are highly conserved in mouse and rat these exons 
were found to be shorter in the human. In the ex on 1, mouse and rat genes have extra 
18 nucleotides inserted into the second half of the ex on compared to human exon 1, 
whereas the ex on 1 c is 12 nucleotides longer in the mouse and at compared to the 
human. Likewise the, the exon 1 f of the mouse and rat plectin genes has a 15 bp 
insertion after the A TG start codon before the similarity to the human ex on 1 f 
commences. Finally, the human ex on 1 g does not show similarity to the corresponding 
mouse or rat exons until 28 base pairs after the A TG start site. (Appendix I lists the 
sequences of the alternative N-terminal exons in mouse, rat and human). Fuchs et al., 
1999, identified two possible A TG start sites in plectin 1 g that were 168 bp apart. The 
human plectin gene did not contain the first A TG site and similarity between human 
and mouse exons 1 g can only be seen in the region following the second A TG codon. 
Furthennore, expression of a truncated plectin-1 g protein (ex on 1 g-8) in a GFP vector 
found that this second ATG is functional to translate the protein (as seen in chapter 4). 
Taken together, these results show that the human plectin gene as well as the rat 
plectin gene could potentially express all eight alternative isoform proteins that are 
present in the murine gene. However, the alternative first exons are not completely 
conserved in the human gene as several of them contain deletions compared to 
alternative first exons in the mouse and rat plectin genes. 
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Table 3.1. Sequence alignment of human plectin alternatives N-terminal 
exons to mouse and rat. 
Ex on Human Matches Gaps Matches Gaps 
ex on compared compared to compared to compared to 
length to mouse mouse rat genome rat 
(bp) genome genome (bp) (bp) 
(bp) (bp) 
Plec-1 * 522 456/451 20/451 455/452 22/452 
84% 3% 83% 4% 
Plec-1a 112 99/112 0/112 99/112 0/112 
88% 0% 88% 0% 
Plec-1b 112 95/112 01112 95/112 0/112 
84% 0% 84% 0% 
Plec-1c* 193 167/202 12/202 165/202 12/202 
82% 5% 81% 5% 
Plec-1d 16 16/16 0/16 16116 0116 
100% 0% 100% 0% 
Plec-1e 46 43/46 0/46 42/46 0/46 
93% 0% 93% 0% 
Plec-lf"'* 70 52/55 0/55 61/66 0/66 
94% 0% 92% 0% 
Plec-1g** 124 80/98% 5/98 81/97 0/97 
81% § 5% 83% 0% 
Plec-1k 43 41143 0/43 40/43 0/43 
95% 0% 93% 0% 
The base pair (bp) matches and gaps observed when the human alternative first exon 
sequences were compared to the mouse and rat genome using the NCBI BLAST2 tool. 
Sequences for plec-1, 1c, If and 1g are longer in the rat and mouse compared to the 
human sequence. * plec-1 and plec-1c have additional nucleotides insertions contained 
within the sequences. ** plec-1f alignment starts at human bp 16 in the mouse and 
human bp 5 in the rat and plec1-g at bp 28 of the human, where there is no significant 
similarity found before this. § Fuchs et al., 1999 predicted two ATG start sites for 
mouse plec-lg, the second start site was used for the alignment above as the human 
does not contain the first ATG. (See Appendix I and Appendix II for sequences). 
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3.2.2. Mapping of the alternative plectin 5'exons. 
In order to characterise the human plectin genome further, the isoforms were mapped 
onto the genome to show the relative positions of the exons (Figure 3.1 A). The whole 
plectin gene from the furthest 5' end coding exon, Ic, was downloaded from the NCBI 
database (NT 02364 954 724-1 015724) and the positions of the alternative isoforms on 
this sequence were found by a blast search using the previously identified sequences 
above. The same procedure was carried out on the rat (NW047780 8864975-8805175) 
and mouse (NT039621 37491514-37429514) genome. The alternative first exons are 
located in identical order on the genomes of human mouse and rat and the relative 
spacing is similar (Figure 3.1 B). Human exons 1 c and If are located 19553 bp 
upstream of 1e, where the remaining exons cluster over 14329 kb (1, 1k, 1d, lb, 1g 
and 1a). The results show that human genome contains similar distribution of 
alternative exons as compared to the mouse and rat. 
3.2.3. Identification of a novel plectin isoform; plectin-lk. 
A novel plectin N -terminal isoform that was named I k (the mouse exons I h, I i and 1 j 
are alternative noncoding 5' -UTR exons) was identified during the bioinformatics 
search for alternative plectin first exons. Exon 1k encodes for a I4 amino acid residue 
(Appendix II). The translation start site in the ex on 1 k (ace A TGgac) resides in a 
consensus Kozac sequence (gccgcc(A/G)ccAUGG) and is preceded by an in-frame 
stop codon 96 nucleotides upstream. Furthermore, a subsequent bioinformatics search 
revealed a human 5' EST clone that contained the ex on 1 k (accession number 
BP315239; Sugano eDNA library, mammary gland OCUB-F Homo sapiens eDNA 
clone OFR081I7 5', mRNA sequence). The exon Ik is located between exon I and Id 
in the human plectin locus; about 1.6 kb upstream of the exon 1d and 3.8 kb 
downstream of the ex on I (Figure 3.1 ). Similar sequences of 95% in mouse 93% in the 
rat genome were identified that further validate the ex on I k (Table 3 .I), and when 
translated at the protein level the amino acid sequence is identical in all three species 
(Appendix II). Therefore, the exon I k adds to the diversity of the alternative first exon 
isoforms in plectin. 
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Figure 3.1. Map of plectin alternative N-terminal first exons. 1e 21809 19330 21452 
(A) Schematic map of the localisation of the 9 coding first exons 1- 1k in the 1 24654 25202 24563 
human plectin gene. Scale bar gives an indication of distance between exons 1k 28560 29122 28979 
1c and 1a only. All human N-terminal first exons splice directly to exon 2. 1d 30408 30888 30634 
(B) Table of the distance in base pairs (bp) from exon 1c in rat, mouse and lb 31101 31680 31474 
human genome. 1g 32633 33264 32847 
1a 35351 35805 35781 
3.2.4. Search of EST clones reveals further possible alternative exons. 
The unusual complexity of the plectin alternative first exons prompted a blast search to 
compare the EST database against the human plectin locus. In addition to the plectin-
1 k isoform, a 5' EST clone was identified that is contained in the human plectin gene 
(accession number AL55160 Homosapiens PLACENTA COT 25-NORMALIZED 
Homo sapiens eDNA clone CSODI063YN08 5-PRIME, mRNA sequence). This exon 
named in this study plect-11 is located 14715 bp downstream ofplec-lfand 4838 bp 
upstream of plec-1 e. The translation start site in the exon 11 (gccaccA TGgat) resides 
also in a consensus Kozac sequence and is preceded by a stop codon 186 bp up stream. 
Several attempts were made to amplify this sequence (Appendix I) without success, 
probably due to tissue specific mRNA expression, as the EST clone was found in 
embryonic sample. This evidence leads to speculate that the previously identified first 
exons do not represent the full diversity of the alternative first exons in plectin. 
3.2.5. PCR sequencing and cloning of plectin alternative N-terminal first exons. 
In order to confirm the expression of the alternative human first exons, PCR was 
carried out using primers targeted for each of the alternative exons (Table 2.1 ). The 
reverse primer was chosen to be located in exon 4 due to the presence of the possible 
alternative second and third exons. Furthermore, exons 2 and 3 were not suitable due 
to the short length and GC richness. eDNA samples from human cell lines were used 
(HT29, SW480, MCF7, and U373 cells) as a template for each isoform and products 
were cloned into pGEM T -easy for sequencing. The PCR products were run on a 2% 
agarose electrophoresis gel that enhances comparison of the sizes of the alternative 
first exons (Figure 2.3A, Figure 3.2B). The remarkable short sizes of the alternative 
first exons, from plec-1 at 522 nucleotides to only 16 nucleotides in plec-1 d, should be 
highlighted for the results that follow in this study. Sequencing of the PCR clones 
extending to the end of the ABD demonstrated that the all of the human alternative 
first exons splice to the exon 2 then 3 and 4. None of the sequences contained the 
alternative second exon 2a or third exon 3a as proposed for the mouse (Fuchs et al., 
1999). These results confirm that all nine alternative plectin N-terminal first exons, 
including the novel ex on 1 k, are expressed in human cell lines. 
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A 
1 1a 1b 1c 1d 1e 1f 1g 1k 
500 bp-
8 Isoform (a) Exon (b) Expected 
length (bp) size (bp) 
1 522 652 
1a 112 242 
1b 112 242 
1c 193 323 
1d 16 146 
1e 46 176 
1f 70 200 
1g 124 254 
1k 43 173 
Figure 3.2. Alternative N-terminal first coding exons in the human plectin 
gene. 
(A) Agarose gel electrophoresis of rt-PCR products of alternative N-termini of the 
human plectin gene. Exons 1-4 were amplified starting from each indicated 
alternative exon 1. The PCR products correspond to the predicted sizes (B) and 
were cloned and sequenced for confirmation. In the above table column (a) is the 
length of each alternative N-terminal first exon and column (b) is the expected 
length of the PCR products on agarose gel above using the ex on 4 reverse primer. 
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3.2.6. Semi-quantitative RT -PCR end point analysis shows distinct expression 
levels of plectin N-terminal isoforms in colon carcinoma cells. 
Plectin N-terminal isoform expression was investigated at the mRNA level in a panel 
of colon carcinoma cell lines, HT29, SW940 and SW480. These cell lines originated 
from grade II (HT29) to grade III/IV (SW480) cancer. The Cancer grading system set 
by, The American Joint commission on pathology is based on pathology of the cancer 
cells. The grading describes the extent or severity of an individual's cancer based on 
the extent of the original (primary) tumour and the extent of spread in the body. 
Grade I cells are early stage carcinomas and are well differentiated and slow growing, 
whereas grade IV cells are considered to be aggressive and undifferentiated. The 
expression was first investigated using semi-quantitative rtPCR, where the expression 
levels are evaluated at the PCR end point. The PCR was run for 25 cycles, as this was 
the lowest number that gave comparable product, therefore was below the plateau 
phase of PCR. Interestingly, in the higher grade SW480 cells compared the lower 
grade HT29 cells, expression of plec-1 was elevated and plec-1 e was decreased (Figure 
3.3). Periplakin and actin expression are shown as positive controls to mRNA levels 
and quality. The findings above show that plectin isoforms 1 and 1 e are altered 
between the grades in colon carcinoma cells. Intriguingly in the murine studies, at the 
protein level plectin-1 was found in the nucleus with faint actin staining and l e 
decorated stress fibres, indicating that these isoforms have specific localisations 
(Rezniczek et al., 2003 ). Plectin-1 was also found as the major transcript expressed in 
cells of mesenchymal origin (Fuchs et al., 1999) and its long sequence gives increasing 
potential to accommodate isoform-specific binding partners (Abrahamsberg et al., 
2005). These findings prompted the investigation into the expression levels of the 
other alternative first exons using the quantitative method of real-time PCR, in an 
attempt to isolate the isoforms that are expressed more prominently in the more 
aggressive cancer cells compared to the low-grade cells. Also, the tissue specific 
expression of plectin transcripts will be investigated in the human as previous studies 
have looked only at expression levels in mouse tissues (Fuchs et al., 1999). 
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HT29 SW940 SW480 T84 
pleclx 
plecle 
pleclf 
periplakin 
Actin 
Figure 3.3. Expression of plectin N-terminal isoforms in colon carcinoma 
cells. 
Equal volumes of PCR end products were loaded onto 2% agarose 
electrophoresis gel. Note the change in expression of isoform lx and le, 
whereas 1 f is uniform. Periplakin and actin is used positive control for RNA. 
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3.2.7. Realtime PCR: a method to quantitatively investigate mRNA expression 
levels. 
Real Time PCR was used on the panel of colon carcinoma cell lines including the 
breast carcinoma cell lines MCF7 (grade II) and MDA-MB-231 (grade III-IV) to 
investigate expression levels of plectin N-terminal isoform transcripts. The breast 
carcinoma cell lines were used to investigate if any altered expression levels identified 
are a product of cancer cell aggressiveness or are specific for cancer cell types. The 
method of real-time PCR is reviewed in section 2.3.8. Due to the large amounts of data 
generated in real-time PCR the following sections 3.2.8 will show examples of the 
products for each N-terminal isoform and 3.2.9 will report on the novel isoform plectin 
1k as an example to demonstrate the method. Finally, sections 3.2.8 and 3.2.9 will 
report on the end results of the carcinoma cell and human tissue expression study in 
condensed graphical form. 
3.2.8. Melt curve analysis confirms the integrity of the PCR product. 
The integrity of the real time PCR products were observed using melt curve analysis 
(Figure 3.4). After the completion of PCR cycling, the temperature is raised in 1 °C 
steps and the product should produce one peak, representing the decreased 
fluorescence at the melting point of the product. Single peaks were observed in the 
analysis of all the nine of the plectin isoforms and in the actin control. Additional 
peaks, which indicate non-specific products or primer or template dimers, were not 
present in any of the samples (Figure 3.4). The results demonstrate that each primer 
pair was specific for the expected size that had previously been cloned and sequenced 
in Figure 3.2 for each alternative N-terminal isoform. Analysis of the final PCR 
products on a 2% agarose gels provided further evidence on the reliability of the 
method, although differences in the expression levels can no longer be observed due to 
the PCR reactions reaching the plateau before the 50 cycles terminates (data not 
shown). No non-specific bands or primer dimers were detected in the agarose gel, 
which confinns the results of the melt-curve analysis. 
3.2.9. Fluorescence curves for isoform plec-lk show real-time PCR progression. 
The representative fluorescence curve of amplification of the isofonn plec-1 k in the 
colon and breast cancer cell lines shows the progress of the real time PCR (Figure 3.5 
A & C). The take off point (the point at which the PCR enters the exponential phase, 
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where the second derivative is at 20% of maximum level and noise level ends) of the 
PCR is around 29.7-33 cycles, which is relatively late compared to cycle 11.3-12 of 
actin PCR reactions (Table 3.2). The take off point is related to the starting copy 
number, but also takes into account the PCR efficiency. The efficiency of PCR is 
largely dependent on primer annealing, GC content and length of PCR product. Next, 
the curve enters the exponential phase where, as each cycle progresses, a doubling of 
product should be taken place if the efficiency of the PCR reaction is 100%, which 
most reactions do not reach due to limitations such as primer annealing efficiency, 
enzyme affinity to RNA or again product length. For plec-1k the average efficiency is 
1.75 across the different samples, the other exons range from 1.7-1.8 with the control 
actin having a lower efficiency at 1.65 (Table 3.2). For the mRNA concentration of 
each sample to be comparable, the amplification efficiency should be around the same 
value. Because the results show that the deviation was less than 2.5 % for any of the 
reactions, this was deemed acceptable (Table 3.2). After the exponential phase, the 
PCR reaches the plateau, where the reaction is no longer in log-linear growth due to 
depletion of PCR components and renaturation of product that prevents further 
annealing. The height of the curve indicates the final product concentration. However, 
identical amounts of starting templates do not always result in identical yields that 
further support the need for real time analysis over semi-quantitative PCR. Figures 
3.5B and 3.5C show the second derivative amplification plots, where the peak 
corresponds to the maximum rate of increase in fluorescence at each cycle. These plots 
give the comparative analysis between the samples. The relative concentration of each 
sample compared to the low-grade carcinomas was calculated based on the efficiency 
and take of point. The results show that in the colon carcinoma cells plec-1 k 
expressions is increased in the aggressive SW480 colon cancer cell line but decreased 
in the aggressive MDA-MB-231 breast cancer cell line compared to the corresponding 
low grade HT29 and MCF7 cells. Similar calculations were carried out for all nine of 
the alternative N-tenninal isofonns. Due to the variable efficiencies of different primer 
pairs for each N-tenninal isofonn, no attempt was made to quantify expression levels 
between the isofonns, but instead differences between cell lines for each isofonn were 
investigated, as this was more relevant to the project. 
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Figure 3.4. Melt curves of real time PCR of plectin N-terminal isoforms. 
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Figure 3.4. Melt curve analysis of real time PCR product. 
Figure shows representative melt curves for each plectin alternative isoform from a 
real time PCR experiment with carcinoma cell lines. Y -axis is the relative fluorescence 
intensity (dF/dT) and X-axis measures the increase in melting temperature (0 C). A 
single peak is shown where the PCR product melts and the decrease in fluorescence is 
detected. The temperature at which each product melts corresponding to the peaks is 
displayed. 
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Figure 3.5. Sybr green fluorescence in real time PCR of plectin-lk isoform. 
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Figure 3.5. Sybr green fluorescence in realtime PCR of plectin-lK isoform. 
Representative real-time PCR amplification plots showing an increase in Sybr green 
fluorescence from colon carcinoma cells HT29, SW948 and SW480 (A) and breast 
carcinoma cells MCF7 and MDA-MB-231 (C). The second derivative dF2/d2C is 
plotted against cycle number for comparative quantification of colon (B) and breast 
(D) carcinoma cells. 
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Table 3.2. Take off points and amplification efficiency of real time PCR. 
(a) The take off range lists the threshold cycle range obtained during realtime PCR of 
colon and breast cell lines for each exon (this is related to starting template). (b) The 
amplification efficiency lists the amplification of product for each cycle in the linear 
range and the deviation(+/-) between each sample for each exon PCR. 
Ex on Take of range Amplification efficiency 
(c)::cle) (a) (b) 
Actin 11.3-12 1.64 +/- 0.03 
1 24.5-26.8 1.73 +/- 0.03 
A 26.7-29.3 1.72 +/- 0.02 
B 26.6-29.6 1.73 +/- 0.02 
c 23.2-27.4 1.74 +/- 0.02 
D 23.3-25.5 1.73 +/- 0.04 
E 17.9-20.0 1.74 +/- 0.04 
F 24.7-28.1 1.70 +/- 0.02 
G 21.7-24.9 1.77 +/- 0.03 
K 29.7-33.5 1.74 +/- 0.02 
Periplakin 17.5-20.6 1.70 +/- 0.02 
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3.2.10. Quantitative Real time PCR shows changes in isoform expression in 
cancer cell lines. 
Comparative analysis was used in order to investigate the relative expression of N-
terminal isoforms between low grade and high-grade colon and breast carcinoma cells. 
These data (Figure 3.6) were obtained from three independent RNA extractions and 
triplicate runs from each cell type shown. The grade II cell lines are used as the 
reference sample, to which all other cell lines are compared to in order to show 
changes between the grades. Actin, which is usually used as an endogenous reference 
gene (a gene that has stable expression between samples and used as a control), is not 
equal in all cell lines so can only be used as a positive control in the experiments. The 
starting RNA was quantified to ensure that comparable total eDNA levels from each 
cell line were used and, as further validation, comparison of independent RNA 
preparations confirmed constant levels of actin expression in the cell lines (note error 
bars for actin in Figure 3.6.). The high grade SW480 colon carcinoma cells show an 
increase in mRNA expression of isoforms 1 and 1 k, and a decrease in the expression of 
isoforms 1 c, 1 d, 1 e, 1f and 1 g compared to HT29 cells, whereas the expression of 
isoforms 1 a and 1 b remain unchanged. The results for the intermediate SW948 cell 
line were less clear, owing to large variation between the samples (see error bars in 
Figure 3.6 A). Intriguingly, the breast carcinoma high-grade MDA-MB-231 cells have 
a relative increase in expression of isoform 1 d and less so 1 a when compared to the 
MCF7 cells. There is also a decrease in the expression levels of 1 c and 1 k, whereas the 
change in expression of the remaining isoforms 1, 1 b, 1 e, 1 f and 1 g is negligible. In 
summary, the correlation between invasiveness and expression of the isoforms is not 
uniform between colon and breast cancer cells. However, changes in mRNA 
expression of isofonns are observed in a cell type specific manner and this may 
contribute to the invasive potential of each cell line. 
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Figure 3.6. Real-time PCR of plectin N-terminal isoform mRNA expression 
in cancer cell lines. 
c 
0 
+=l 
6 
~ 5 
-c ~ 8 4 
Q) 
> 
+=l 
~ 3 
~ 
E 
8 2 
Q) 
> 
+=l 
ro 
Q) 1 
0::: 
0 
6 
0 
D HT29 
l!ilB SW948 
• SW480 
1 
0 MCF7 
a 
• MDA-MB-231 
1 a 
b c d e f g k 
b c d e f g k 
78 
Figure 3.6. Realtime PCR of plectin N-terminal isoform mRNA expression in 
colon and breast cancer cells. 
Realtime PCR analysis of the expression of plectin alternative N-terminal isoforms 
mRNA in a panel of colon (A) and breast carcinoma cells (B). Expression levels (from 
three independent RNA extractions with each sample run three times) are shown 
relative HT29 (A) or MCF7 (B). Error bars show mean standard deviation. Actin 
expressiOn (right hand panel) was analysed as a positive control for each mRNA 
sample. 
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3.2.11. Expression of plectin N-terminal isoforms in a panel of human tissues. 
Plectin is a ubiquitous protein that is expressed in all tissues. Detailed analysis of the 
expression of the mouse plectin isoforms reveals that there are tissue-specific 
differences in the expression of the alternative first exons (Rezniczek et al., 2003). To 
analyse the tissue distribution of the alternatively spliced isoforms of human plectin 
gene, I investigated a panel of human tissue RNAs by quantitative PCR (Figure 3.7). 
The human tissue RNAs were obtained from Ambion. First Choice Human Total RNA 
survey panel consists of pools of total RNA from 20 different normal human tissues 
and each pool consists of at least three tissue donors. Due to the high cost of the RNA 
panel the results have been repeated only twice to investigate any major differences 
between tissues. Plectin isoforms 1 b, 1 c, 1 e and 1 g show a constitutive expression 
pattern in the studied tissues. In contrast, the novel isoform 1 k, as well as plectin-1, 1 a, 
1 d and 1 f displayed tissue specific differences in their expression patterns. 
Interestingly, plectin-1 k expression was elevated in the colon and oesophagus. Plectin-
1 expression was elevated significantly in the brain, oesophagus and thyroid. Plectin 1 a 
was elevated in the placenta and ovary. Plectin-1 d was upregulated remarkably in the 
heart and brain and also elevated in the spleen. Finally, plectin-1 f expression was 
elevated in the brain and was hardly detectable in the kidney. These results show that 
there are tissue specific differences in the expression of a subset of human plectin 
isoforms. 
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Figure 3.7. Real-time PCR analysis of the expression of the plectin N-tenninal 
splice variants in human tissues. 
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Figure 3.7. Realtime PCR analysis of the expression of the N-terminal splice 
variants in human tissues. 
Real-time PCR was used to investigate the expression of plectin isoforms in a panel of 
total RNA samples form human tissues. Each isoform was analysed separately and the 
expression in different tissues is shown relative to mRNA levels in the skeletal muscle. 
The bars display two independent analyses. 
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3.3. Discussion. 
The human plectin gene was shown to have similar diversity of plectin N-terminal 
isoforms as the mouse gene. In this study, the precise genomic localisation was 
determined for all plectin alternative N-terminal exons identified in the human gene 
and was found to be identical to both rat (Elliot et al., 1997) and mouse genes (Fuchs 
et al., 1999). Alterative splicing of the exons 2 and 3 (2a and 3a) that are found in the 
actin-binding domain of the mouse plectin were not identified in the human gene in 
this study since sequencing of all the PCR products showed direct splicing to a 
common exon 2. 
Using semi-quantative PCR to measure mRNA expression in the colon carcinoma cell 
panel, it was shown that isoform 1 was up-regulated and 1 e down-regulated in the 
higher grade carcinoma cell SW480 compared to the lower grade HT29 and isoform If 
was constitutively expressed. These results indicated that a subset of plectin isoforms 
could be altered during progression of cancer. To further investigate these results, 
Real-Time PCR was used to provide a quantitative analysis of the plectin isoform 
expression in the colon carcinoma cell line panel and in two breast carcinoma cell 
lines. The results of upregulation of the isoform 1 and down regulation of the isoform 
1 e correlated with the semi-quantative PCR results. Furthermore, the down regulation 
of isoforms 1 c 1 d 1 e 1 f was observed in high grade S W 480 cells compared to low 
grade carcinoma cells. The intermediate SW948 (grade II/III) cell line showed large 
variation between the samples. One possible explanation is presented in chapter four 
(Figure 4.5B) where the SW948 cells are shown to grow in unusual stratifying colonies 
of variable size which may affect the plectin isoform mRNA levels between samples. 
The results from the breast carcinoma cells were partially different than in the colon 
carcinoma panel. This result is of interest as it shows that even though the expression 
levels of plectin isoforms do change when low grade carcinoma cells are compared to 
high grade cells, the changes are cell type specific. The study of the role of these 
isoforms in human carcinoma cell invasion and migration will be investigated at the 
protein level in the subsequent chapters. 
Interestingly, the upregulation of isoform I in the higher-grade carcinoma cells may 
support a recently found role for isoform 1 in cell migration. Dermal fibroblasts 
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isolated from plectin-1-deficient mice exhibited abnormalities in their actin 
cytoskeleton and impaired migration (Abrahamsberg et al., 2005). Evidence that the 
expression of theN-terminal exons has an important role in the subcellular localisation 
of plectin was found when a GFP-plectin-ABD fusion protein was expressed without 
any of the first exon sequences. Transfections of this construct resulted in mostly 
diffuse, only weakly stress fibre -associated expression pattern, which is in stark 
contrast to localisation of protein domains containing the alternative first exons to 
either stress fibers or focal adhesion sites (Rezniczek et al 2003). My results suggest 
that changes in regulation of mRNA levels of the plectin N-terminal isoforms take 
place during cancer progression and it may, thus, be worthwhile to investigate plectin 
isoform mRNA expression levels in carcinomas compared to normal tissues or less 
aggressive cancers. 
This study also provides the first quantitative realtime analysis of plectin alternative N-
terminal first exon expression in human tissue samples. The results indicate that 
several isoforms have unique tissue-specific expression patterns, whereas some 
isoforms, such as plectin-1 b that co-localises with mitochondria (Rezniczek et al., 
2003), are constitutively expressed in all tissues contained in the RNA panel (Figure 
3.7). Thus, it is likely that the regulation of the alternative plectin promoters is 
complex and may involve both shared and unique, tissue-specific regulatory elements. 
Previously the expression levels of some plectin N-tenninal isoforms has been 
investigated using RNA protection assays of total RNA isolated from various mouse 
(Fuchs et al., 1999) and in rat (Elliot et al., 1997) tissues. The mouse study used a 
small panel of tissues including lung, brain, kidney, small intestine, heart, muscle, 
skin, liver, uterus, spleen and salivary gland. The mouse plectin isofonns 1 d and 1 b 
were exclusively found in skeletal muscle, heart and skin. Plectin-1 a was found in 
epithelial tissue types such as lung, small intestine and skin. Plectin= 1 transcripts were 
found in tissues with high connective tissue content such as muscle skin and uterus. 
Finally, isoforms 1 e, 1 f and 1 g had a broad expression pattern. The rat study included 
muscle, heart, brain, testis, lymph nodes, thymus, and kidney tissues. Transcripts 
containing exons 1, 1 a and 1 b were found in all the investigated tissues. Plectin-1 and 
1 b were expressed in heart muscle in hemi, whereas plectin-1 a was predominantly 
expressed in lymph nodes, thymus and kidney. When comparing the human, mouse 
and rat data, it is apparent that there are tissue specific expression differences in 
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expression of plectin isoforms across the species. The subset of isoforms that show 
specific differences in human tissues, plectin isoforms 1, 1 a and 1 d are also variably 
expressed in the mouse tissues and the constitutively expressed isoforms 1 e, 1 f and 1 g 
are also broadly expressed in the mouse tissue panel. However, the expression of 
isoforms 1 b and 1 c is variable in the mouse tissues but constitutive in the human RNA 
panel. Although variable expression pattern of the isoforms is in most cases conserved 
between different species, the tissue-specific differences between are not always 
conserved. This is most evident in the case of plectin-1 d that shows elevated 
expression in murine skeletal muscle and heart tissues and low expression in the brain 
whereas in the human study plectin-1 d mRNA is markedly elevated in brain and heart 
tissues compared to the skeletal muscle. The tissue specific expression of the N-
terminal plectin isoforms suggests that multiple promoters may control expression of 
the gene. The complexity of the plectin gene was further underlined by findings that 
the 5' end on the plectin-1 gene overlaps in a head to tail manner with the 3' end of the 
Parp-1 0 gene, a recently identified poly (ADP-ribose) polymerase (Lesniewicz et al., 
2005). This result indicates that the promoter of plectin-1 isoform is actually located in 
the Parp-1 0 gene and could provide an interesting example of regulated gene 
expressiOn. 
In summary the complexity of the human plectin gene with the ability to generate 
several N-terminal isoforms that show tissue specific expression could provide an 
important regulatory mechanism of protein function. Furthermore, understanding the 
expression of plectin isofonns in cancer may lead to a better understanding of 
metastatic potential. 
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CHAPTER4 
EXPRESSION AND SUBCELLULAR 
LOCALISATION OF PLECTIN PROTE:U:N 
ISOFORMS ][N CARCINOMA CELLS. 
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4.1. Introduction. 
There has been no published study investigating the localisation of plectin in cancer 
cells of increasing invasiveness, as focus has been mainly on the expression in the 
epidermis and muscle and their related diseases. Plectin was originally identified as a 
component of hemidesmosomes, where it was shown to localise to the cellular 
periphery at cytoskeleton-membrane interaction sites in frozen sections of stratified 
skin epithelia and muscle tissues (Wiehe et al., 1983, 1984; Hieda et al., 1992; Foisner 
et al., 1994 ). Additionally, Eger et al., 1997 showed that upon a loss of cell polarity 
plectin is relocated from the cell periphery at the desmosomal plaque to a cytoplasmic 
vimentin- and cytokeratin-related network. Further work investigating cytoskeletal 
dynamics in plectin null fibroblasts has established that, in addition to its structural 
role, plectin regulates actin dynamics as plectin-deficient fibroblasts show delayed 
actin re-organisation and impaired motility (Andra et al., 1998). Plectin has the ability 
to interact with actin through its N-terminal calponin homology actin-binding domain. 
Moreover, Rezniczek et al., 2003 showed that small alternative N-terminal sequences 
(5-180 residues) coding for eight of the mouse plectin isoforms could profoundly 
affect the sub-cellular localization of plectin. Thus, it was interesting to find out, if the 
human N-terminal plectin isoforms characterised in Chapter 3 could also effect the 
sub-cellular localisation of plectin in the carcinoma cells and whether the localisation 
could have a specific role in migration and invasion. In this chapter, I first characterise 
the breast and colon carcinoma cell lines using a collagen invasion assay to determine 
the invasive potential. Next, the expression of plectin and other cytoskeletal proteins 
was investigated in the panel of carcinoma cell line using immunofluorescence and 
immunoblotting. 
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4.2. Results. 
4.2.1. High-grade SW480 and MDA-MB-231 cells show an increase of invasive 
potential compared to their lower grade counterparts. 
To investigate whether the observed changes in plectin isoform expression levels were 
related to invasive phenotype of the cells, it was important to determine the 
invasiveness of the studied cancer cell lines. The invasive potential of the carcinoma 
cell lines was investigated using collagen coated Boyden chambers (Figure 4.1 ). 
Collagen gels, rather than basement membrane preparations, were chosen, as we were 
interested in invasion through the stroma in the later stages of cancer cell invasion. 
Fibrillar collagen is the main constituent of the connective tissue matrix that is 
degraded by several proteases during cell invasion (Wolf et al., 2003). Within the 
colon carcinoma cell panel, SW480 (grade III/IV) cell line displayed approximately 20 
fold increase in the invasion through collagen compared to lower grade HT29 (grade 
II) cells. The intermediate grade SW948 cell line was only slightly more invasive than 
the HT29 cell line. The breast carcinoma cells panel were more invasive than the colon 
carcinoma cells (note scale difference), with the MDA-MB-231 cell line demonstrating 
an invasive potential that significantly exceeded the lower grade MCF7 cells by 9 
times. The results show that in a collagen invasion assay the higher grade SW480 and 
MDA-MB-231 cells invade more aggressively than their lower grade counterparts. The 
mechanisms of invasion will be further discussed and investigated in Chapter 5. In 
conclusion the breast and colon panel of cell lines, with the demonstrated differing 
invasive potential is a powerful tool for the further investigation of the role of plectin 
in cancer cells. 
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Figure 4.1. Collagen gel invasion of carcinoma cells. 
(A) Invasion assay of colon carcinoma cells through collagen-coated cell culture inserts. 
Mean invaded cells/microsopic field from three independent experiments are shown. Error 
bars denote standard deviation. (B) Migration assay of breast carcinoma cells. 
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4.2.2. Investigation of expression levels of cytoskeletal and related proteins in the 
panel of carcinoma cell lines. 
In order to study migration and invasion in the panel of cell lines and to expand on the 
results of mRNA expression analysis, the expression levels of plectin and other related 
cytoskeletal proteins were investigated at protein level. Immunoblotting of total cell 
extracts from the panel of breast and colon cells allowed identification of proteins that 
could play a key role in the invasive potential of carcinoma cells. The total cell extract 
from five independent experiments was quantified and identical quantities of protein 
were loaded to each lane so they could be compared. Actin was originally used as a 
loading control, but it's to be noted that the cell lines have slight differences in actin 
expression; therefore the BCA protein assay (Section 2.7.2) was used to quantify 
protein levels prior to loading of the gel. Equal loading was further confirmed visually 
by staining of the filters with Ponceau S (which stains total proteins red). Molecular 
weight markers were used to identify correct band sizes of the proteins. 
4.2.3. Plectin is over-expressed in the more invasive cell lines. 
Strikingly, plectin was found to be over-expressed in the invasive SW480 and MDA-
MB-231 cell line compared to the less invasive cells. Furthermore, desmoplakin is 
down regulated in the invasive colon and breast carcinoma cells which correlates to the 
previous study on breast tumours (Davies et al., 1999). Surprisingly, there is a high 
expression of desmoplakin in SW948 cell line; this will be investigated using 
immunofluorescence. The invasive phenotype is also associated with vimentin 
expression with a decreased keratin expression in MDA-MB-231 cells, which is 
typical of epithelial to mesenchymal transition (Franke et al., 1982) that will be 
discussed in Chapter 5. Interestingly, periplakin, another member of plakin family of 
cytoskeletal linker proteins, also shows an increase of expression levels in the more 
invasive cell lines. Periplakin has been implicated in formation of the cornified 
envelope (Di Colandrea et al., 2000), but recent work has shown that periplakin can 
co-distribute with plectin to regulate keratin organisation and epithelial migration 
(Long et al., 2006 and Boczonadi et al., 2007), so its not surprising that an 
upregulation of periplakin is seen along with plectin in more invasive cells. Vinculin 
and talin, which are components of the focal adhesion complex, were up regulated in 
the invasive MDA-MB-231 cell line compared to MCF7 cells, but in the colon 
carcinoma cells only the metastasis-derived T84 cell line demonstrated an upregulation 
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compared to HT29. Vinculin is traditionally viewed as a stabiliser of focal adhesions 
(Gallant et al., 2005) that suppresses cell migration, however vinculin has been found 
to modulate signalling pathways regulating focal adhesion dynamics (reviewed in 
Ziegler et al., 2006). Furthermore, focal adhesions located at the edge of several 
endothelial cell types show association with both the microfilament and vimentin 
intermediate filament cytoskeletons (Gonzales et al., 2001). It is, therefore, not 
necessarily surprising that the MDA-MB-231 cells, which express a vimentin 
cytoskeleton instead of the keratins 8 and 18 have a high expression of vinculin. 
HSP27 a small heat shock protein is upregulated in SW480 cells, which is in 
agreement with several studies showing an increase in HSP27 expression in many 
cancers (reviewed by Ciocca et al., 2005). However, contrasting this, down regulation 
ofHSP27 was seen in the more invasive MDA-MB-231 breast carcinoma cells, HSP27 
expression in breast carcinoma cells has been widely studied and over expression in 
the MDA-MB-231 cell line leads to an increase in invasiveness but decreased motility 
(Morino et al., 1997, Lemieux et al., 1997). E-cadherin expression is down regulated in 
the invasive SW80 cell line compared to HT29 with recovery in the T84 cell line. Even 
more pronounced is the absence of E-cadherin expression in MDA-MD-231 cells 
compared to MCF7 cells. E-cadherin has also been widely studied in cancer with 
down-regulation of the protein seen in the progression of many cancers leading to a 
decreased survival in patients (see reviews by Mareel et al., 1992, Mareel et al., 1994, 
Jiang et al., 1996 and Bremnes et al., 2002). 
These results show that that a subset of cytoskeletal proteins is altered as the invasive 
potential increases. The localisation of these proteins in cancer cells and their possible 
roles in migration and invasion will be investigated in the Chapters to follow. The 
elevated expression of plectin in the invasive SW480 and MDA-MB-231 cells was 
intriguing as previous studies on plectin in epithelial cells have concentrated on its role 
as a hemidesmosomal protein but not addressed the role of plectin in mvastve 
carcinoma cells. Furthermore, the difference in vimentin, keratin and vinculin 
expression between the invasive MDA-MB-231 and SW480 cells may indicate that 
these cells use different mechanisms of migration invasion and attachment. 
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Figure 4.2. Expression of cytoskeletal and related proteins in carcinoma cell lines. 
The changes in expression of cytoskeletal proteins, in a panel of carcinoma cell lines, is 
investigated by immunoblot analysis. Actin is used as positive control between cell 
extracts. Shown is a representative immunoblot of at least three independent cell extracts 
for each protein. (A) Immunoblot analysis of expression of cytoskeletal proteins in colon 
carcinoma cell lines. (B) Immunoblot analysis of cytoskeletal proteins in breast carci-
noma cell lines. Note, the plectin antibody detects two distinct bands and several faint 
bands lower than the 500 kDa marker, possibly due to alternative isoform expression. 
* denotes a lower molecular weight band of the rodless plectin. 
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4.2.4. Plectin is recruited away from the cell periphery in the more invasive 
carcinoma cells. 
To study the role of the cytoskeletal proteins further, immunofluorescence was used to 
investigate their subcellular localisation and organisation within the colon and breast 
carcinoma cell lines. The results obtained in this study show that in the non-invasive 
HT29 cells, plectin is localised to the cell periphery and lamellipodia, co-localising 
with the keratin 8118 filaments (Figure 4.3A, arrow). The plectin expression in SW948 
cells, which have similar invasive potential to HT29 cells, (Figure 4.1) is also found at 
the cell periphery localising with keratin bundles. Contrasting this, plectin localisation 
in the invasive SW480 cells plectin is found throughout the cytoplasm localising with 
the cytoplasmic keratin 8118 network and not especially to the cell periphery in the 
manner observed in the HT29 cells (Figure 4.3A). The T84 cell line, derived from lung 
metastasis has a less well-defined intermediate filament network where plectin 
expression is cytoplasmic. Plectin is also found at the cell edges along with keratin 
bundles in T84 cells. In all studied colon carcinoma cell lines, plectin is observed to 
colocalise with the keratin cytoskeleton (Figure 4.3A), which supports both previous 
work showing that the C-terminal domain of plectin links to the intermediate filament 
cytoskeleton (Sevcik et al., 2004) and initial studies showing the co-purification of 
plectin with the intermediate filament protein vimentin (Wiehe et al., 1982). Similar 
observations were made in the breast carcinoma cells. In MCF7 cells, plectin is 
preferentially localised at the cell periphery (Figure 4.3B), where it is co-localised with 
keratin. MDA-MD-231 cells, that almost exclusively express vimentin with extremely 
low levels of keratin 8118 (as shown immunoblotting Figure 4.2), show a dense 
vimentin network around the nucleus with plectin co localisation. Plectin and vimentin 
expression is also found throughout the cytoplasm and at cell periphery in these cells 
(Figure 4.4B). Plectin was also shown to localise with the vimentin cytoskeleton in 
SW480 cells (which expresses vimentin along with the keratin 8118 network). In these 
cells, vimentin is localised both to the perinuclear area in a dense cage together with 
plectin (Figure 4.4A) and throughout the cytoplasm. When the sub-cellular localisation 
of vimentin and keratin 8/18 networks was investigated by double staining (Figure 
4.4C), it was found that they both co-localised in a cytoplasmic network, but vimentin 
expression was more intense at the perinuclear region than the keratin expression. To 
summarise the above findings, plectin was found at the cell periphery of non invading 
cells co-localising with the keratin 8/18 network, whereas in the invasive cells that 
93 
express vimentin, the strongest plectin expression was observed in the vimentin rich 
cage surrounding the nucleus. 
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Figure 4.3. Co-expression of keratin 8 & 18 and plectin protein in carcinoma cells. 
(A) Confocal microscopy of single plane immunofluorescence indicating the sub-
cellular localisation of plectin (green) with keratin 8 & 18 (red) in colon carcinoma cell 
lines. Co-localisation of the two proteins is shown in the cells with arrows pointing to 
examples of strong co-localisation (yellow). (E) Keratin 8 & 18 expression in breast 
carcinoma cell line MCF7 showing a dense intermediate filament network with co-
localisation of plectin, note the elevated plectin expression at the cell periphery 
(Arrow). Scale bars 20J.lm. 
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Figure 4.4. Subcellular expression ofvimentin in SW480 and MDA-MB-231 cells. 
Single plane confocal images of immunofluorescence showing the vimentin network 
expression in the colon carcinoma SW480 and breast carcinoma MDA-MB-231 cells. 
(A) Partial co-localisation of plectin and vimentin expression is visible in SW 480 cells 
with a dense network around the nucleus (arrow). (B) Co-expression of vimentin and 
plectin in MDA-MB-231 cells. Arrows points to co-localisation of filaments. (C) Co-
expression of the keratin 8 & 18 and vimentin intermediate filament networks in SW480 
cells showing partial co-localisation (arrow). Scale bars indicate 20J..tm. 
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4.2.5. Invasive cell lines are not able to form a well-organised epithelial 
monolayer. 
Desmoplakin is arranged in desmosomal-like junctions at the cell periphery of HT29 
cells with plectin localising to the cell periphery and cell junctions (Figure 4.5A). The 
above finding is supported by the previous work that found plectin to be closely 
associated with the desmosomal plaques in Madin-Darby canine kidney (MDCK) 
cells, (Eger et al., 1997). Desmoplakin was found to be highly expressed in the SW948 
cell line (Figure 4.2) compared to the other carcinoma cells, this result is also mirrored 
in immunofluorescence (Figure 4.5B). The SW948 cells were observed to grow in 
multilayered colonies formed around three days after passaging the cells. The cells in 
this arrangement are tightly packed and form dense desmosome-like junctions, evident 
from the elevated desmoplakin expression at the cell junctions (Figure 4.5B arrow 
head). Interestingly, the invasive SW480 cells were observed to form some epithelial-
like islands with desmoplakin decorating cell borders (Figure 4.5C arrowhead). 
However, the majority of cells formed a disarranged monolayer of cells with sparse 
desmosomal-like adhesions and low desmoplakin expression. Furthermore, high-
resolution confocal images of HT29 cells showed that desmoplakin is located to cell-
cell contacts as dense cytoplasmic plaques (Figure 4.5D). This finding correlates with 
previous work that has shown desmoplakin-containing fluorescent bright dots 
associated with keratin IF in the cytoplasm of cells grown in low calcium conditions. 
The authors interpreted these "dots" as desmosome precursors that translocate to the 
membrane to assemble the plaque (Jones et al., 1985). More recently, live cell imaging 
experiments utilizing GFP-tagged forms of desmoplakin demonstrate the translocation 
of non-membrane bound cytoplasmic desmoplakin-containing dots to sites of 
desmosome assembly (Godse} et al., 2005). Interestingly, plectin is seen to colocalise 
to the cell junction but not specifically with the desmoplakin dots in the HT29 cells, 
speculating that plectin is not involved in desmosomal assembly but can localise to 
desmosomes at later stages. 
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Figure 4.5. Desmoplakin and plectin immunofluorescence in colon carcinoma 
cells. 
(A) Desmoplakin expressiOn m HT29 cells decorating cell borders with plectin 
localised to the cytoplasm and at the cell periphery (scale bar 50 ~-tm). (B) 
Desmoplakin and plectin expression in a colony of SW948 cells, arrow points to 
desmoplakin and plectin localisation at cell borders and arrow head points to tightly 
packed cells in the centre of the colony with desmoplakin decorating cell borders 
(scale bar 20 ~-tm). (C) SW480 cells with occasional epithelial islands (arrow head) 
with desmoplakin localising to desmosome-like adhesions (scale bar 20 11m. Note 
plectin expression localising more to the cytoplasm and in perinuclear areas in SW480 
cells compared to the lower grade HT29. (D) A larger resolution of the cell-cell 
junctions between HT29 cells with high expression of desmosome-like plaque areas, 
plectin is also localised at cell-cell contacts (arrow) along with expression at the cell 
periphery and in the cytoplasm (scale bar 20 ~-tm). 
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4.2.6. Plectin co-localised with the actin cytoskeleton in cancer cell lines. 
In the HT29 cells, that have a rounded morphology with small cytoplasm, the actin 
cytoskeleton is arranged at the cell periphery with thick bundles of fibers. The 
arrangement of plectin in the HT29 cells was found to interact primarily with 
intermediate filament network (as seen in Figure 4.3A) with partial actin co-
localisation at the cell periphery (Figure 4.6A). Immunofluorescence analysis of 
SW948 cells show that within the multilayered cell colony, there is an elevated actin 
expression in the central cells, where the tightly packed filaments cannot be resolved 
with confocal microscopy. The cells at the edge of the colony show peripheral co-
localisation of actin and plectin (Figure 4.6B). The invasive SW480 cell line has a tight 
basket actin network around the nucleus similar to that observed with vimentin. Figure 
4.4C shows a section through the middle of SW480 cells showing plectin and actin co-
localising in thick actin bundles, plectin can also be observed to localise to the fine 
actin meshwork at the leading edge of the cell (arrow). Further investigation of 
actively migrating SW480 cells revealed a third type of co-localisation of actin and 
plectin in round adhesion foci. These structures, which are investigated in Chapters 5 
and 6, were abundant in scratch wound edge cells but rarely seen in resting cells of 
SW480 monolayer. In the T84 cells actin is localised to the cell periphery in long 
stress fibres and also elevated at the perinuclear region, actin plectin expression in 
these cells is not defined (Figure 4.6 D). The invasive MDA-MD-231 cells show 
expression of actin and plectin that is localised in the cells similar to the SW480 colon 
cancer cells. However, actin is arranged into more pronounced stress fibres in these 
cells (Figure 4.6E). These results show that plectin is able to colocalise with the actin 
cytoskeleton in carcinoma cells and it can suggested that the more invasive cell lines 
have more pronounced co-localisation of actin and plectin than the non-invasive cells 
and this may have a bearing on the migratory potential of these cells. Further 
elucidation of the role of the alternative N-terminal isoforms have on the localisation 
of plectin to actin will be investigated using GFP expressing alternative plectin N-
tenninal domains fused to a GFP tag and by isofonn specific antibodies. 
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Figure 4.6. F -actin sub-cellular localisation in carcinoma cells. 
Confocal single plane images of carcinoma cells showing F -actin (phalloidin staining) 
expression co-stained with plectin. (A) Thick actin bundles localise at the cell 
periphery of HT29 cells, with plectin co-localising at actin bundles (arrowhead). The 
arrow points to actin cytoskeleton extensions co-localising with plectin. (B) Colony of 
SW948 with high expression ofF-actin in the cells located in the central of the colony, 
arrow shows actin and plectin co-localisation at cell periphery of cells of the outer 
layers of the colony. (C) SW480 cells with thick actin bundles co-localising with 
plectin, arrow shows co-localisation of filaments. (D) T84 cells expressing actin and 
plectin, note a plectin cytoskeleton networks are not defended in these spindle shaped 
cells. Actin is expressed perinuclear and at the cell periphery. (E) Stress fibres are 
visible in MDA-MB-231 cells throughout the cytoplasm with thick actin bundles at the 
periphery and plectin is localised as a network in the cytoplasm in this case. Scale bars 
indicate 20f.lm. 
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4.2.7. Expression of eGFP-tagged alternative plectin actin-binding domains in 
stable cell lines. 
Alternative N-termini of the human plectin gene, including the actin-binding domain to 
exon 8, were tagged with C-terminal eGFP and transfected into SW480 cells (Figure 
4. 7 A). Stable cell lines for each isoform were established using antibiotic selection 
(refer to Section 2.4.4) in order to obtain cultures of constitutively expressing N-
terminal isoform-GFP protein. Due to the heterogeneous nature of the SW480 cell line, 
it was decided that stably selected mixed clones would be used, as single cell clones 
gave cultures of variable phenotypes that were difficult to compare. Use the 
heterogeneous cell lines allowed for a wide spectrum of subcellular localisation of the 
N-terminal GFP constructs to be validated. It should be noted that the short N-terminal 
constructs lack the C-terminal intermediate filament binding domain of plectin that can 
play a role in the localisation of the protein. However, the aim of these experiments 
was to investigate the effect the N-terminal exons have on localisation of plectin to 
actin-rich structures. The immunoblot (Figure 4.7B) shows the expression of GFP 
constructs in stable selected cells. Lane one shows the control cell line expressing GFP 
alone with a band at the expected size of 27 kDa. Plec-1-eGFP is seen as a higher 
molecular weight band compared to the other isoforms as expected. Note that the GFP-
antibody used also recognised non-specific proteins in every lane and a star denotes 
the specific protein bands. Expression of the construct plec-1 a-eGFP was not visible in 
transient transfections and no stable cell line could be established in these cells, 
although the cloned sequence was confirmed as correct using BLAST (NCBI) and the 
GFP-tag was in frame with the A TG start site. 
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Figure 4. 7. Expression of eGFP-tagged plectin N-terminal isoforms. 
(A) Plectin alternative N-terminal exon-eGFP construct used to investigate how the 
alternative N-terminal exons targets the actin-binding domain ofplectin in SW480 cells. 
Purple oval, N-terminus encoded by the alternative first exon. Red oval, calponin-
homology actin binding domain. Green star, enhanced Green Fluorescent Protein. (B) 
Immunoblot showing the expression of the eGFP-tagged plectin N-terminal isoforms in 
stable transfected SW480 cells detected by an anti-GFP antibody. Note that some of the 
non-specific bands are close to the correct bands that are indicated by * marks. Control 
lane is eGFP alone. In the composite image one lane has been cut out between isoform 
1 and 1 b. 
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4.2.8. Alternative first exons target plectin actin binding domains to unique 
cytoskeletal structures. 
Confocal microscopy was used to investigate the sub-cellular localisation of the 
alternative N-terminal plectin-GFP proteins. As expected, due to expression of only 
the actin-binding domain, these isoforms localised with sub-cellular actin structures. 
Differences in the subcellular and cytoskeletal localisation were observed with the 
alternative plectin isoforms similar to those found in the mouse (Rezniczek et al., 
2003). For example, plectin-1 was found to be localised to actin microspikes and in the 
nucleus, plectin-I b to mitochondria and focal adhesions, 1 c to actin stress fibres, I d to 
adhesion like plaques and in the nucleus, I e to focal adhesions and stress fibers, 1 f to 
focal adhesion sites at the ends of stress fibers and focal complexes in lamellipodia and 
filopodia and finally I g in membrane ruffles of lamellipodia (Figure 4.8). The novel 
isoform plectin-I k was shown to localise to dorsal ruffles and focal adhesion-like foci 
(Figure 6.5) that were later recognised as podosome-type adhesions (Chapter six). It 
was noted, that although the alternative isoforms had a preferential sub-cellular 
localisation these were not mutually exclusive as most of the N-terminal-GFP 
constructs (with the exception of 1 b) could localise to the podosome like adhesion 
plaques. Three independent transfection experiments in SW480 cells were carried out 
and the localisation of the isoforms to podosome-like adhesions, membrane ruffles, 
focal adhesion sites, and thick actin stress fibres and finally to the nucleus was scored 
(summarised in Table 4.1 ). Additional images can be found in appendix III providing 
detailed sub-cellular expression using deconvoluted single plane images (Delta Vision 
60x lens) of the N-terminal plectin-GFP proteins in the SW480 cells. In summary, 
these results reveal that human plectin N-terminal have the potential to influence 
isofonn localisation as previously identified for the mouse alternative isoforms 
(Rezniczek et al., 2003). 
4.2.9. Plectin-lb GFP colocalised with a transfected mitochondrial marker. 
Plectin has previously been found to link desmin intermediate filaments to 
mitochondria at Z-disc in muscle (Reipert et al., I999). Furthermore, an EBS-MD 
mutation in plectin close to the intennediate filament-binding domain was shown to 
cause severe mitochondrial dysfunction (Schroder et al., 2002). Appaix et al., 2003, 
showed that cytoskeletal proteins participate in the intracellular organization and 
control of mitochondrial function in vivo, where mitochondria are incorporated into 
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functional complexes with sarcomeres and sarcoplasmic reticulum. Interestingly, the 
mouse isoform plectin-1 b has been described as the specific isoform that can localise 
to mitochondria (Rezniczek et al., 2003) and possibly link to desmin intermediate 
filaments. To confirm the above finding in human cells, SW480 cells were double 
transfected with pDsRed2-Mito vector (BD biosciences UK), containing a 
mitochondrial targeting sequence of human cytochrome c oxidase subunit VIII and 
plec-1 B-eGFP. Plectin-1 b-eGFP was found to co-localise with the transfected 
mitochondrial target sequence expressed protein (Figure 4.9). The mitochondria are 
rod shaped concentrated around the nucleus extending through the cytoplasm, plec-1 b-
eGFP can be seen to be expressed around these structures confinning the similarities to 
mouse plectin-1 b (Rezniczek et al., 2003 ). These results further demonstrate the 
complexity of the N-terminal exons on sub-cellular localisation and that each isoforms 
could harbour a specific function. 
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Figure 4.8. Subcellular localisation of alternative plectin N-terminal domains. 
Representative examples of co-localisation of GFP fluorescence and actin cytoskeleton 
(red, phalloidin staining) in SW480 cells transfected with the indicated constructs. 
Plec-1 and plec-1 g are single plane Delta Vision images, whilst the remaining images 
are single plane Zeiss confocal images. Note co-localisation of plectin with actin at 
focal adhesions and stress fibres. Scale bars represent 20 J..Lm. 
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Figure 4.9. Co-localisation of plec-lb-GFP and mitochondria. 
Confocal single plane image of SW480 cells transfected with cytochrome-c 
(component of mitochondra) and plec-1 b-GFP constructs. Arrows show co-
localisation of mitochondria with plec-1 b-GFP. Scale bar 20 ~m. 
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Table 4.1. 
Summary of subcellular localisations of alternative plectin N-terminal eGFP 
constructs. 
Isoform Podosomes Membrane Focal Thick actin Nucleus 
ruffles Adhesions stress fibres 
++ + 
IB* + 
IC +I- + + 
ID ++ + 
IE +I- + ++ + 
IF +I- + + + 
IG +I- ++ +I-
IK ++ + +I-
The table summarises observations from three independent transfection experiments. 
All indicated GFP-positive structures for each construct were not usually present in the 
same cells. ( ++) Major subcellular target in most transfected cells in all experiments. 
( +) Localisation seen in several cells in all transfection experiments. ( +/-) Localisation 
seen only in a small number of cells. (-) Localisation not detected. 
*Note, that majority ofPlec-1 b was localised at mitochondria. 
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4.2.10. Investigation of the human plectin isoforms using polyclonal antibodies 
raised to plectin isoforms 1, 1 b, lf, 1k. 
To investigate the plectin alternative isoform proteins further, two polyclonal 
antibodies for each of plectin-1, -1 b, -If and -1 k (named LM 1-LM8 respectively) were 
raised to synthetic peptides corresponding to amino acids in each of the alternative first 
exons (Table 2.6). These isoforms were selected due to their interesting specific 
localisation as seen in the GFP transfection experiments with plec-1-eGFP localising 
to microspikes and the nucleus, plec-1 b-eGFP to mitochondria and focal adhesions, 
plec-1 f-eGFP also to focal adhesions and membrane ruffles and the novel isoform 
plec-lk-eGFP localising to podosome like structures. The antibodies were first 
characterised by immunoblotting to determine that they were specific for the isoform 
they were raised to. 
4.2.11. Polyclonal plectin isoform antibodies recognise full-length plectin. 
The antibodies recognise a band corresponding to a 500-kDa polypeptide m 
immunoblots of both SW480 colon carcinoma and MDA-MB-231 breast carcinoma 
cells (Figure 4.1 0). Plectin C-terminal antibody ( c-20) was used as a positive control 
and High Molecular weight ladder from Invitrogen UK confirmed the 500-kDa sizes. 
This is the expected size of full-length plectin as, for example, mouse plectin isoforms 
have deduced range of molecular mass from 499 to 533 kDa (Rezniczek et al., 2003). 
The antibodies LM6 and LM8 recognised single clean protein bands on a gradient gel. 
LM2 antibody is more specific than LM I with LM I recognising an additional band at 
~I 00 kDa. Antibodies LM3 antibody recognised a weak band at 500 kDa in the 
carcinoma cell lines but LM4 did not bind to 500 kDa proteins. Using a cell extract 
from BHK21 cells that express desmin, vimentin and keratin intermediate filaments 
(Schroder et al., 2003), LM3 recognised a strongly positive 500-kDa band, so it may 
be that expression of plectin-1 b is low in the epithelial carcinoma cells. Subsequent 
immunoblots using lower dilutions of the antibodies resolved the non-specific binding 
seen for LM2 and LM7; however LMI and LM5 continued to show non-specific bands 
and therefore would be unreliable for immunofluorescence or immunoprecipitation 
studies. 
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4.2.12. The specificity of plectin N-terminal human antibodies was further 
supported by siRNA transfection experiments with total plectin. 
The peptide competition assay is the traditional method of determining specificity of 
polyclonal antibodies as described in section 2.9.2. However, after trial of this method 
it was found that use of a siRNA method, as described in section 2.9.2, was much more 
convincing. Depletion of all plectin isoforms in SW480 cells by siRNA transfection 
abolished the 500 kDa band both when LM 2,5,6,7,8 or a control antibody against 
plectin C-terminus (c-20) was used for immunoblotting, whereas the 500 kDa protein 
band was still present when the cells were transfected with a scrambled control siRNA 
(Fig. 4.11 ). These results confirm the specificity of the N-terminal plectin isoform 
antibodies. Note the LM3 specificity could not be evaluated in this assay due to low 
expression levels of this isoform in the plectin positive sample. 
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Figure 4.10. Detection of plectin-1, 1b, 1f and 1k with polyclonal antibodies. 
Immunoblots of total cell extracts using plectin polyclonal antibodies recognising ~500 
kDa band in SW480 (1) and MBA-MD-231 cells (2) or BHK21 cells (3). (A) LMI and 
LM2 rabbit polyclonal anti-peptide antibody against exon 1. (B) LM3 and LM4 rabbit 
polyclonal anti-peptide antibody against exon 1 b. (C) LM3 rabbit polyclonal anti-
peptide antibody against exon I b in BHK21 cells. (D) LM5 and LM6 rabbit polyclonal 
anti-peptide antibody against exon 1 f. (E) LM7 and LM8 rabbit polyclonal anti-peptide 
antibody against exon lk. (D) Positive control, c-20, goat polyclonal anti-peptide 
antibody against total plectin. 
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Figure 4.11. Conformation of the specificity ofpolyclonal antibodies using siRNA. 
Plectin knock-down by siRNA transfection in SW480 cells ablates the 500 kDa protein 
detected by antibody against exons 1 (LM2), lf(LM5 & LM6) and lk (LM7 & LM8). Total 
plectin antibody against the C-terminus ofplectin common to all isoforms (c-20; top panel) 
shows knockdown of the same 500 kDa band. Vimentin antibody (bottom panel) was used 
to confirm equal loading of plectin siRNA and control scrambled siRNA transfected 
samples in all experiments. 
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4.2.13. Expression of plectin isoforms 1, 1 b, 1f and 1k in cancer cell lines. 
Analysis of plectin isoform expression by immunoblotting revealed an increased 
expression in the invasive SW480 colon carcinoma cells compared to the non-invasive 
HT29 cells (Figure 4.12). Likewise MCF -7 cells had considerably lower expression of 
plectin isoforms compared to invasive MDA-MB-231 cells (Figure 4.12). Plectin-1 
and plectin-1 f were the dominantly expressed isoforms with plectin-1 k expressed at 
extremely low levels in the non-invasive cell lines. Plectin-1 b was detected in these 
extracts as a weak 500 kDa band. It was found that plectin-1 b was constitutively 
expressed at low levels in all the cells, which correlates to the mRNA expression data 
(Figure 3.7). Actin was used as a reference for loading, but again Ponceau Sand BCA 
assay is used to load accurate protein levels for each lane due actin being expressed at 
different levels in these cells. 
4.2.14. Immunofluorescence using isoform specific antibodies in carcinoma cells. 
Immunofluorescence staining of SW480 and MDA-MB-231 cells was used to map the 
sub-cellular localisation of plectin-1, 1 b, 1 f, and 1 k (Figure 4.13 A B C D). Plectin 
isoforms were localised to the perinuclear regions and in a filamentous network in the 
cytoplasm. The antibodies LM1 and LM2 show expression to be localised to a 
cytoplasmic filament network with evidence of adhesion like structures at the cell 
periphery. Although immunoblotting using LM3 and LM4 showed low expression in 
these cells, immunofluorescence data contrast this and displays localisation of plectin-
1 b to focal adhesions along with elevated expression at perinuclear regions. It could be 
that the antibody does not have a high affinity for use in immunoblotting. Antibodies 
LM5 and LM6 could be seen to localise to focal adhesion like structures at the edges 
of migrating cells and finally LM7 and LM8 showed particular localisation to 
podosome-like adhesions in both cell types. Pre-immune serum was used as a negative 
control to confirm the specificity of the antibodies, no specific staining was observed 
in these samples (not shown). These antibodies were shown to correlate with the data 
obtained for the altemative N-tenninal GFP constructs. A more detailed 
characterisation of the sub-cellular localisation and function of the novel isoform 
plectin-1 k will be presented in Chapter 6. In summary, the generation of human 
isoform specific antibodies provides an excellent tool for the further study of the N-
terminal plectin isoform and their binding partners and may lead to better 
understanding of the human plectin protein. 
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Figure 4.12. Expression of plectin isoforms in carcinoma cell lines. 
Immunoblot of colon carcinoma cell lines; HT29 and SW 480, and breast carcinoma cell 
lines; MCF7 and MDA-MB-231, using rabbit polyclonal antibodies for plectin isoforms 
1, lb, If and lk. Total plectin is detected using plectin c-20 antibody and actin is used 
as a loading control. Note the detection of the lower molecular weight rodless isofom 
in plectin-1 and plectin 1-f as well as total plectin. 
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Figure 4.13. Subcellular localisation of plectin alternative first exon isoforms 
using polyclonal antibodies. 
Immunofluorescence staining of SW480 cells and MDA-MB-231 of (A) plectin-1 (B) 
plectin-1 b (C) plectin-lf (D) plectin-1 k staining using both rabbit polyclonal anti-
peptide antibodies against plectin alternative N-terminal isoforms. Alexa Fluor 488 
(Invitrogen UK) anti-rabbit is used as the secondary antibody. Note expression at cell 
periphery and filamentous network throughout the cytoplasm. Scale bars represent 50 
f..tm for all panels. 
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4.3. Discussion. 
To study the role of plectin in the invasive potential of cancer we used a panel of colon 
and breast carcinoma cells, where high-grade colon SW480 and breast MDA-MB-231 
carcinoma cells showed an increased invasive potential in a collagen gel invasion 
assay. Immunoblotting was used to identify possible cytoskeletal and related proteins 
that could play a role in the invasive potential. Surprisingly, plectin protein expression 
showed a marked increase in the more invasive cell lines, including also the cell line 
derived from colon metastasis to the lung (T84). Plectin, a cytoskeletal linker protein, 
is viewed traditionally as a hemidesmosomal protein involved in skin architecture and 
also in muscle where it predominantly resides at the Z-lines of striated muscles, dense 
plaques of smooth muscle cells and intercalated discs of cardiac muscles (Leung et al., 
2002). However, it has never before been studied in depth in cancer. Other plakin 
family members have been studied in relation to cancer progression namely 
desmoplakin where a reduction in desmosomes associated with invasive behaviour. 
Previously, Alroy et al., 1981, and Davies et al., 1999, suggested that a loss of 
desmoplakin in breast cancer is likely to be important in the progression and metastasis 
of breast cancer. In the carcinoma panel presented here desmoplakin protein 
expression is also reduced in the higher-grade carcinoma cells correlating with the 
widely held view that decrease of cell-to-cell adhesion is associated with metastatic 
ability of cancer cells (Depondt et al., 1999 and Bankfalvi et al., 2002). Of interest, 
periplakin, vinculin, HSP27, talin, E-cadherin, keratin and vimentin expression were 
all altered in the carcinoma cell panel; with exception of periplakin, all these proteins 
have been widely studied in cancer cell progression showing altered expression levels 
(refer to previous references in Section 4.2.3). Loss of E-cadherin and its associated 
proteins a-catenin and P-catenin has been found in a wide range of cancers and 
correlates with increased metastatic potential (reviewed by Birchmeier et al., 1995 and 
Bosch et al., 2004). Vimentin is of particular interest as previous studies have found 
that in epithelial to mesenchymal transition, the intermediate filament cytoskeleton of 
epithelial carcinoma cells changes from a keratin-rich network, which connects to 
desmosomes and hemidesmosomes, to a vimentin-rich network connecting to focal 
adhesions (reviewed by Kokkinos et al., 2007), this will be visited in Chapter 5. 
The characterisation of expression levels of these proteins will help to fully understand 
the role plectin plays in invasion and migration of the carcinoma cells in the chapters 
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to follow. These results indicate that the expression of cytoskeletal and related proteins 
may have a role in the invasive potential of these cell lines and could be implicated in 
the progression of cancer. 
When the subcellular localisation of plectin was investigated in the invasive carcinoma 
cells, it was observed using an antibody for total plectin ( c-20) the protein was 
recruited away from the hemidesmosomes and cell periphery as seen in the low 
invasive HT29 and MCF7 cells and localised in a dense actinlvimentin cage around the 
nucleus in the high invasive SW480 and MDA-MB-231 cell lines. Intriguingly, the 
observations also suggested that in the low invasive carcinoma cells plectin associated 
with mainly the intermediate filament cytoskeleton, whereas in the invasive cell lines 
plectin was associated more with the actin cytoskeleton. 
To further investigate the localisation of plectin to the actin cytoskeleton and also the 
effect the plectin N-terminal isoforms have on recruitment of the protein to specific 
actin structures, Human plectin N-terminal sequences including the actin binding 
domains from the nine identified human isoforms were cloned into GFP expressing 
vector. The previous study on the murine alternative isoforms showed the alternative 
N-terminal exons yielded an effect on the sub-cellular localisation of plectin 
(Rezniczek et al., 2003 ). In the study the authors found plectin-1 to be localised in the 
nucleus and weakly throughout cells with faint staining of actin stress fibers in which 
they suggest that exon 1 contains a putative nuclear localization signal. Isoforms plec-
1 a, 1 c, 1 d, 1 e and 1 g decorated actin stress fibers, although less so in the case of 
plectin 1 d. Plectin-1 b was concentrated at the perinuclear region encasing 
mitochondria. Plectin-1 f was concentrated at stress fiber ends and at the cell periphery 
concentrated in vinculin-positive structures. These results were similar to the sub-
cellular localisations observed for the human N-terminal exons (Figure 4.8 and Table 
4.1) in the SW 480 colon carcinoma cell lines. However, isofonns 1 f, l d and 
specifically 1 k also localised to actin rich foci at the cell periphery that are later 
identified as podosomes (Chapter 6). The identification of plectin N-terminal isoforms 
that localise to migratory actin structures or actin stress fibers may provide a 
mechanism through which cancer cells could modulate adhesion migration and 
invasion by regulating expression of plectin isoforms. 
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The probability that full-length plectin isoform proteins may have a different sub-
cellular localisation than the N-terminal GFP constructs in the carcinoma cells was 
recognised. This was observed previously in the murine plectin isoforms where the 
full-length proteins expressed in mouse keratinocytes showed plectin-1, unlike the N-
terminal domain of the same protein, to be distributed throughout the cytosol with 
punctuated diffuse staining, but not in the nucleus. Additionally, only the full-length 
plectin-1 a was concentrated in patchy structures that were suggested to be 
hemidesmosomes (Rezniczek et al., 2003). Thus, expression of full-length human 
plectin isoforms was investigated in the carcinoma cells by using polyclonal antibodies 
raised to plectin-1 1b lfand 1k. 
To start with, the relative expression levels of these isoforms were investigated using 
immunoblotting to identify if any of the four isoforms contributed to the increased 
expression observed in total plectin (Figure 4.12). The results show that plectin-1 and 
plectin-1 fare strongly expressed in the carcinoma cells and upregulated in the more 
invasive cells. This is interesting considering that plectin-1 is the isoform prominently 
expressed in cells of mesenchymal origin (Fuchs et al., 1999) and ablation of this 
isoform caused reduced migration of T -lymphocytes and murine dermal fibroblasts 
(Abrahamsberg et al., 2005). Moreover, plectin-1 f is localised to focal adhesion 
structures rather than hemidesmosomes (Rezniczek et al., 2003 ). Plectin-1 b was 
constitutively expressed in these cell lines. Most interestingly, the novel isoform 
plectin-1 k was expressed at significantly lower levels in the low-grade carcinoma cells 
than in SW480 and MDA-MB-231 cells, indicating the potential of plectin-1k to 
participate in cancer cell invasion. 
In some cell lines two high-molecular weight proteins were detected using plectin 
antibodies. It is possible that the lower band observed in immunoblotting using the C-
terminal plectin antibody could be the rodless plectin splice variant which lacks exon 
31 (Elliott et al., 1997). The lower protein migrates at the expected size of 390 kDa 
(Steinboeck et al., 2005) and is depleted in a protein extract from plectin siRNA 
transfected cells. Interestingly, the lower band is more prevalent in the MDA-MB-231 
cells and a corresponding band is expressed at lower levels within the carcinoma cell 
panel (Figure 4.2). Plectin-1 and 1 f show positive expression of the lower band 
however plectin 1 b and 1 k do not. Previously ex on 1 c was identified as the first coding 
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exon of the rodless isoform in neuronal tissues (Steinboeck et al., 2005 and Fuchs et 
al., 2005). My results show that plectin-1 and 1 f could possibly also code for the 
rodless domain. 
Immunofluorescence in SW480 and MDA-MB-231 carcinoma cells, using isoform 
specific antibodies, demonstrates similar subcellular localisations as observed 
previously in murine keratinocytes (Rezniczek et al., 2003) and the human plectin GFP 
fusion proteins. Plectin-1 (antibodies LMl and LM2) was expressed in a filamentous 
network around the nucleus, not in the nucleus and also at punctuated structures in the 
cytoplasm and at cell periphery. Plectin-1b (antibodies LM3 and LM4) showed 
localisation around the perinuclear area and to focal adhesions. Plectin-1 f (LM5/LM6) 
was targeted to a filamentous network and at focal adhesions. Finally, the novel 
isoform, plectin 1 k, was expressed at adhesion like foci at the basal surface of the cells 
and in the perinuclear cage around the nucleus (Figure 4.13). The sub-cellular 
localisation of plectin in the vimentin and actin-rich cage encasing the nucleus in the 
invasive colon and breast carcinoma cell lines is of interest as the mechanisms that 
maintain the nucleus in its proper position in the cell is not yet fully understood 
(Wilhelmsen et al., 2005). The expression of plectin in Sertoli cells was also observed 
to concentrate at the nuclear surface, suggested to link intermediate filaments centrally 
to the nucleus (Guttman et al., 1999). Importantly, the identification of nesprin-3 an 
outer nuclear membrane protein that binds to plectin and the demonstration that over 
expression results in a dramatic recruitment of plectin to the nuclear perimeter further 
adds to the versatility of plectin (Wilhelmsen et al., 2005). 
There is an increasing interest in the function of up regulation of alternatively spliced 
plectin isoforms. Plectin is expressed at Z-disks and sarcolemma in skeletal muscle 
and the alternative plectin isoforms show differential regulation during myotube 
differentiation. It has been shown that plectin-1 and 1 f an associate with the 
sarcolemma whereas plectin-1 d localises exclusively to Z-disks (Rezniczek et al., 
2007). In epidermal keratinocytes, isoforms plectin-1 a and 1 c were shown to interact 
with integrin p4, with isoform 1 a suggested to be important for regulating the affinity 
of the ABD for P4 and F-actin (Litjens et al., 2003). A subsequent study found that 
only the full-length isoform 1a, but not plectin-lc or 1, could restore hemidesmosomal 
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contacts in plectin deficient keratinocytes. These data suggest that plectin-1 a is the 
isoform responsible for skin blistering in plectin related diseases (Andra et al., 2003). 
Plectin has been shown to interact with another plakin family member periplakin 
(Boczonadi et al., 2007) and this study shows that periplakin is upregulated in the more 
invasive cell types along with periplakin. In addition, immunofluorescence of mouse 
skin show plectin-1 staining to be low in the suprabasal layers, however both plectin-1 f 
and I k were present at the cell borders of differentiated epidermal cell layers similar to 
periplakin staining. Thus, it appears that only a subset of plectin splice isoforms co-
localise with periplakin in differentiated epidermal keratinocytes in granular and 
cornified cell layers (Boczonadi et al., 2007). 
To summarise it was demonstrated that higher-grade invasive carcinoma cells had a 
elevated expression of plectin protein along with periplakin and down regulation of 
desmoplakin implicating the plakin family members as possible modulators of cell 
migration and cancer progression. I also found that plectin is located away from 
hemidesmosomal plaques and intermediate filaments in the invasive carcinomas and 
shows a predominant expression in actin rich structures. Investigation of short plectin 
N-terminal GFP fusion proteins demonstrate the localisation of these isoforms at 
specific actin migratory structures and suggest that regulation of the plectin N-terminal 
isoforms could contribute to carcinoma cell migration. Polyclonal antibodies raised to 
four of the nine human plectin isoforms support the GFP data and show upregulation 
of isoforms I, If and I k but not I b in the carcinoma cell lines. This study provides 
fundamental research on human plectin isoform expression including the expression 
cancer cells that could lead to a better understanding of the full versatility of this 
complex protein. 
125 
CHAPTERS 
ROLE OF PLECTIN AND VIMENTIN IN 
INVASION AND MIGRATION OF 
CARC:n:NOMA CELLS. 
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5.1. Introduction. 
Over 90% of human tumours are carcinomas where transformed epithelial cells grow 
uncontrollably, breaking though through the basement membrane and invading the 
underlying mesenchyme. Moreover, the metastatic spread of tumour cells to distant 
organs via haematogenous routes represents the most important cause of morbidity and 
mortality in cancer (Chambers et al., 2002). Carcinomas are characterised by invasion 
of malignant cells into the underlying connective tissue and migration of malignant 
cells to form metastases at distal sites (Lyons et al., 2007). Cell migration is a highly 
complex and integrated process that involves the assembly and disassembly of 
adhesions initiated by signalling transduction pathways orchestrating the cytoskeleton. 
Plectin, a cytoskeletal linker protein and more recently as a recognised scaffolding 
protein for signal transduction pathways, was found to be up regulated in the more 
invasive cell lines that also express vimentin (Figure 4.2). 
Ongoing elucidation of molecular interactions of vimentin gives clues of the potential 
functions of vimentin in migration and invasion. Unlike keratin intermediate filaments 
that are connected to cellular junctions promoting adherence and tissue integrity, 
hemidesmosomes and desmosomes, vimentin can be localised with transient, actin-rich 
adhesion sites that play a role in cell migration. For example, in macrophages vimentin 
co-localises with fimbrin (T-plastin) in podosomes (Corriea et al., 1999) whereas in 
endothelial cells, vimentin filaments associate with av~3-positive focal contacts. 
Finally, vimentin is phosphorylated by PKC£ on vesicles that recycle ~1 integrins in 
mouse embryonic fibroblasts and expression of mutant vimentin harbouring PKC 
targets that are replaced with phosphomimetic amino acid residues results in a rescue 
of cell migration in PKC£ null cells (Ivaska et al., 1999). The recently recognised role 
for vimentin in the recycling of integrin heterodimers (Ivaska et al., 2005) and reports 
demonstrating requirement of vimentin for focal adhesion complex stability in 
endothelial cells (Tsuruta et al., 2003) prompted the investigation into the 
consequences of vimentin ablation on cell-matrix adhesion. Intriguingly, the 
expression of vimentin in breast cancer cells has been shown to be downstream of 
several signalling proteins implicated in carcinogenesis. Smad-interacting protein 1 
(SIP 1 ), a transcription factor implicated in epithelia-mesenchymal transition, up-
regulates vimentin expression (Bindels et al., 2006). Likewise, ~-Catenin/TCF 
complex can directly transactivate the vimentin promoter (Gilles et al., 2003). Finally, 
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over-expression of tiam-1, a guanine nucleotide exchange factor (GEF), results in an 
increased invasiveness and vimentin expression in colon carcinoma cells (Minard et 
al., 2006). However, none of the above studies have conclusively established, whether 
vimentin expression is only a marker of epithelial-mesenchymal transition (EMT) -
like changes or if vimentin expression is required for the invasive behaviour of the 
cells. 
The role of plectin in the migration of keratinocytes and fibroblast has recently been 
investigated. It has been shown that depletion of plectin (Andra et al., 1998), or 
plectin-1 isoform only (Abrahamsberg et al., 2005) leads to impaired migration of 
fibroblasts. However, plectin-null keratinocytes migrate faster than their wild-type 
counterparts (Osmanagic-Myers et al., 2006). In contrast to that ablation of plectin 
caused impaired migration of MCF-7 epithelial sheets (Boczonadi et al., 2007). The 
a6~4 integrin, a direct interacting partner of plectin, has been implicated in carcinoma 
cell invasion and migration. Increased suprabasal expression of a6~4 integrins 
correlated with poor prognosis in both mouse and human squamous cell carcinomas 
(Tennenbaum et al., 1993 and Van Waes et al., 1995). Furthermore, a6P4 is relocated 
from hemidesmosomes to actin rich protrusions in invasive carcinomas (Rabinovitz et 
al., 1999). This integrin also has a significant impact on cell signalling pathways that 
are involved in cell migration and invasion, especially PI3-K, Rho GTPase (Mercurio 
et al., 2001). A recent study has also shown that in p53-deficient cells, a6P3 can 
mediate a tumour-suppressive effect, dependant on its ability to recruit plectin to the 
plasma membrane (Raymond et al., 2007). 
Although plectin has been well characterised for its role as a hemidesmosomal plaque 
protein, a link has also been shown for plectin at vimentin positive focal adhesions 
(Gonzales et al., 2001). In this chapter the effect plectin and vimentin ablation has on 
migration, invasion and attachment in colon and breast carcinoma cell lines will be 
addressed. In this chapter a summary of cancer cell migration is given with the results 
section following. 
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5.1.1. Cell migration. 
Cell migration is important in many processes including embryogenesis, inflammation, 
tissue repair and regeneration, and cancer (Webb et al., 2002). A key event of 
migration involves the reorganisation of actin dynamics controlled by a large number 
of effectors. The small GTPases of the Rho family (Rho, Rae and Cdc42) are essential 
for both cell motility and cell-cell adhesion (Braga et al., 2000). Rae is required for 
new adhesions at the cell front and Rho is required for the maturation of existing 
contacts and disassembly of adhesions at the rear of cells and its effecter Rho kinase 
promotes retraction of the tail by altering integrin nature (Kiosses et al., 1999; Chung 
et al., 1999). Increased motility and invasiveness is often associated with decreased 
cell adhesion, degradation of basement membranes and stroma, and enhanced growth 
of tumour cells (Grille et al., 2003). Thus, understanding cell migration and adhesion 
could lead to new therapeutic designs for various diseases. 
5.1.1.1. Modes of cell migration. 
Three distinct modes of cell migration have been described: amoeboid, mesenchymal 
and collective migration (Figure 5.1 ). Amoeboid movement is described in certain 
tumour cells that use fast crawling movement with weak substrate interactions. 
Mesenchymal cells on the other hand follow a series of events. First, cell polarisation 
and protrusion of actin structures such as pseudopodia, lamellipodia, next, the 
formation of adhesions to the extra cellular matrix, mediated by integrins at focal 
adhesions and podosomes with the recruitment of surface proteases such as MMPs that 
are thought to widen scaffolds. During this, actin engages with contractile proteins 
myosin and local cell contractions occur with disassembly of contacts at the rear 
(Friedl, 2004). In collective migration cells maintain contact at adherence junctions 
through cadherins and cortical actin reinforces collective integrity. At the leading edge 
the cells utilise actin mediated ruffles and integrins and drag adhering cells along 
established tracks. This movement is important in wound healing, and also in primary 
cancers, clusters of cells can disseminate though connective tissue (Perez-Moreno et 
al., 2003; Farooqui et al., 2005). 
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5.1.1.2. Cell-matrix attachments. 
Focal adhesions are the main adhesive structures that are involved in cell-matrix 
attachment, consisting of a transmembrane component of clustering integrin molecules 
linked to the matrix, and a sub-membranous component made by complex of specific 
proteins such as vinculin, talin, focal adhesion kinase (Vasiliev et al., 2004). The 
definition of focal adhesions is often confused. Wozniak et al., 2004 defines four 
different structures focal complexes, focal adhesions, fibrillar adhesion and 3D matrix 
adhesions. Focal complexes are small focal adhesions at the periphery of spreading or 
migrating cells regulated by Rae and Cdc42 and that precede larger focal adhesions 
that are regulated by Rho activity (Wozniak et al., 2004). Under tension the small 
adhesions can mature into larger more organized adhesions called focal adhesions 
(Webb et al., 2002). Tyrosine phosphorylation is also an important signalling event 
and regulates focal adhesions; vinculin, focal adhesion kinase (F AK) and paxillin are 
all recruited to the complex preceding tyrosine phosphorylation (Kirchener et al., 
2003). Focal adhesions mediated adhesion links to the actin cytoskeleton via integrins 
and proteoglycans (Wozniak et al., 2004) and are usually found associated with the 
ends of stress fibers, but it's not yet clear which components of a focal complex 
distinguish it from a focal adhesion (Zamir et al., 2001 ). Fibrillar adhesions form as an 
elongation of focal adhesions containing a5p 1 integrin and tensin (Pankov et al., 
2000). The final adhesion arises from studies showing that cells form 30 matrix 
adhesions that are not the same as their 20 counterparts, suggesting that these different 
focal adhesions can alter signalling events to regulate cell behaviour and phenotype 
(reviewed in Wozniak et al., 2004). 
5.1.1.3. Integrins. 
Integrins are transmembrane glycoproteins that mediate cell adhesion to extracellular 
matrix components such as laminin, collagens, fibronectin, and vitonectin (Hynes, 
2002). They form heterodimeric receptors in a non-covalent association that comprise 
of one a subunit and one P subunit. Eighteen a and eight p subunits combine with a 
partial overlap to form 24 integrins (Hynes, 2002; Guo et al., 2004). Integrins are 
mainly found coupled to actin cytoskeleton with the exception of the integrin a6p4, 
and aVp3, which is linked to the intermediate filament cytoskeleton (as described in 
Chapter 1 ). The binding of integrins to their ligands and subsequent integrin-mediated 
cell adhesion is a tightly regulated process, which involves a change in affinity of the 
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receptor for its ligand (Kreis et al., 2005). Receptor binding and clustering of integrin 
at the cell surface appears to be a trigger of events that initiates interactions with 
cytoskeletal components (Yamada et al., 1995). Talin, a cytoskeletal linker protein is 
involved in the activation of integrins (Calderwood et al., 2004; Critchley et al., 2004) 
and in tum the integrins activate focal adhesion kinase (F AK), thus, initiating 
phosphorylation and modulation of signalling cascades such as the Src-family kinases 
(Guo et al., 2004). Vinculin, a binding partner of talin is one of the best-characterised 
focal adhesion proteins and cycles between active and inactive states. The crystal 
structure of vinculin displays an open or closed conformation, where C-terminal tail 
interacts with the N-terminal head masking the ligand binding sites in the closed 
conformation (Bakolitsa et al., 2004). Despite being well characterised, vinculin's 
precise role at focal adhesions is not known, although overexpression has been shown 
to reduce cell migration whereas downregulation can enhance cell motility (Zeigler et 
al., 2006). Altered integrin expression has been reported in many tumours (Lyons et 
al., 2007). Furthermore, there is also evidence that integrin trafficking pathways that 
recycle adhesion components can contribute to cell migration, and that integrin 
deregulation contributes to the pathogenesis of many diseases including cancer 
(Caswell et al., 2006). Therefore, the dynamic regulation of focal adhesion and the 
integrin cytoskeleton associations play a central role in balancing adhesion and 
migratory responses in the cell (Cohen et al., 2006). 
5.1.1.4. Epithelial to mesenchymal transition. 
Epithelial to mesenchymal transition (EMT) with a loss of cell adhesion is seen as an 
important step in cancer progression (Figure 5.2), allowing benign non-invasive 
tumour cells to metastasize (Depondt et al., 1999; Bankfalvi et al., 2002). During 
EMT, cells progressively redistribute or downregulate their apical and basolateral 
epithelial-specific proteins such as E-cadherin, catenins and re-express mesenchymal 
molecules such as vimentin, fibronectin and N-cadherin (Wicki et al., 2006). Several 
studies have also identified a "metastable cell" phenotype (termed defined by Pierre 
Savagner) that is able to express attributes of both epithelial and mesenchymal cells 
(reported in Lee et al., 2006). Vimentin expression is an important marker of EMT 
and could be an important target for drug development in cancer (Reviewed by Lee et 
al., 2006). Loss of E-cadherin by transcriptional repression and its associated proteins 
a-catenin and P-catenin has been found in a wide range of cancers and correlates with 
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increased metastatic potential (reviewed by Birchmeier et al 1995, Bosch et al., 2004; 
Cowin et al., 2005). E-cadherin is a transmembrane protein of the cadherin super-
family and forms cell-cell junctions through homotypic interactions, which results in 
the formation of stable junctions. The cadherin proteins dimerise in a calcium 
dependent manner, triggering ~-catenin linkage to actin leading to the formation of 
stable adherence junctions. The loss of E-cadherin is contrasted with the gain of 
mesenchymal cadherins such as N-cadherin is described as the "cadherin switch" 
(Cavallaro et al., 2002). Interestingly, in human colorectal cancer, cells at the central 
tumour mass display polarised epithelial organisation with junctional localisation of~­
catenin and E-cadherin whereas cells at the invasive front are characterised by a loss of 
cell surface E-cadherin nuclear localisation of ~-catenin (Brabletz et al., 2001 ). 
Interestingly, there are arguments that EMT does not always occur in the progression 
of cancer, as in colon tumours loss of cell adhesion could not be correlated with poor 
prognosis and increase invasion (Bosch et al., 2004). Furthermore, continued 
expression and synthesis of junctional proteins in colon carcinomas was also reported 
supporting this result (Kartenbeck et al., 2005). 
5.1.1.5. Matrix degradation. 
Efficient tumour invasion requires partial degradation and remodelling of the ECM at 
the invasive front (Guo et al., 2004). Increased expression of multiple classes of 
extracellular matrix degrading enzymes are often up regulated and activated in cancer, 
such as the matrix metalloproteinases (MMPs ), serine proteases and cathespins 
(Birkedal-Hansen, 1995; Baker et al., 2006; Impola et al., 2004). MMPs are a family of 
related zinc containing proteases that have the ability to degrade the ECM 
(Brinckerhoff et al., 2002). Fibrillar collagen, the main constituent of the connective 
tissue is degraded by several proteases, including MMP-1, -2, -8 and 13 and membrane 
anchored MT1-MMP, MT3-MMP and cathepsin B, K and L (Wolf et al., 2003). 
Matrix metalloproteinases have been localised to podosomes and invadopodia 
described in Chapter 6, and were found to be involved in matrix degradation (Chen et 
al., 1989 reviewed in Linder, 2007). Fibroblast and tumour cells have been shown to 
tunnel through cross-linked type 1 collagen via a similar process that requires MMP 
activity (Sabeh et al., 2004). Furthennore, the significant role of MMPs in tumour cell 
invasion has led to the development of MMP inhibitory drugs (Lyons et al., 2007) 
highlighting the importance of cell invasion therapies for the treatment of cancer. 
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c 
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Figure 5.1. Modes of cancer cell migration. 
(A) Amoeboid motility involves an irregular cell shape and rapid changes in direction. 
(B) Mesenchymal motility is dependant on substrate attachments with small integrin 
rich contacts at the leading edge where the matrix is degraded. Cells also are 
characterised by an elongated morphology. (C) Cell-cell attachments are retained in 
collective migration where groups of cells can disseminate through tissue. Red lines 
circumference the cells represent thick actin cables and short red lines represent actin 
polymerization at the leading edge. Orange dashes represent adherence junctions. Dark 
green squares are large integrin-rich focal adhesions that connect to the matrix and blue 
dashes are the small focal contacts. Light green lines represent receptors that sense 
chemokines. (Adapted from Sahai, 2005) 
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Epithelial cells metastable cell 
-/Adherence junctions Y"'N-cadherin 
-/Tight junctions V"' Cytokeratin and vimentin 
-/Desmosomes Y"'Sheet movement 
-/ Apico-basal polarity Y"'Membrane extension and 
-/Stationary polarity 
-/Cytokeratins cortical actin Y"'Nuclear P-catenin 
-/E-cadherin V"' Collective groups 
mesenchymal cell 
Y"'No junctions 
Y"'Focal adhesions 
Y"'Motile and invasive 
Y"'Front-back polarity 
Y"'Vimentin expression 
Y"'Fibronectrin 
-/Increase Rho 
Y"'Increase scattering 
Y"'Elongated cell shape 
Y"'Increased MMPs 
Figure 5.2. Summary of epithelial to mesenchymal transition. 
The main characteristics of each cell type including a metastable intermediate that is a 
hybrid cell showing both epithelial and mesenchymal traits (Figure adapted from Lee et 
al., 2006). 
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5.2. Results. 
5.2.1. Transfection of short interfering RNA (siRNA) to down-regulate expression 
of plectin and vimentin proteins. 
Prior to the invasion and migration assays, it was necessary to investigate the 
efficiency of siRNA to knock down protein expression in SW480 and MDA-MB-231 
carcinoma cell lines. To target plectin and vimentin proteins we ordered three 
alternative siRNA oligonucleotides for each protein (Table 2.5). The validation of 
siRNA was carried out on the SW480 cells; which were transfected with the siRNA of 
interest and a scrambled control siRNA. The scrambled control contains a mixed 
sequence of nucleotides that does not correspond to any known human mRNA 
sequence and therefore provides a negative control for the experiments. After 
transfection, cells were harvested at either 48, 72 and 96 hours and the knock down 
efficiency was analysed by immunoblotting. A 95 % depletion of plectin expression 
was achieved 48 hours after the transfection with siRNA 10144451 compared to 
transfection of the scrambled siRNA control (Figure 5.3A). Plectin siRNA 
oligonucleotides ID 144452 and 10144453 showed a less efficient knock down of 50% 
and 12%, respectively. Furthermore, when the scrambled control siRNA was 
compared to a control transfections using water instead of any siRNAs plectin 
expression was not affected therefore confirming the scrambled siRNA as a suitable 
control. In later experiments, plectin siRNA transfection with 10144451 was analysed 
at time points up to 96 hours (Figure 5.11 C) showing that a continued efficient knock 
down of plectin expression could be achieved. Each plectin siRNA targets a different 
exon and the efficiency of each siRNA is dependent on their ability to target the 
plectin RNA sequence which may be affected by conformation and specific binding 
properties of the RNAs. This result shows that siRNA 10144451, gives the most 
efficient knock down at the time points from 48 hours to 96 hours. These parameters 
for the ablation of plectin in epithelial cells were then used in subsequent assays. 
To achieve vimentin ablation in SW480 and subsequently in MOA-MB-231 cells, 
three siRNAs targeted to vimentin (Table 2.5) were used to transfect SW480 cells that 
were harvested 96 hours after the transfections to detennine the efficiency of each 
siRNA. Optimization of vimentin siRNA resulted in over 90% knock down after 96 
hours using vimentin siRNAs, 10 138993 and 10 138995 (Figure 5.4A). However, 
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siRNA ID 138994 was less efficient with only a 48% knock down after 96 hours 
(Figure 5.2A). Actin was used as a loading control showing equal loading of total 
proteins from each sample. These samples were run simultaneously on the same gel in 
the adjacent lanes to ensure that the blotting conditions were constant. In order to 
investigate the optimum time point after transfection, the experiment was repeated 
with the cells harvested also at 48 and 72 hour time points. When the cells were 
harvested 48 hours after transfection, vimentin siRNAs ID 138993 and ID 138995 
depleted vimentin expression by 60%and by about 80% after 72 hours. After 96 hours 
the knockdown efficiency was again over 90% (Figure 5.4B, 5.4C). The less efficient 
siRNA, ID 138994 showed 20%, 30% and 40% depletion ofvimentin expression after 
72, 48 and 96 hours, respectively (Figure 5.4B, 5.4C). Additionally, it was observed 
that siRNA transfections reached the greatest efficiency when the cells were 
transfected 12 hours after seeding at 40% confluency. Seeding cells at over 40% 
confluency resulted in increasingly less efficient vimentin depletion possibly due to 
stabilisation ofthe intermediate filament network (Figure 5.11C 5.12C). This extent of 
down-regulation of vimentin at 48 hours is similar to that seen in experiments with 
another intermediate filament, keratin 8 (Long et al., 2006). These results confirm that 
an efficient vimentin knock down can be achieved after 48 hours and up to 96 hours 
using two out of three of siRNA o1igomers. 
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Plectin c-20 
Keratin 8/I8 
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PI P2 P3 scr neg 
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Figure 5.3. Comparison of plectin siRNA nucleotides. 
(A) Immunoblot using Plectin c-20 antibody on 48-hour total cell extractions 
from SW480 cells, after transfection with siRNAs ID144451 (PI), ID144453 
(P2), ID 144453 (P3), a control with scrambled siRNA(scr) and a control trans-
fected with water (neg). Keratin 8/18 bands from the same blot confirm equal 
loading. (B) The relative expression of plectin when compared to the siRNA 
control, measured by Image J software from raw tiff format images taken with 
FujiFilm Intelligent Dark Box II. 
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Figure 5.4. Comparison ofvimentin siRNA nucleotides. 
(A) lmmunoblot using vimentin polyclonal antibody on total protein extracts from 
SW480 cells transfected with siRNAs 10138993 (VI), 10138994 (V2), 10 138995 
(V3) and a control with scrambled siRNA (scr). Actin bands act as a loading control 
from the same extract loaded in duplicate on a single 10% SDS page gel. (B) Repeat 
of above experiment (A) however, cells are harvested at 48, 72 and 96-hours before 
immunoblotting with vimentin polyclonal antibody. (C) The relative expression of 
vimentin when compared to the control siRNA, measured using Image J software 
from raw tiff format images taken with FujiFilm Intelligent Dark Box II. 
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5.2.2. Cell viability is not affected by either vimentin or plectin siRNA 
transfections. 
To ensure that any changes observed in the assays to follow were not due to decreased 
cell survival after plectin or vimentin down regulation, the cell numbers were analysed 
after 72 hours. Both vimentin and plectin siRNA transfected cells had similar, only 
slightly lower survival compared with scrambled control transfected cells in the 
SW480 cells (Figure 5.5A). Moreover, the cell survival of breast carcinoma cells 
MDA-MB-231 gave similar results to the SW480 cells for both plectin and vimentin 
transfections (Figure 5.5B). Overall cell viability did not change more than 5% 
compare to the scrambled control for plectin or vimentin knock-down in these cells, 
therefore changes in cell viability should not have a significant effect in the migration 
and invasion assays used below. For the attachment assay and invasion assays, cell 
numbers were adjusted to the equal concentration of cells per ml prior to assay so the 
slight decrease in survival did not affect the assays. These results also confirm that the 
depletion of these proteins do not have a significant effect on cell proliferation after 72 
hours and that none of these proteins are essential for cell survival. When comparing 
the scrambled siRNA control to a non-transfected control, in both cell types, a slight 
(<10%) cytotoxic effect was observed due to the transfection reagent (Figure 5.5A and 
Figure 5.5B). As the assays to follow will be compared to the scrambled control this 
will not affect the results. 
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72-hour transfection 
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Figure 5.5. Cell survival after siRNA transfections. 
MDA-:MB-231 cell viability 
72-hour after transfection 
Cell survival was measured using CellTiter cell proliferation kit (Promega UK). 
Mean and standard deviation of three measurements each, from three transfections 
are shown. (A) Cell survival of colon carcinoma SW480 cells after a 72-hour 
transfection. (B) MDA-MB-231 breast carcinoma cell survial. 
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5.2.3. Plectin depletion causes impairment of carcinoma cell invasion through 
collagen gels. 
The ability of the plectin depleted carcmomas cells to migrate in a collagen gel 
invasion assay was investigated. Again, as in the invasion assays companng the 
invasive potential of the carcinoma breast and colon cell panel, collagen was used 
instead of laminin, as the study was interested in the later stages of carcinoma cell 
invasion through the stroma. Serum starved cells were induced to migrate from cell 
culture inserts through collagen gel-coated filters using 10% Fetal Calf Serum (Sigma 
Aldrich UK) as a chemoattractant. Migrated cells were visualised by Dapi (Invitrogen 
UK) staining using randomised counting, where each insert was given a number at 
random that corresponds to the correct sample to ensure unbiased results. For each of 
the cell line the results were quantified from three independent experiments using 
triplicate filters for each transfection. Depleting SW480 cells of plectin caused a 
decrease of 72% in the number of invading cells compared to the control at twelve 
hours (Figure 5.6B). Figure 5.6A shows a representative filter from one of the assays 
demonstrating the marked decrease of invaded plectin depleted cells compared to the 
control. A similar decrease in invasion was not observed in the breast carcinoma 
MDA-MB-231 cells, where plectin-depleted cells showed a modest decrease of 
invasion at 14% compared to the control in six hours (Figure 5.7B). Figure 5.7A shows 
representative filters from one of the assays demonstrating the modest decrease. The 
degree of protein expression knockdown in both cell lines at the end of each assay was 
confirmed by immunoblotting showing at least an 84% down regulation of protein 
expression in both cell lines (Figure 5.6C, Figure 5.7C). The results presented above 
suggest that the degree of invasion in plectin depleted carcinoma cells is dependent on 
the cell type, although the observed trend is that plectin siRNA transfection causes a 
decrease in the invasion of carcinoma cell lines. 
5.2.4. The depletion of vimentin dramatically reduces the ability of SW480 and 
MDA-MB-231 cells to invade through collagen gels. 
A representative experiment illustrated by Dapi stained insert filters demonstrates a 
marked reduction in the invasion of both SW480 and MDA-MB-231 cells after 
vimentin siRNA transfection compared to a control siRNA transfection (Figure 5.8A 
and Figure 5.9A). Again, the results were quantified from three independent 
experiments usmg triplicate filters for each transfection, confirming significant 
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decrease in the number of vimentin-ablated SW480 (Figure 5.8B) and MDA-MB-231 
(Figure 5.9B) cells migrating through collagen. The cells used in the experiment were 
analysed for vimentin depletion after the end point of each assay, Figure 5.9C shows 
that in SW 480 cells vim en tin was depleted by 82%. However, vimentin depletion in 
MDA-MB-231 cells demonstrates only a 58% knock down efficiency possibly due to 
the vimentin network having an increase stability or lower turnover in these cells that 
predominantly express vimentin but not keratins. The dramatically reduced invasion of 
the MDA-MD-231 cells after 58% depletion demonstrates the importance of vimentin 
in this process. The SW 480 cells express a keratin network alongside the vimentin 
network (Figure 4.2) that may be able to circumvent the requirement of vimentin for 
integrin targeting which, in tum, could account for the differences observed between 
the two cell lines. 
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Figure 5.6. Impaired migration ofplectin siRNA transfected SW480 cells. 
(A) Dapi stainings to visualise cells migrated through collagen coated filters towards 
10% FCS in a collagen invasion assay. Cells were transfected with control scrambled 
siRNA or plectin siRNA 72 hours prior to the assay. (B) Quantification of SW480 cell 
migration. Dapi stained nuclei were counted from three independent migration experi-
ments at 12 hour time points, the graphs show average number of cells per microscopic 
field and standard error. (C) lmmunoblot analysis of siRNA knockdown efficiency 
detected from same poulation of cells, extracted 96 hours after transfections. 
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Figure 5.7. Invasion ofplectin siRNA transfected MDA-MB-231 cells. 
(A) Dapi stainings to visualise cells migrated through collagen coated filters towards 
10% FCS in a collagen invasion assay. Cells were transfected with control scram-
bled siRNA or plectin siRNA 72 hours prior to the assay. (B) Quantification of 
MDA-MB-231 cell migration. Dapi stained nuclei were counted from three indepen-
dent migration experiments at 6 hour time point, the graphs show average number of 
cells per microscopic field and standard error. (C) Irnmunoblot analysis of siRNA 
knockdown efficiency detected from same poulation of cells, extracted78 hours after 
transfections. 
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Figure 5.8. Impaired migration ofvimentin siRNA transfected SW480 cells. 
(A) Dapi stainings to visualise cells migrated through collagen coated filters towards 
10% FCS in a collagen invasion assay. Cells were transfected with control scrambled 
siRNA or vimentin siRNA 72 hours prior to the assay. (B) Quantification of SW480 
cell migration. Dapi stained nuclei were counted from three independent migration 
experiments at 12 hour time point, the graphs show average number of cells per micro-
scopic field and standard error. (C) Immunoblot analysis of siRNA knockdown effi-
ciency detected from same poulation of cells, extracted 96 hours after transfections. 
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Figure 5.9. Impaired migration ofvimentin siRNA transfected MDA-MB-231 cells. 
(A) Dapi stainings to visualise cells migrated through collagen coated filters towards 10% 
FCS in a collagen invasion assay. Cells were transfected with control scrambled siRNA 
or vimentin siRNA 72 hours prior to the assay. (B) Quantification ofMDA-MB-231 cell 
migration. Dapi stained nuclei were counted from three independent migration experi-
ments at 6 hour time point, the graphs show average number of cells per microscopic field 
and standard error. (C) Immunoblot analysis of siRNA knockdown efficiency detected 
from same poulation of cells, extracted 78 hours after transfection. 
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5.2.5. Plectin ablation decreases attachment to fibrillar collagen in both MDA-
MB-231 and SW480 carcinoma cells. 
The results obtained in the invasion assay prompted the study of the ability of the 
carcinoma cells to attach to a collagen surface to find out if cell attachment could 
account for the differences observed in the invasion experiments. The ability of the 
siRNA transfected cells to attach to fibrillar collagen was measured after 5, 10, 20 and 
40 min of incubation. Depletion of plectin in SW 480 colon carcinoma cells resulted in 
a significant decrease in adhesion to collagen (Figure 5.1 OA) at all time points, 
determined at T-test acceptance of p<0.05. When plectin was depleted in the MDA-
MB-231 attachment was also impaired although not to the same extent that was seen in 
the SW480 cells (Figure 5.10B). The efficiency of the knockdown was evaluated using 
immunoblotting after the assay had terminated showing similar results to the invasion 
assay (Figure 5.6 C and Figure 5.7C). 
5.2.6. Vimentin ablation alters attachment to fibrillar collagen in both MDA-MB-
231 and SW 480 carcinoma cells. 
In MDA-MB-231 breast cancer cells, siRNA ablation of vimentin resulted in a 
significant decrease in adhesion to fibrillar collagen (Figure 5.1 OD). Impaired adhesion 
was evident at 10 min time point and the difference in the adherent cells was even 
more pronounced in the later time points with more than 30% less cells attaching. On 
the contrary, vim en tin ablation had only a modest effect on cell adhesion in SW 480 
cells with no clear trend observed in comparison with control siRNA transfected cells 
(Figure 5.1 OC). Thus, the effect of vimentin on cell adhesion is cell type specific. 
Again, it is possible that the expression of keratin in the SW480 cells unlike the MDA-
MB-231 cells could account for the observed differences in this assay. The efficiency 
of the knockdown was evaluated using immunoblotting after the assay had terminated 
showing similar results to the invasion assay (Figure 5.8C Figure 5.9C). 
5.2.7. Depletion of plectin and vimentin in SW480 cells reduce number of cells in 
suspension compared to scrambled control. 
The colon carcinoma SW480 cell line is unusual compared to the other epithelial 
carcinoma cell lines used in this study as a subset of cells go through cycles of 
detaching and reattaching in culture (observed during routine cell maintenance and Dr 
Naomi Willis, personal communication). Interestingly, during experiments using 
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siRNA transfections it was observation that plectin or vimentin depletion decreased the 
number of cells growing in suspension. In order to quantify this, the media was 
collected after a 72-hour transfection and centrifuged to pellet the suspended cells that 
were then resuspended in equal volumes of media and counted discounting any dead 
cells with Trypan blue (Sigma Aldrich UK). The results confirm the observation 
demonstrating that plectin or vimentin depletion significantly reduced the number of 
cells in suspension by 66% and 54%, respectively (Figure 5.1 OE). Furthermore, when 
immunoblot analysis was performed on the detached cells it was found that they had 
the same degree of plectin depletion compared to the control as the adherent cells 
(Figure 5.1 OF). It should be pointed out that in the attachment assays described above 
all cells were suspended by trypsinization, which strips the cell surface of integrin 
attachments. However, it can be speculated that the decreased level of the cells in 
suspension is not due to an inability of plectin and vimentin depleted cells to detach 
and reattach. Instead, knockdown of these proteins may result in a slower kinetics of 
adhesion possibly by interfering with the ability of the cell to remodel the 
cytoskeleton. This is further supported by the observation that in longer cell 
attachment assays lasting 2 hours the plectin and vimentin depleted SW480 and MDA-
MD-321 cells had all attached to the same degree as the control cells. 
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Figure 5.10. Adhesion of carcinoma cells to fibrillar collagen. 
Cell attachment assay of plectin siRNA (white bars) or control siRNA (black bars) 
transfected SW480 cells (A) and MDA-MB-231 cells (B). Cell attachment assay of 
vimentin siRNA (white bars) or control siRNA (black bars) transfected SW480 cells 
(C) and MDA-MB-231 cells (D). Cells were suspended 72 hours after transfection and 
left to attach to collagen coated tissue-culture wells. Non-adherent cells were washed 
away at indicated time points and the adherent cells were quantified by colorimetric 
cell viability kit (measured by absorbance units (AU) at 490 nm). Mean and standard 
error of mean of three independent experiments (Three repeats each) are shown. The 
difference between control and vimentin or plectin siRNA transfected cells was 
statistically significant (T -test, p< 0.05) at 10, 20 and 40 minutes time points for (C). 
(D) Percentage of plectin and vimentin siRNA transfected SW480 cells in suspension 
after 96-hour transfection with a 48-hour media change compared to control 
transfected cells. (E) Immunoblot analysis of protein extracted from siRNA plectin and 
control transfected suspended cells compared to adherent cells, with vimentin as a 
loading control. 
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5.2.8. Scratch wound assay as a tool to measure wound closure rates in epithelial 
cells. 
Scratch-wound assays on confluent monolayers were utilised as an additional way of 
investigating cell migration. Growing cells to a confluent monolayer and scratching 
with a pipette tip to produce a wound is a widely used classical method to measure 
migration rates of epithelial cells (Wong et al., 1988; Yarrow et al., 2005; Valster et 
al., 2005 and recently Long et al., 2006). Cell monolayers were wounded in triplicate 
and the closure was measured at 2, 4, 6, hours after wounding using phase contrast 
imaging of exactly the same area of the wounds. Control transfected MDA-MB-231 
cells migrated particularly rapidly in this assay filling the empty wound space within 
the 6 hours, whereas the control transfected SW480 cells migrated at a slower rate of 
only 80% wound closure after the 6 hours. This correlates with the invasion assay 
where the MDA-MB-231 cell had a high invasive potential. Moreover, after 6 hours 
the floating SW 480 cells started to re-attach and fill the wound space making 
measurement of wound edge closure in the subsequent time points difficult. The 6-
hour time point was, therefore, chosen to provide a fair and representative assay of 
wound closure. It is noted that in this case the cells do not form coherent epithelial 
sheets, have sparse cell-cell contacts and are able to detach from the wound edge. 
Thus, the measurements here are an indication of migration of cells to fill a wound 
space. 
5.2.9. The ability of cells to close a wound in vitro was impaired by plectin siRNA 
in SW480 carcinoma cells but not in MDA-MB-231 carcinoma cells. 
Scratch wound assays indicated that plectin contributes to SW480 carcinoma cell 
migration as plectin knockdown wounds started to close more slowly than control 
scrambled siRNA transfected wounds (Figure 5.llA). Moreover, plectin depleted 
wounds remained open up to 24 hour time point when control transfected scratch 
wounds were completely closed (Figure 5.11 D). On the contrary, plectin depletion in 
MDA-MB-231 cells demonstrated a slight increase in the rate of wound closure at 2 
and 4 hours compared to control cells. Both control and plectin depleted wounds were 
completely closed after the six hours in two out of three wounds (Figure 5.12B). The 
extent of the down-regulation of plectin was confirmed by immunoblot analysis of an 
extract from the scratch wound after the 6 hours showing depletion of 83% in SW480 
cells and 80% in MDA-MB-231 cells (Figure 5.11 C and Figure 5.12C). The above 
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results indicate that the down regulation of plectin affects the ability of epithelial cells 
to close a wound in a cell-dependent manner. 
5.2.10. The ability of cells to close a wound in vitro is significantly impaired by 
vimentin depletion in both colon and breast carcinoma cells. 
Wound closure was also investigated in vimentin siRNA transfected SW480 and 
MDA-MB-231 monolayers. Control transfected MDA-MB-231 cells migrated to fill 
the empty wound space in about 6 hours, whereas the vimentin knock-down wounds 
remained largely open at that time point (Figure 5.148). SW480 cells migrated more 
slowly than MDA-MB-231 cells (Figure 5.13A), but the difference between control 
transfected and vimentin siRNA transfected cells was evident at the 6 hour time point 
and was confirmed by measurements of the relative closure of the wound in three 
independently transfected wounds. Closure of vimentin ablated MDA-MB-231 
wounds was quantified at 2, 4 and 6 hour time points demonstrating significantly 
slower closure at all studied time points compared to control transfected cells. Notably, 
two out of three control wounds were completely closed after 6 hours, whereas all 
vimentin siRNA transfected wounds remained almost 80% open (Figure 5.14 A). The 
down regulation of vimentin was confirmed by immunoblot analysis of an extract after 
the 6 hours showing depletion of 72% in SW480 cells and only 48% in MDA-MB-231 
cells (Figure 5.13C and Figure 5.14C). The low efficiency of vimentin depletion in the 
MDA-MB-231 cell line is possibly due to transfection of the cells at a higher density 
of 50-60% that was needed for the cells to form a monolayer at the 96 hour time point. 
The decrease in knockdown efficiency could be possibly due to the stabilisation of 
vimentin networks in confluent monolayers. This result further demonstrates the 
dramatic impainnent of migration that even a partial loss of vim en tin causes in this cell 
line. 
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Figure 5.11. Wound migration properties of plectin depleted SW480 cells. 
(A) Open wound distance of SW480 wounds. Three locations of three independent 
control and plectin siRNA transfected wounds were photographed at 0, 2, 4 and 6 
hours. Open wound distance at the start of the experiment designated as 1 00% and 
closure of the wounds is shown relation to that. Error bars denote standard error. (B) 
Representative phase contrast micrographs of closure of scratch-wounded confluent 
cultures of control siRNA or plectin siRNA transfected SW480 cells at time point 
immediately after wounding and six hours post wounding. Scratch wound edges are 
marked by dotted lines. Scale bar represents 500 f..tm. (B) Closure of the control (black) 
and plectin (grey) siRNA transfected scratch wounds at 24 hours after wounding was 
measured from photomicrographs. 100% indicates a completely closed wound. The 
bars represent mean and standard deviation of three measurements. (C) Immunoblot 
analysis of knockdown efficiency of cell extracted from representative wound shown 
after assay termination. Vimentin expression is shown as a loading control. 
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Figure 5.12. Open wound migration distance ofplectin depleted MDA-MB-231. 
(A) Open wound distance ofMDA-MB-231 wounds. Three locations ofthree indepen-
dent control and plectin siRNA transfected wounds were photographed at 0, 2, 4 and 6 
hours. Open wound distance at the start of the experiment designated as 100% and 
closure of the wounds is shown relation to that. Error bars denote standard error. (B) 
Representative phase contrast micrographs of closure of scratch-wounded confluent 
cultures of control siRNA or plectin siRNA transfected MDA-MB-231 cells at time 
point immediately after wounding and six hours post wounding. Scratch wound edges 
are marked by dotted lines. Scale bar represents 500 J.tm. (C) Immunoblot analysis of 
knockdown efficiency of cell extract from representative wound shown after assay ter-
mination. Vimentin is shown as a loading control. 
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Figure 5.13. Open wound migration distance ofvimentin depleted SW480 cells. 
(A) Open wound distance of SW 480 wounds. Three locations of three independent 
control and vimentin siRNA transfected wounds were photographed at 0, 2, 4 and 6 
hours. Open wound distance at the start of the experiment designated as 100% and 
closure of the wounds is shown relation to that. Error bars denote standard error. (B) 
Representative phase contrast micrographs of closure of scratch-wounded conflueqt 
cultures of control siRNA or vim en tin siRNA transfected SW 480 cells at time point 
immediately after wounding and six hours post wounding. Scratch wound edges are 
marked by dotted lines. Scale bar represents 500 J.lm. (C) lmmunoblot analysis of knock-
down efficiency of cell extract from representative wound shown after assay termina-
tion. Actin is shown as a loading control. 
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Figure 5.14. Open wound migration distance ofvimentin depleted MDA-MB-231 cells. 
(A) Open wound distance of MDA-MB-231 wounds. Three locations of three independent 
control and vimentin siRNA transfected wounds were photographed at 0, 2, 4 and 6 hours . 
Open wound distance at the start of the experiment designated as 100% and closure of the 
wounds is shown relation to that. Error bars denote standard error. (B) Representative phase 
contrast micrographs of closure of scratch-wounded confluent cultures of control siRNA or 
vimentin siRNA transfected MDA-MB-231 cells at time point immediately after wounding and 
six hours post wounding. Scratch wound edges are marked by dotted lines. Scale bar represents 
500 ~m . (C) Immunoblot analysis of knockdown efficiency of cell extract from representative 
wound shown after assay termination. Actin is shown as a loading control. 
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5.2.11. Vimentin depletion is confirmed by immunofluorescence on scratch wound 
monolayers. 
Confocal microscopy using immunofluorescence confinns that vimentin is uniformly 
down regulated in the scratch wound migration experiments in both SW480 and MDA-
MB-231 cells (Figure 5.15A/B). Vimentin expression in these cells was visualised 
using Cy3-conjugated antibody that gives a very bright fluorescent signal especially 
around the nucleus where the vimentin cytoskeleton is organised into a dense cage-like 
network. The confocal settings for detection of fluorescent signal were unchanged for 
vimentin-depleted cells as control cells to demonstrate the difference in fluorescent 
signal. These results confirm that siRNA transfections were efficient in causing a 
consistent and reproducible downregulation of vimentin expressiOn. 
Immunofluorescence analysis with antibodies against plectin demonstrated that 
vimentin ablation did not cause major changes in cell morphology (Figure 5.15). 
However, it was noted that in scratch-wound experiments, there were markedly less 
SW480 cells that quickly escaped the wound edge and started to fill in the wound 
space (Figure 5.15A). This observation was a further indication that cell migration is 
affected by absence of vim en tin. 
5.2.12. Plectin depletion alters actin dynamics at the wound edge. 
In order to investigate the possible causes for the decrease of migration in plectin 
depleted SW480 cells, confocal microscopy was used to characterise the appearance at 
the wound edge using co-staining with the cytoskeletal protein actin. In control-
transfected monolayers, wound edge cells were actively migrating away from the edge, 
whereas plectin knockdown cells retained a flattened morphology and remained tightly 
packed at the wound edge (Figure 5.16A). Actin staining of the control transfected 
cells demonstrated the presence of round adhesion structures at the cell periphery that 
were absent in plectin knockdown cells (Figure 5.168). These results show that plectin 
is involved in actin dynamics at the wound edge and supp01t previous work showing 
plectin to be involved in the regulation of actin organisation (Andra et al., 1998). 
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5.2.13. Plectin depletion alters the appearance of actin in confluent monolayers in 
SW 480 cells. 
Further evidence to support that plectin is involved in the remodelling of actin was 
provided by confocal microscopy of plectin depleted unwounded SW480 monolayers 
(Figure 5.17). Actin and plectin staining in control layers show cells to be irregularly 
shaped with areas in the monolayer where cells do not form cell-cell junctions (arrow). 
Furthermore, actin is arranged at the cell periphery and at a dense cage around the 
nucleus where it co-localises with plectin. In contrast, plectin depleted monolayers 
resemble an epithelial sheet as observed in the less aggressive cell lines (HT29, Figure 
4.5) where the cells are arranged in a regular array and are tightly packed. In the 
plectin depleted cells there was also an observed increase in actin stress fibers in these 
cells that also display flattened cell morphology, with loss of the dense actin cage 
around the nucleus (Figure 5.17). In conclusion depletion of plectin causes an 
alteration of actin dynamics in colon carcinoma cells and leads to a flattened cell 
morphology. 
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Figure 5.15. Immunofluoresence analysis of vimentin ablation in carcinoma cell 
monolayers. 
(A) Vimentin (red channel) and plectin (green channel) and merged image (on the right) 
immunofluorescence staining ofvimentin siRNA or control siRNA transfected SW480 
monolayers, that were scratch-wounded 72 hours after transfection. (B) Vimentin and 
plectin immunostainings of siRNA transfected and scratch wounded MDA-MB-231 cell 
monolayers. Note in both panel A and B that vimentin siRNA transfection leads to 
uniform downregulation ofvimentin expression. Scale bars corresponds to 20 11m for all 
panels. 
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Figure 5.16. Plectin knock-down inhibits actin dynamics at the wound edge of 
SW 480 cells. 
(A) SW480 cell monolayers were transfected with either scrambled control siRNA(top 
row) or plectin siRNA (bottom row) and scratch wounded. The panels show immuno-
fluorescence analysis of actin organisation and expression of plectin two hours after 
wounding. (B) Magnified detail: Arrows point at podosome-like actin foci that are 
absent in plectin siRNA transfected migrating wound edge cells . Scale bar corresponds 
to 50 Jlm panel A and 10 Jlm in panel B. 
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Figure 5.17. Plectin knock-down alters monolayer characteristics of SW480 cells. 
SW480 cell monolayers were transfected with either plectin siRNA (top row) or scrambled 
control siRNA (bottom row). The panels show immunofluorescence analysis of actin 
organisation and expression of plectin. Scale bar represents 50f.1m. Control monolayers 
expressing high levels of plectin show a more disordered monolayer with heterogeneous 
cell morphologies. 
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5.3. Discussion. 
In order to investigate the role of the intermediate filament protein vimentin and its 
associated linker protein plectin in carcinoma a cell migration, vimentin expressing 
SW480 and MDA-MB-231 cell lines were used. From previous results it can be seen 
that these cell lines were the most invasive in the investigated carcinoma cell panel. 
Furthermore, these cells were vimentin positive and had significantly elevated protein 
expression of plectin compared to the lower grade carcinoma cells HT29 and SW480 
(Figure 4.2). The SW480 cells had also retained relatively high expression of keratin 
8/18 intermediate filaments and desmoplakin, the major cytolinkers protein connecting 
keratin intermediate filaments to desmosomes (Leung et al., 2002). Thus, these cell 
lines provide a model where the effect of vim en tin ablation could be investigated in the 
presence or absence of an intact keratin cytoskeleton. Co-expression of vimentin and 
keratin intermediate filaments in the same cells is intriguing, as previous experiments 
have shown increased motility in vimentin positive melanoma cells that were 
transfected with keratin 8 and 18 constructs (Chu et al., 1996). Vimentin and keratin 
intermediate filament expression is also associated with recurrent and metastatic 
disease in melanoma (Hendrix et al., 1992). The relative increased expression of 
plectin in both the high-grade breast and colon carcinoma cell lines is interesting, as 
plectin has previously been found to link to vimentin via the C-terminal plectin repeat 
domain (Wiehe et al., 1993). Plectin has also been shown to localise with vimentin 
positive focal adhesions in endothelial cells (Gonzales et al., 2001) and also to link 
intennediate filaments to hemidesmosomes via a6~4 integrin (Foisner et al., 1988; 
Rezniczek et al., 1998; Schaapveld et al., 1998). Moreover, an additional vimentin-
binding site in plectin residing within the CHI subdomain of its ABO has been 
identified. Vimentin has been shown to bind to this site via the amino-terminal part of 
its rod domain (Sevcik et al., 2004). The authors speculate that this additional amino-
terminal intermediate filament protein-binding site of plectin may have a function in 
intermediate filament dynamics and assembly, rather than in linking and stabilizing 
intetmediate filament networks (Sevcik et al., 2004). All these previous findings above 
prompted the investigation of the role of plectin and vimentin in the migration and 
invasion of SW480 and MDA-MB-231 cells that express these proteins in high levels. 
Table 5.1 at the end of .this discussion summarises the main results of migration 
invasion and adhesion assays of carcinoma cells used in this study. 
163 
To first investigate the role of plectin in these cell lines, down regulation of plectin 
expression was carried out using transient siRNA transfection in SW480 cells. The 
stability or the turnover of a plectin is relatively fast showing over 95% knockdown 
using plectin siRNA ID144451 in 48 hours and a continued knockdown to the same 
efficiency still after 102 hours. Transfection of plectin siRNA into the MDA-MB-231 
cell line showed similar levels of depletion as in the colon carcinomas cells. The use of 
transient transfection of siRNA to knockdown plectin was found to be a suitable tool 
for migration, invasion and attachment assays. 
Since plectin is involved in remodelling of the cytoskeleton (Wiehe et al., 1998), 
knocking down plectin may affect the ability of the cell to do this efficiently. It was 
found that the plectin depleted SW480 cells invaded 72% (Figure 5.6) less than the 
control transfected cells in an invasion assay. However, the MDA-MB cell line showed 
a modest decrease of only 14% less cell invasion in the collagen invasion assay (Figure 
5. 7). This result indicates that plectin is involved in the invasion of carcinoma cells in 
a cell type specific manner. This is further supported by the finding that in a scratch 
wound assay, plectin-depleted SW480 cells show impairment in the ability to close a 
wound (Figure 5.11 ), whereas plectin depletion of the MDA-MB-231 cells results in a 
modest increased rate of wound closure compared to control cells (Figure 5.12). The 
above results suggest that the breast carcinoma and colon carcinoma cells use different 
modes of migration and invasion and plectin plays a key role in modulating these 
processes in a regulatory manner in both cell lines. In other previous studies of plectin 
depletion impaired migration was displayed in fibroblasts, and epithelial cells (Andra 
et al., 1998; Boczonadi et al., 2007; Abrahamsberg et al., 2005). These results are 
contrasted by the finding of plectin-depleted keratinocytes that migrate faster than the 
control (Osmanagic-Myers et al., 2006). One possible explanation for the contrasting 
effects of plectin on cell migration could be that different cell lines exhibit cell-specific 
expression of plectin N-terminal isoforms as seen in the mRNA expression (Figure 
3.6) where the MDA-MB-231 cells had a high expression of isofom1 la and ld 
compared to SW 480 cells. Also plectin-1 a is a major isofonn expressed m 
keratinocytes where the primary function of plectin is in hemidesmosomes (Rezniczek 
et al., 2003), whereas in fibroblasts it is likely that plectin isofom1s associated with 
actin stress fibers or focal adhesion complexes play a more important role. It would, 
therefore, be of interest to investigate the effect on carcinoma cell migration and 
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invasion of specific plectin isoforms by knocking down each isoform individually. 
However, due to the short length of most of the alternative exons finding suitable 
siRNA targets is challenging. The generation of plectin isoform specific null mice 
(Abrahamsberg et al., 2005) will provide a tool for investigation of the specific 
isoforms in cell migration and invasion. 
When the ability of plectin-depleted cells to attach to fibrillar collagen was 
investigated, the attachment was impaired in MDA-MB-231 cells and to a greater 
extent in the SW480 cells (Figure 5.1 0). Interestingly, after two hours all the cells had 
attached demonstrating that plectin was not essential for the attachment of cells to a 
substrate but increased the rate in which cells could attach. Furthermore, in the SW 480 
cell line where cells in culture cycle through attaching and reattaching it was found 
that plectin depleted cells had fewer cells in suspension and therefore decreased the 
ability of the cells to carry out this process. Previously, the attachment ofkeratinocytes 
from a patient with plectin deficiency was found to unexpectedly have increased 
adhesion compared to normal keratinocytes. However, it was found that these cells 
could be detached from a matrix-coated surface much easier than the normal 
keratinocytes (Kurose et al., 2000). In this case, the authors suggested that plectin 
depletion could cause an increased expression of other cell adhesion molecules in 
keratinocytes and plectin may then be involved in stabilising long-term adhesions. The 
differences in the matrix attachment of plectin-depleted cells lead to the suggestion of 
cell-type specific roles possibly again due to the difference in plectin N-terminal 
isoform expression between cell types. 
To investigate the role of vimentin expressiOn on carcmoma cell migration and 
invasion, siRNA transfections were used to deplete the protein in SW480 cells. After a 
48 hour transfection vimentin was depleted by around 60% and by 90% after 96 hours. 
Compared to plectin, vimentin is more stable in these cells possibly due to stabilisation 
of the intermediate filament network. This is further supported by scratch wound 
assays of MDA-MB-231 cells, where the cells were transfected at a higher confluency 
of over 40% and subsequently showed only 58% depletion ofvimentin expression. 
The results presented in this chapter indicate that siRNA down-regulation of vimentin 
can inhibit migration of epithelial carcinoma cells that have acquired vimentin 
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expression as a part of epithelial-mesenchymal transition. These results correlate with 
previous findings that showed that vimentin was involved in the migratory status of 
human epithelial cells by expressing vimentin in MCF1 OA cells (Gilles et al., 1999). 
Furthermore, impaired wound healing in embryonic and adult mice lacking vimentin 
has been reported (Eckes et al., 2000). This inhibition of migration can be observed 
both in MDA-MB-231 cells and in the SW480 cells that co-express vimentin and 
keratin. These results also support other recent functional studies on vimentin. 
Reduced migration and invasion is consistent with a role for vimentin in controlling 
recycling of ~ 1 integrins {lvaska et al., 2005) and reduced size of focal contacts in 
vimentin-ablated endothelial cells (Tsuruta et al., 2003). Vimentin-depleted MDA-
MB-231 cells also showed a significant decrease in the rate of attachment to fibrillar 
collagen compared to the control. However, this was not observed in the SW480 cell 
line, where no clear trend was observed. It is possible that carcinoma cells that, like 
SW480 cells, have retained expression of keratin intermediate filaments are able to 
compensate for the requirement of vim en tin for integrin targeting. 
The importance of vimentin in cancer progression is underlined by the recent finding 
that expression of vimentin in the tumour stroma of colorectal cancer was associated 
with shorter survival suggesting a higher malignant potential (Ngan et al., 2007). 
Furthermore, an increase of over 20-fold vimentin eDNA expression was found in a 
prostate cancer model in which subsequent depletion of plectin led to a significant 
decrease in the invasive potential (Singh et al., 2003). Notably, a 58% inhibition of 
vimentin expression is sufficient to impair migration in MDA-MB-231 cells, which 
suggests that it could be plausible to investigate strategies to reduce vimentin 
expression in vivo. In future studies it would be of interest to elucidate molecular 
interactions of vimentin that are required for invasion and migration. Based on the 
results of this study a putative candidate for mediating the effects of vimentin could be 
plectin and further investigation into the interaction of these proteins in cell migration 
and invasion may yield interesting results. 
The impaired adhesion observed in plectin-deficient SW480 and MDA-MB-231 cells 
and vimentin-deficient MDA-MB-231 cells is intriguing as a loss of cell adhesion is 
often correlated with increased invasion and progression of cancer, which had been 
studied extensively in E-cadherin mediated adhesion (see reviews by Wijnhoven et al., 
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2000; Bremnes et al., 2002). However, in colorectal tumours loss of cell adhesion 
could not be correlated with poor prognosis and increased invasion (Bosch et al., 2004) 
and a subsequent study in metastasising colon carcinoma cells concluded that 
continued expression and synthesis of junctional proteins do not necessarily contribute 
to the suppression of tumour invasion and metastasis of colon cancer (Kartenbeck et 
al., 2005). Therefore, it is clear that the regulation of adhesions in cancer cell 
progression is a complicated process that is governed by cell-type and cancer cell 
environment. 
Interestingly, depletion of vimentin did not show any obvious morphological changes 
in the MDA-MB-231 and SW480 cells at the wound edges or monolayers compared to 
the control. Plectin subcellular localisation was also unaltered by vimentin depletion 
suggesting that vimentin does not have a regulatory role in plectin localisation. In 
contrast to this, plectin depleted SW480 colon carcinoma cells showed a flattened 
morphology and rearrangement of actin at the wound edge. Monolayers of plectin-
depleted SW480 cells resembled the lower grade HT29 cells observed in Chapter 4 
(Figure 4.5), which have a relatively lower plectin expression. In control wound edge -
actin positive foci were abundant at the leading edge of the cells, however these 
structures were mostly absent in plectin-depleted cells. These results further support 
involvement of plectin in actin remodelling and regulation (Andra et al., 1998, Fontao 
et al., 2001 ). The adhesion structures observed were similar to those observed using 
the plectin N-terminal GFP fusion proteins (Chapter 4) that were more prevalent for 
the plectin-1 k GFP fusion protein-transfected cells. This prompted an in depth 
investigation of this novel isoform and the characterisation of the observed adhesive 
foci, the results of this study will be presented in the Chapter 6. 
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Plectin depletion Vimentin depletion 
SW480 IMDA- I SW480 I MDA-
MB-231 ~B-231 
Collagen gel invasion ttt t tt ttt 
Wound migration i tl ttt 
Collagen attachment il tl 
Table 5.1. Summary of cell migration assays. 
Table depicts a summary of the SW480 and MDA-MB-31 cells lines ability to invade, 
migrate and attach when depleted of plectin or vimentin. Arrows indicate a (t) 
decrease in ability or (j) increase ability. 
168 
CHAPTER6 
CHARACTERISATION OF SUBCELLULAR 
LOCALISATION AND FUNCTION OF 
PLECTIN-1K 
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6.1. Introduction. 
One unanswered question in plectin biology is whether any of the plectin isoforms are 
involved not only in the assembly ofhemidesmosomes and focal adhesions, but also in 
the formation of invasive cell junctions such as podosomes and invadopodia. These 
podosome-type adhesions are found in cells of macrophage/monocyte lineage and in 
invasive carcinoma cell lines (reviewed by Linder, 2007; Buccione et al., 2004; Linder 
and Aepfelbacher, 2003) and were originally identified and named in RSV transformed 
fibroblasts (Tarone et al., 1985). They contain an F-actin rich core surrounded by a 
ring of proteins that are also constituents of focal adhesion complexes, such as 
vinculin, talin and Src. However, unlike focal complexes, podosomes and invadopodia 
are also enriched in proteins regulating actin dynamics such as N-WASP, cortactin, 
gelsolin, T-plastin (fimbrin) and Arp2/3 complex (see reviews by Buccione et al., 
2004; Linder and Aepfelbacher, 2003, Linder, 2007). The Arp2/3 complex is activated 
by Wiskott/ Aldrich-syndrome protein (WASP) and this complex nucleates a branched 
actin network (Amann et al., 2001 ). Interestingly, both podosomes and invadopodia 
have been recognised as sites of accumulation and activation of matrix 
metalloproteinases, which may have further implications for the role of these structures 
in carcinoma invasion. Podosome-like structures have also recently been described in 
epithelial cells where they are proposed to participate in hemidesmosome assembly 
(Spinardi et al., 2004). 
Recent mapping of the protein-protein interactions of plectin has identified binding 
sites for several signalling molecules, such as AMP-activated protein kinase (Gregor et 
al., 2006), RACK-I receptor for activated protein C kinase 1, (Osmanagic-Myers and 
Wiehe, 2004) and Fer Kinase (Lunter and Wiehe, 2002). The data collectively 
strengthens the case for plectin as a regulatory scaffolding protein in actin mediated 
processes. 
In this chapter isoform, plectin-1 k is demonstrated to be localised to podosome-type 
adhesions in SW480 colon carcinoma cells. siRNA knockdown of plectin inhibited 
podosome assembly that was rescued by transfection of Plectin-1 k N-terminus. Thus, 
plectin-1 k is a novel cytoskeletal linker protein that regulates actin dynamics in 
migrating cells. 
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6.2. Results. 
6.2.1. Partial co-localisation of plectin-lk and total plectin in SW480 cells. 
Immunofluorescence staining of SW480 cells was used to map the subcellular 
localisation ofplectin-1k (LM-7) and total plectin (c-20) (Figure 6.1A). Plectin-lk co-
localised with the C-20 staining in some but not all plectin-positive subcellular 
structures. Notably, plectin-1k was found in round adhesion sites similar to those 
found in Figure 5.16B that were most prevalent in cells at edges of scratch wounds 
made to confluent monolayers and in single migrating cells. In contrast, LM-7 
antibody did not stain some of the cytoskeletal structures that were positive for total 
plectin antibody, such as apparent stress fibers along cell edges and the vimentin 
intermediate filament network. However, plectin-1 k and total plectin antibodies could 
co-localise in the cytoskeletal cage surrounding the nucleus. 
6.2.2 Plectin-lk localisation in MDA-MB-231 cells. 
To investigate, if the localisation of plectin-1 k to similar adhesion structures is 
observed in other carcinoma cells, MDA-MB-231 cells were stained with LM7 and 
plectin c-20 antibodies and found that plectin-1 k is localised at round actin foci at 
basal aspect of MDA-MB-231 cells (Figure. 6.1 B). The p1ectin foci were reminiscent 
of podosomes that have previously been described in MDA-MB-231 breast cancer 
cells, where they are implicated in the invasiveness of the cells (Seals et al., 2005). 
6.2.3 Plectin-lk is localised in podosome-type adhesions 
To investigate if the plectin-1 k rich foci in scratch wound edge cells were involved in 
cell adhesion and migration, co-immunofluorescence staining of plectin-1 k with 
antibodies against integrin subunits a3, a6, ~ 1 and ~4 was used. Previously, SW 480 
cells have been shown to express also a 1, a2 and a5 subunits as well as ~5 integrin 
subunit (Koretz et al., 1994, Agrez et al., 1994), but this study concentrated on 
epithelial integrins as redistribution of both a3 ~ 1 and a6~4 has been implicated in 
epithelial migration and carcinoma invasion (Goldfinger et al., 1999; Lotz et al., 2000; 
Rabinovitz et al., 1999). Moreover, a3~ I integrin has been shown to participate in the 
regulation of degradatiotl. and phagocytosis of extracellular matrix by breast carcinoma 
cells (Coopman et al., 1996). 
171 
Confocal microscopy of slices at cell-substratum attachment level revealed that 
plectin-1 k co-localises with both ~ 1 and ~4 integrins (Figure 6.2A). Close-up views of 
the double immunofluorescence staining of integrin subunits and plectin-1 k revealed 
apparent internal structure in the plectin-rich foci. The strongest immunofluorescence 
staining for integrin subunits formed ring-like structures that seemed to surround 
punctae with strong plectin-1 k immunofluorescence (Figure 6.2B arrows). Some 
smaller integrin foci at edge of lamellipodial extensions (arrow in Figure 6.2B) were 
negative for plectin-1 k staining suggesting that the initial focal contacts do not contain 
pelctin-1 k. Likewise, immunofluorescence staining of phalloidin-labelled actin and a6 
integrin subunit demonstrated an integrin-containing ring that surrounded dense core 
of actin (Figure 6.2C). Finally, unlike the non-invasive HT29 cells (Chapter 4, Figure 
4.3), there were no hemidesmosomal-like structures observed in SW480 cells. 
6.2.4. Co-localisation of plectin-lk with podosome components. 
In order to further characterise the plectin-1 k foci observed m the prevtous 
experiments double immunofluorescence was carried out with previously published 
podosome components. Co-staining with phalloidin (filamentous actin) showed that 
plectin-1k did not co-localise with actin stress fibres or the meshwork at lamellipodial 
cell edges. Instead, plectin-1 k and actin co-localised at adhesion foci at the basal 
surface of the cells (Figure 6.3A). Immunofluorescence staining of plectin-1 k in cells 
transfected with eGFP-tagged N-WASP (Figure 6.3B) was undertaken to provide 
further conformation that plectin1k was located to podosome structures. WASP is 
required for podosome formation in haematopoietic cells (Linder et al., 1999) and the 
ubiquitously expressed N-WASP has been shown to be essential for podosome 
assembly in src-transformed fibroblasts (Mizutani et al., 2002) and in metastatic 
mammary carcinoma cells (Lorenz et al., 2004; Yamaguchi et al., 2005). Thus, the co-
localisation of N-WASP and plectin-1 k confirmed the identification of plectin-1 k 
containing adhesive foci as podosome-type adhesions. This identification was 
supported by co-localisation of plectin-1 k with dynamin (Figure 6.3C) and cortactin 
(Figure 6.3D). The large GTPase dynamin is involved in membrane organisation, 
which involves tubulations or invagination of membranes and is required for 
podosome formation in osteoclasts and carcinoma cells (Ochoa et al., 2000). Cortactin, 
an actin organising protein, is also required for assembly of podosomes and 
invadopodia (Webb et al., 2006). Likewise, there was a partial co-localisation of 
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plectin-1 k and vinculin. Both vinculin and plectin-1 k were found in podosome-type 
adhesions but only vinculin was present in focal adhesion sites or, uniformly, at 
lamellipodia (Figure 6.3E arrow head). At podosomes, vinculin was mostly localised 
as small rings with a diameter of 0.5-1 Jlm (Figure 6.3E), which is characteristic to 
these structures (Gavazzi et al., 1989). Finally vimentin has been previously described 
as a component of podosomes where it binds T-plastin (T-fimbrin) an actin bundling 
protein (Correia et al., 1999). Plectin-1 k was able to co-localise with both vimentin 
(Figure 6.3F) and T-plastin (Figure 6.3G) in podosomes (arrows). To summarise the 
results above demonstrate that plectin-1k is a novel component of podosome-type 
adhesions in the SW480 colon carcinoma cell line. 
6.2.5. Plectin-lk is localised to podosomes in macrophages. 
Localisation of plectin in podosomes has not been described previously, although a 
review by Gimona et al., 2006 includes plectin in a list of proteins involved in the 
formation of podosomes and invadopodia. However podosomeslinvadopodia of 
epithelial carcinoma cells have not been characterised as extensively as cells of 
macrophage/monocyte lineage or RSV transformed fibroblasts. Therefore, localisation 
of plectin-1 k in THP-1 cell line that was differentiated towards macrophage lineage by 
PMA and allowed to adhere to collagen was examined. Double immunofluorescence 
staining demonstrated that plectin-lk co-localised with N-WASP in podosomes in 
THPl cells (Figure 6.4). Thus, plectin is also a constituent of podosomes in cells of 
macrophage/monocyte origin. 
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A 
LM7 Plectin c-20 Merge 
B 
Figure 6.1. Plectin-lk localised to podosome-like foci. 
Immunofluorescence staining of (A) SW480 cells and (B) MDA-MB-231 cells with 
plectin-lk (LM-7 staining, anti-rabbit secondary in green channel) and total plectin 
antibodies (c-20 staining, anti-goat secondary in the red channel). The arrows point at 
examples ofpodosome-like plectin foci . Scale bars equal20 J.lm. 
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Plectin-1 K lntegrins Merge 
A 
a3 
a6 
~1 
~4 
B c 
a6 
~1 
a6 Actin Merge 
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Figure 6.2. Co-localisation of plectin lk with integrin subunits. 
(A) SW480 cells were double immunofluorescence stained with plectin-1k (Green 
channel) and monoclonal antibodies against integrin subunits (order from top row to 
bottom row) a3, a6, P 1 and P4. Scale bars equal 20 f.!m. Arrows in merged panels of 
a6 and P 1 rows indicate regions shown in detail in close-up images in panel (B). In the 
merged panel of P 1 integrin and plectin-1 k staining in panel 8, the arrow indicates 
small integrin focal contacts at the edge of the cell that are negative for plectin-1 k and 
the arrowhead points at larger, podosome-type adhesion. (C) Double 
immunofluorescence staining of actin (red) and a6 integrin (green). Arrow in the top 
panel indicates the region that is shown in detail below. 
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A 
8 
c Plectin-1 k Dynamin Merge 
D 
E 
177 
F 
G Plectin-1 k T-Piastin Merge 
Figure 6.3 . Subcellular localisation ofPlectin-lk in SW480 cells. 
(A) Confocal optical slice close to the basal surface of SW480 cells double stained for 
plectin- lk (LM-7 antibody, green channel) and actin (Phalloidin, red channel). Arrows 
point to a podosome positive for actin and plectin-lk in all panels. (B) Immunofluores-
cence staining of plectin-lk (red) in cells expressing GFP-tagged N-Wasp (green 
channel). (C) Double immunofluorescence staining of plectin-1 k (green) and dynamin 
(red). (D) Double immunofluorescence staining of plectin-lk (green) and cortactin (red). 
(E) Double immunofluorescence staining of plectin-lk (green) and vinculin (red) . The 
arrow points at a podosome where plectin-lk and vinculin co-localise. The arrowhead 
points at broad lamellipodial vinculin staining. (F) Co-localisation of plectin-lk (green) 
and Vimentin (red). (G) Double immunofluorescence staining of plectin-lk (green) and 
T-plastin (red). Arrow indicates co-localisation ofplectin-1k and vimentin in podosomes. 
The scale bars corresponds to 20 llm in all panels. N-wasp construct was kindly provided 
by Dr. Michael Way (Cancer Research UK, London Institute). 
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Plectin-1 k N-Wasp Merge 
Figure 6.4. Plectin-lk co-localised with N-Wasp in macrophages. 
THP-1 cells, differentiated towards macrophage lineage by PMA and attached 
to collagen-coated coverslips, were double immunofluorescence stained for 
plectin-1 k (green channel) and N-Wasp (red). Confocal section shown is from 
the basal aspect of the cells, with arrows pointing to podosome foci . Scale bar 
indicates 20 J..lm . 
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6.2.6. Plec-lk -Actin Binding Domain -GFP construct is targeted to podosomes. 
Plectin-1 k-eGFP construct was observed to be targeted mostly to podosomes m 
transfected SW480 cells (Figure 6.5BCD), the eGFP construct co-localised with the 
plectin C-terminal antibody in actin structures, but not at IF-network (Figure 6.5A). 
Analysis of XY and XZ confocal sections (Figure 6.5B) demonstrated that plectin-lk-
eGFP construct localised to the actin core but also partially surrounded the core. The 
podosome-like adhesions were not restricted to ventral surface of the cells but 
extended upwards almost throughout the cell as shown by the co-localisation ofF-actin 
and GFP fluorescence in the XZ-section (Figure 6.5B panel b). Over-expression of the 
plectin-1 k ABD was observed to cause a re-organisation of actin in podosomes with 
more actin present in podosome ring compared to untransfected cells (compare Figure 
6.5B and Figure 6.3A). Double staining with cortactin was used to confirm the identity 
of the Plec-1 k-eGFP - positive structures as podosome-type adhesions (Figure 6.5C). 
Finally, analysis of vimentin cytoskeleton in transfected cells demonstrated that 
plectin-1 k N-terminus is targeted only to actin-rich structures as the vimentin-cage 
surrounding the nucleus was not GFP positive whereas podosomes contained both 
vim en tin and plec-1 k-eGFP construct (Figure 6.5D). Taken together, the ex on I k was 
sufficient to target the plectin ABD to podosome-type adhesions and the localisation 
does not require the intermediate-filament binding domain of plectin. 
6.2.7. Inhibition of ROCK activity impairs podosome assembly and alters plectin-
lk localisation. 
Podosomes and invadopodia are a characteristically found m Src-transformed cells 
(Buccione et al., 2004; Linder and Aepfelbacher, 2003) and Rho GTPase activity has 
been implicated as a downstream mediator of Src in podosome formation (Berdeaux et 
al., 2004). Rho-activation can also re-organise the vimentin cytoskeleton (Inada et al., 
1999) and could therefore influence the localisation of vimentin-binding proteins such 
as plectin. In order to investigate the possible role of signalling pathways downstream 
of active Rho in targeting plectin-1 k to podosomes, we scratch-wounded a stably 
transfected SW480 cell line expressing the plec-1 k-GFP construct and then treated the 
culture with Rho-kinase inhibitors (Figure 6.6). Control wound edge cells assembled 
several podosomes, two hours after wounding. In addition, the cells at the wound edge 
did not behave like an epithelial sheet, but the cells were seen to frequently escape 
from the wound edge and migrate individually or in small clusters into the wound 
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space (Figure 6.6A). Treatment of the cells with a Rho-kinase inhibitors prevented 
formation of circular podosome-type structures. Instead, the cells had smooth and wide 
lamellipodia-like edges with a dense actin staining along the cell edge (Figure 6. 7 AB 
bottom rows). Plectin-1 k was co-localised with actin at the leading edge, but did not 
form regular circular podosome structures or focal-adhesion complexes. Compared to 
control cells, Rho-kinase inhibited cells were much less likely to escape from the 
wound edge and behaved like collectively migrating epithelial sheet (Figure 6.6A). 
These results indicate that podosome formation and plectin-1 k localisation in SW 480 
cells are dependent on Rho-kinase activity. 
6.2.8. The N-terminal Actin-binding domain of plectin-lk rescues podosome 
formation in plectin knockdown cells. 
The observations that plec-1 k-GFP transfected cells appeared to have more podosome 
like adhesions than control transfected cells prompted the study of, whether the N-
terminus of plectin-lk alone was sufficient to induce podosome formation. Stably 
transfected SW480 cells were used that were expressing either plec-1k-eGFP construct 
(Figure 6.7A) or GFP alone (Figure 6.7B). Depletion ofplectin expression in these cell 
lines was carried out with siRNA targeted to the C-terminus of the full-length plectin 
mRNA leading to downregulation of the endogenous plectin but not pleclk-eGFP 
(Figure 6. 70). The results show that podosome-type adhesions were abundant at 
wound edges of both control siRNA and plectin siRNA transfected plec-1 k-eGFP cells 
(Figure 6.8A) whereas podosomes were almost completely absent in a control GFP 
cell line transfected with plectin siRNA (Figure 6.8B). Counting of podosome positive 
cells at scratch wound edges confirmed these observations and demonstrated that the 
N-terminus of plectin-1 k was sufficient for promoting assembly of podosome-type 
adhesions (Figure 6. 7C). 
6.2.9. Plectin-lk is shown localising to actin adhesive structures in cells attaching 
to collagen. 
In order characterise the participation of plectin-1 k in adhesive actin structures, 
immunofluorescence Z-projection microscopy of plecin-1 k-GFP cells and actin was 
carried out on cells attaching to a collagen substrate. Cells were fixed at 1 0, 20, 40 and 
80 minutes after being allowed to attached to collagen coated glass coverslips. In all 
instances as expected, plectin co-localised with actin in the attaching cells. At 1 0 
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minutes (Figure 6.8A) the cells have a rounded appearance where actin is localised to a 
dense ring around the nucleus. At the 20-minute time point the cells have started to 
spread and the actin cage around the nucleus is forming with dense actin staining at the 
cell periphery where plectin-1 k co localise. At 40 minutes the actin and plectin staining 
is similar to the 20-minute time point except that changes in cell polarity is starting to 
take place. The 80-minute time point is where we find the majority of cells forming 
podosome like adhesive structures although a proportion of cells at the earlier 20-40 
minutes are able to do this. These results show that during attachment to collagen, 
actin is actively reorganised in adhesive structures with co-localisation of plectin-
1 k. This observation provides further evidence that plectin-1 k interacting with actin is 
involved in the formation of adhesive structures. 
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Figure 6.5. Exon lk targets plectin actin-binding domain to podosomes and dorsal 
actin ruffles. 
(A) Plec-lk-eGFP and endogenous plectin (red channel, c-20 antibody) co-localise in 
podosomes (example indicated by an arrow). (B) Plec-lk-eGFP fluorescence (green) 
and phalloidin-stained filamentous actin (red). Top panel (a) show an optical slice 
taken from the basal surface of the cells. The white dotted line in the merged image 
indicates the location of the XZ section shown below in (b); the arrow points at the 
edge one podosome-type junction. Both actin staining and eGFP fluorescence extend 
inwards in the cell from the basal surface. Scale bar 20 ~-tm in (a) and 5 11m in (b). (C) 
GFP fluorescence (green) and cortactin staining (red). (D) Plec-1 k-eGFP construct 
(Green) does not co-localise with vimentin (red) in the intermediate filament cage 
surrounding nucleus but only in podosomes (arrow). The scale bar represents 20 ~-tm in 
panels A, C and D. 
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Figure 6.6. Rho-ROCK signalling regulates podosome assembly and plectin-1 k 
localisation. 
(A, B) Stably transfected SW480 cell monolayers expressing the plec-1 k-EGFP con-
struct were scratch wounded in the presence or absence of Rho-kinase inhibitors. 
Two different inhibitors (compounds Y-27632 and Rho-Kinase inhibitor, H-1152) were 
used separately or together with identical results. Top row, control cells, bottom row 
Rho-kinase inhibitor-treated cells. (B) Close-up detail of the wound edge. Note the 
lack of circular podosomes in the cells with ROCK inhibition. Scale bar is 50 1-1m in A 
and 20 1-1m in B. 
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Figure 6.7. Plectin-lk N-terminus rescues podosome assembly in plectin 
knockdown cells. 
(A) Stably transfected SW480 cells expressing plec-lk-eGFP construct were scratch 
wounded and subsequently transfected transiently with control siRNA (top row) or 
plectin siRNA (bottom row). Confocal imaging of eGFP fluorescence and phalloidin 
stained F-actin show the presence of podosome-type adhesions in plectin knockdown 
cells. (B) SW480 cells were stably transfected with eGFP alone, scratch wounded and 
siRNA transfected as in panel A. Note, that plectin siRNA transfection (Bottom row) 
inhibits podosome assembly in eGFP expressing cells. Scale bar is 20 !Jill in A and B 
(C) Wound edge cells containing podosome-type adhesion structures were counted 
from three independent experiments of plectin or control siRNA transfected cells 
expressing either plec-lk-eGFP construct or eGFP alone error bars indicate average 
deviation. (D) Immunoblot showing plectin siRNA depletion in (a) plec-1 k-eGFP 
stable transfected cells and (b) control eGFP stable transfected cells. Total plectin is 
detected with plectin c-20 antibody and actin is shown as a loading control. 
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Figure 6.8. Plectin-lk localisation of cells attaching to collagen. 
Confocal Z-projection images show stably transfected plect-lk-eGFP expressiOn m 
SW480 cells that are stained with phalloidin (to show actin localisation). Cells were 
fixed at 10, 20 40 and 80 minutes on attachment to fibrillar collagen before processing 
for staining. Note the plec-lk-eGFP localisation at the cell periphery (arrows) co-
localising with actin. In the 80 min panel the formation of podosome like adhesion 
structures are visible (arrow). Scale bars indicate 20flm in all panels. 
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6.3. Discussion. 
The results presented in this chapter show that the novel isoform plectin-1k is localised 
to podosome-like adhesions in invasive SW480 and MDA-MB-231 cell lines. This 
provides a previously uncharacterised subcellular localisation for plectin and further 
implicates the role of plectin in carcinoma cell adhesion and invasion. 
The localisation of the novel plectin isoform 1 k to podosome like adhesions was 
particularly obvious in the wound edge cells of SW480 colon carcinoma monolayers. 
In accordance with described criteria (Linder and Aepfelbacher, 2003 ), I classified the 
observed actin structures as podosomes since they were found in the basal aspect of 
cells, contained a round actin core surrounded by a vinculin-positive ring and were 
positive for N-WASP, cortactin, dynamin, vinculin and vimentin. The carcinoma cell 
podosomes were between 0.5 and 1 J..lm in diameter and, when observed in XZ 
dimension by confocal microscope were not restricted to a flat adhesive plaque but 
extended inwards into the cytoplasm. It was demonstrated that plectin-1 k co localised 
with N-WASP in podosomes of THP-1 macrophages indicating that plectin is a 
component of podosomes in macrophage/monocyte lineage in addition to epithelial 
carcinoma cells. The nomenclature of podosome-type adhesions is not completely 
resolved, with more persistent and larger actin-rich foci in carcinoma cells often 
named as invadopodia, as opposed to more transient and smaller podosomes in 
macrophages, smooth muscle cells and endothelial cells (reviewed in Gimona et al., 
2007 and Linder, 2007). However, in line with Seals et al., 2005 who show podosomes 
in invasive cancer cells I called the podosome-type adhesions, in both MDA-MB 231 
and SW480 cells, podosomes. 
The localisation of plectin-1 k to podosomes was supported by immunofluorescence 
staining of plectin-1 k specific antibody, plectin C-terminal antibody and by 
localisation of transfected plec-1 k-eGFP fusion protein. By investigating the 
subcellular distribution of other plectin N-terminal isoforms as eGFP-fusion proteins, 
we also found that also isoforms plectin-1 and, to a lesser extent, I d and 1 g are 
localised to podosomes (see Chapter 4, Table 4.1 ). It is likely that different plectin 
isofonns function at these sites as heterodimers via their coiled-coil rod domains. 
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In the previous chapter it was observed that knockdown of plectin expression by 
siRNA inhibited both podosome assembly at scratch wound edge cells and SW480 cell 
migration and invasion (Figure 5.14). The inhibition of podosome assembly was 
rescued by the N-terminal domain of plectin-1 k (Figure 6. 7) suggesting plectin is 
required for podosome assembly in invasive carcinoma cells. Previous studies have 
identified instrumental roles for other cytoskeletal proteins, such as dynamin and 
cortactin, in podosome assembly (Ochoa et al., 2000; Bruzzaniti et al., 2005). Dynamin 
binds cortactin and both proteins can regulate actin assembly. Another actin-binding 
protein, 1-caldesmon, has been shown to play an important role in podosome assembly 
in smooth muscle cells (Eves et al., 2006). Finally, a scaffolding protein, Tsk5/Fish 
that contains several SH3-domains is implicated in podosome assembly in invasive 
carcinoma cell lines (Seals et al., 2005). Plectin is both an actin binding protein and a 
scaffolding protein for protein kinases and could be considered in the same functional 
category as, cortactin, caldesmon and Tsk5. 
Podosome-like actin rings in epithelial carcinoma cells have been suggested to be 
related to hemidesmosome assembly (Spinardi et al., 2004). As previously mention 
plectin interacts with ~4 integrin in assembly of hemidesmosomes (Chapter 1 ). It could 
be possible that invasive cell-matrix junctions, such as podosomes and invadopodia 
utilise existing components of epithelial cell-matrix adhesion sites. However, the 
results suggest that plectin isoforms that are not involved in hemidesmosome assembly 
in vivo, such as plectin-1, are targeted to podosomes. It is possible that epithelial 
carcinogenesis involves selective expression or activation of a subset of plectin 
isoforms. This is supported by the finding that plectin-1 k is over-expressed in invasive 
colon and breast cancer cell lines (Chapter 4, Figure 4.12.). 
Plectin siRNA transfection leading to ablation of plectin protein expression reduced 
invasiveness of SW480 cells through collagen gels (Chapter 5, Figure 5.4). In addition 
depletion of vimentin also slows down invasion and migration (Chapter 5, Figure 5.6). 
Since vimentin participates in PKCE-mediated recycling of integrins (lvaska et al., 
2005) and vimentin has been identified as a component of podosomes (Correia et al., 
1999), it appears possible that the protein complex between vimentin and plectin plays 
a role in the assembly of podosome-type adhesions. This suggestion is also supported 
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by impaired migration of immune cells m isoform specific plectin-1 null mice 
(Abrahamsberg et al., 2005). 
Rho signalling plays an important role in podosome assembly (Berdeaux et al., 2004; 
Osiak et al., 2005). I found that formation of podosomes and dorsal actin ruffles in 
SW480 cells is sensitive to Rho kinase (ROCK) inhibitors (Figure 6.6). ROCK activity 
has previously been shown to be important in amoeboid mode of cancer cell invasion 
(Sahai and Marshall, 2003), but has not been implicated in podosome assembly. In 
fact, it appears that several Rho-dependent pathways can regulate podosome assembly. 
In Src transformed fibroblasts, C3 exotoxin, a Rho-inhibitor, blocks podosome 
formation, whereas Rho-kinase inhibitors do not affect podosome assembly (Berdeaux 
et al., 2004). In mouse osteoclasts, Rho acts upstream of PI4-P-5 and PI3 kinases to 
promote podosome assembly (reviewed by Chellaiah, 2006) and in HUVEC 
endothelial cells treated with phorbol esters a linear signalling pathway involving 
PKC, Src and Cdc42 leads to podosome assembly (Tatin et al., 2006). Thus, signalling 
events leading to podosome formation can be cell-type specific and it is possible that 
podosome-like structures and invadopodia in epithelial carcinomas are regulated by 
different mechanisms than 'physiological' podosomes in osteoclasts and macrophages. 
Finally, further evidence that plectin-1 k is localised to actin rich adhesion structures 
was demonstrated by investigation of plec-1 k-GFP transfected SW480 cells attaching 
to collagen (Figure 6.8). Interestingly, at the early stages of attachment plec-1k-eGFP 
colocalised with actin at short filopodia like structures at the cell periphery. At later 
stages of attachment, upon possible polarisation of the cell, the appearances of 
podosomal-like adhesions were apparent. It is possible that this is the stage when 
SW480 cells are becoming polarised and matrix remodelling takes place. Podosomes 
were also most abundant in wound assays two hours after wounding. It would be of 
interest to investigate what signalling pathways in this cell trigger the formation of 
podosomes in single cells and at the wound edge. On another note, further 
investigation using live cell imaging may provide answers on the regulation of 
turnover of the carcinoma cell podosomes after their appearance in the SW480 cells. In 
summary localisation of plectin isoforms, including plectin-1 k, to actin structures 
involved in carcinoma invasion suggests that plectin could play a role in the regulation 
of invasive and metastatic behaviour of colon cancer cells. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE OUTLOOK 
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Discussion and future outlooks. 
Approximately 90% of all cancer deaths arise from the metastatic spread of primary 
tumours (Chambers et al., 2002, Christofori et al., 2006). Thus, understanding cell 
migration and invasion is invaluable in cancer cell biology research. Furthermore, 90% 
of cancers originate from epithelial tissues and show characteristics of epithelial to 
mesenchymal transition (Christofori et al., 2006). Current anti-cancer therapies are 
targeted to the ability of a cancer cell to proliferate. However, many tumours are 
resistant to this treatment. Furthermore, migrating cells are known to show a decreased 
proliferation rate and tend to be less sensitive to standard chemotherapy (reviewed in 
Hayote et al., 2006). The cytoskeletal networks (microfilaments, microtubules and 
intermediate filaments) along with the numerous cytoskeletal-associated proteins are 
intrinsically involved in cell migration. Additionally, alterations in cell-cell and cell-
matrix adhesion have been shown to have a central role in facilitating tumour cell 
migration, invasion and metastatic dissemination (Kartenbeck et al., 2005; Christofori 
et al 2006; Lyons et al 2007). With the above in mind, I set out to investigate the role 
of the plakin family members, particularly plectin, in carcinoma cell migration, 
invasion and attachment with the hypothesis that plectin could act as a mediator in the 
regulation of these processes. 
Plectin, a versatile cytoskeletal linker protein, has been implicated in many cellular 
functions. Firstly, plectin was recognised as a component of hemidesmosomes and a 
linker of intermediate filaments and actin. More recently, plectin has been shown to act 
as a scaffolding protein for signalling events (reviewed in Sonnenberg et a!., 2007). 
Previous studies have focused on the role of plectin in skin and muscle integrity due to 
the defects found in plectin deficient mice and patients. Plectin mutations result in 
EBS-MD, epidermolysis bullosa simplex with muscular dystrophy (Pfender et a!., 
2005). In addition to the role of plectin in skin architecture, it has also been widely 
studied in striated muscle where it's a component of the Z-line associated with desmin 
(Andra eta!., 1997; Hijikata eta!., 1999). Plectin null mice show skin and tissue 
fragility with reduced desmosomes and hemidesmosomes resulting in blisters. 
Moreover, the revealed abnormalities were reminiscent of minicore myopathies in 
skeletal muscle and disintegration of intercalated discs in heart (Andra et al., 1997). 
Plectin has also been shown to be a modulator of intermediate filament and actin 
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dynamics (Wiehe et al., 1998; Andra et al., 1998). Additionally, plectin may have a 
possible role in reorganisation of the actin cytoskeleton during death receptor-mediated 
apoptosis as an early substrate for caspase 8 (Stegh et al., 2000). The emerging data, 
implicating plectin in various signal transduction pathways (Lunter et al., 2002; 
Osmanagic-Meyers et al., 2004; Osmanagic-Meyers et al., 2006; Gregor et al., 2006) 
further emphasises the dynamic and versatile properties of plectin and the role that it 
may play in the regulation of cell migration adhesion and attachment. 
Plectin was shown to have a complex N-terminal gene organisation, where there were 
eight possible first exons and two possible 2nd and 3rd exons found in the murine gene 
(Fuchs et al., 1999). I demonstrated in Chapter 3 that the human gene also contains a 
similar diversity of alternative first exons. I identified an additional N-terminal 
alternative first exon that encoded for a novel isoform that I named plectin-1 k. The 
plectin isoform mRNAs were widely expressed in human tissue with a subset of N-
terminal isoforms displaying a variable expression (specifically isoforms plec-1, 1 a, 
1 d, 1 f and 1 k). Interestingly, plectin-1 k showed variable expression across the tissue 
panel with up regulation in colon tissue. Plectin-1 k was also found to have an elevated 
mRNA expression in the invasive SW480 colon carcinoma cell lines compared to the 
low invasive HT29 colon carcinoma cells but was not elevated in the invasive breast 
carcinoma cell lines. This result is of particular significance, as further in this study, 
plectin-1 k is identified as a constituent of podosome like adhesions that are involved in 
carcinoma cell migration. 
Using a panel of colon and breast carcinoma cells lines, which were shown to have 
variable invasive potential through collagen gels, I demonstrated plectin to have 
altered expression at the mRNA, protein and subcellular localisation levels. Strikingly, 
plectin protein expression was elevated in the more invasive cell types (SW480 and 
MDA-MB-231) compared to their low invasive counterparts (HT29, MCF7). 
Immunofluorescence data of the invasive carcinoma cells show the sub-cellular 
expression of plectin to be recruited away from hemidesmosomes (as observed in the 
low invasive carcinoma cells and other previously studied epithelial cells) and to be 
relocated at an actin/vimentin rich cage around the nucleus, to focal .adhesions and 
actin rich foci that are later identified as podosomes in Chapter 6. I also confirm that 
similar to the murine data (Rezniczek et al., 2003), the expression ofN-terminal exons 
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and the sequence encoding actin binding domain alone show preferences in sub-
cellular localisation to the actin cytoskeleton. Thus, the alternative first exons could 
determine the subcellular localisation of the human plectin isoforms. Isoform specific 
antibodies raised to plectin-1, 1 b, 1f and 1 k provided an invaluable tool to understand 
the expression of the full length plectin isoforms. These isoforms were of particular 
interest as expression of the alternative first exons tagged to GFP showed preferential 
subcellular location at focal adhesions, actin adhesion structures or actin rich foci. The 
antibodies confirmed the localisation of plectin isoforms in the carcinoma cells to 
specific preferential subcellular localisation as observed using N-terminal plectin-GFP 
truncated proteins and the previous murine data (Rezniczek et al., 2003 ). The results 
also suggest that as the majority of the isoforms can be found at similar localisation a 
possible role of heterodimerisation of plectin isoforms may exist. Finally, a cancer cell 
may be able to regulate the expression levels of specific plectin N-terminal isoforms 
compared to each other, with the outcome of modulating invasion, migration and cell 
attachment. 
Plectin depletion in invasive cells caused impairment in colon carcmoma cell 
migration, invasion and attachment. However, the severity of the impairments was cell 
type specific as the breast carcinoma cells exhibited defects in attachment only, with 
migration and invasion not significantly altered. On analysis of the cytoskeletal related 
protein expression profile, possible explanations as to why plectin ablation is shown to 
have a different effect in the breast and colon invasive cell lines are revealed. The 
invasive breast carcinoma cells predominantly express a vimentin intermediate 
cytoskeleton with an increase in focal adhesion proteins vinculin and talin, whereas the 
invasive colon carcinoma cells express a keratin and vimentin intermediate 
cytoskeleton. Both SW480 and MDA-MB-231 carcinoma cells show a loss of E-
cadherin characteristic of epithelial to mesenchymal transition and also desmoplakin a 
component of desmosomes that mediate cell-cell attachment. Plectin was found to 
interact with vimentin as a linker protein and at vimentin positive focal adhesions and 
several previous studies show that vimentin is involved in migration and invasion in 
many cell types, including breast cancer derived cell lines (see Chapter 5). However, 
none of the previous studies conclusively established whether vimentin expression is 
only a marker of epithelial to mesenchymal transition changes or if vimentin 
expression is required for the invasive behaviour of the cells. I show that siRNA 
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mediated knockdown of vimentin results in impaired migration and adhesion of breast 
carcinoma cells that have acquired vimentin expression as a part of the epithelial to 
mesenchymal transition. However, in the SW480 colon carcinoma cells, depletion of 
vimentin caused only a modest effect on cell adhesion. This is possibly due to the 
ability of the retained keratin intermediate filaments to circumvent the requirement of 
vimentin for integrin targeting. Vimentin was shown to have role in controlling 
recycling of P 1 integrins (lvaska et a!., 2005) moreover there was reduced size of focal 
contacts in vimentin ablated cells (Tsuruta et al., 2003) which is consistent with the 
migration, invasion and attachment defects found in the vimentin ablated MDA-MB-
231 cells. In future studies, it would be of interest to investigate the molecular 
interactions of vimentin that are required for migration and invasion and whether 
plectin is involved in mediating these effects. This could be investigated using double 
siRNA transfections in these cells for simultaneous depletion of vimentin and plectin 
and also transfection of specific plectin isoforms to demonstrate any defects of cancer 
cell migration, invasion and attachment that are dependent on specific N-terminal 
isoform expression. 
Protein constructs with alternative plectin N-termini demonstrated that the first exons 
of isoforms 1 k, 1 and 1 d target the actin-binding domain of plectin to podosomes. The 
plectin 1 k isoform was observed to be preferentially located to podosomes more than 
the other isoforms. Both the localisation of plectin-1k and podosome assembly was 
disrupted with Rho-kinase (ROCK) inhibitors. Down regulation of plectin expression 
by siRNA inhibited podosome assembly at wound edge cells of scratch wounded 
SW480 monolayers, impaired cell migration and inhibited invasion through collagen. 
Most strikingly, only the plectin-1 k N-terminus was needed to rescue podosome 
formation in plectin knockdown cells. Thus, plectin was shown to participate in 
podosome assembly and invasiveness in carcinoma cells. Identification of plectin-1 k 
adds to a growing list of cytoskeletal linkers that can be targeted to specific organelles 
or subcellular structures. Plectin has recently been shown that alternatively spliced 
MACFl b localizes to the Golgi complex (Lin eta!., 2005). The plakin family members 
can have remarkably versatile effects on both architecture and function of various cell 
types and tissues. Furthermore, the results presented in this thesis suggest that plectin 
could play a role in the regulation of invasive and metastatic behaviour of colon cancer 
cells. 
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In addition to the involvement of plectin in migration, invasion and adhesion of 
carcinoma cells, many interesting areas have arisen during this study. The localisation 
of plectin in a network surrounding the nucleus in migrating cells and the interaction of 
plectin with nesprin-3 implicate plectin as a linker to the cell nuclear membrane could 
provide enlightenment on the function of the nuclear envelope during mitosis and 
proper nuclear positioning during quiescence and cell migration (Wilhelmsen et al., 
2003). The possible role that plectin may play in the positioning mitochondria is 
starting to be addressed (Reipert et al., 1999; Appaix et al., 2003) and may yield 
further insight into the treatment and understanding of myofibrillar myopathies (Vita et 
al., 2003; Reimann et al., 2003). Plectin has been previously shown to have numerous 
interacting partners with the newly identified interaction with periplakin showing that 
interactions may be isoform specific (Boczonadi et al., 2007). It would be of high 
interest to investigate the molecular interacting partners of each of the alternative N-
terminal plectin isoforms and what effect this interaction has on signal transduction 
pathways. The unlocking of the human alternative first exons with the generation N-
terminal GFP expression proteins, along with the generation of isoforms specific 
antibodies will provide vital tools in the discovery of the specific molecular 
interactions of the human plectin N -terminal isoforms. The numerous interactions of 
plectin and the implication in pathogenesis continues to be an expanding area of cell 
biology, yielding surprising and exciting results, highlighting the importance of plectin 
in the integrity of the cell. 
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APPENDIX I. SEQUENCES OF PLECTIN ALTERNATIVE N-TERMINAL 
FIRST EXONS 
PLEC lX 
HUMAN 
ATGGTGGCCGGCATGCTCATGCCACGGGACCAGCTGCGGGCCATCTATGAGGTGCTCT 
TCCGCGAGGGCGTGATGGTGGCCAAGAAGGACCGGCGGCCCCGCAGCTTGCACCCCCA 
TGTGCCCGGCGTCACCAACCTGCAGGTCATGCGTGCCATGGCGTCCCTGCGGGCACGG 
GGCCTGGTCCGCGAGACCTTTGCCTGGTGCCACTTTTACTGGTACCTCACCAATGAAG 
GCATCGCCCACCTCCGCCAGTACCTGCACCTGCCGCCAGAGATCGTGCCCGCCTCTCT 
GCAGCGCGTGCGCCGCCCCGTCGCCATGGTGATGCCCGCACGCCGCACCCCCCACGTG 
CAGGCTGTGCAGGGTCCCCTGGGCTCCCCACCCAAGCGGGGGCCGCTGCCGACGGAGG 
AGCAGCGGGTCTACCGTCGGAAGGAGCTTGAGGAGGTGTCACCTGAGACCCCTGTGGT 
GCCTGCTACCACCCAGCGGACCCTGGCCAGGCCAGGCCCGGAGCCTGCCCCAGCCACA 
G 
MOUSE 
ATGGTGGCTGGCATGCTCATGCCGCTGGACCGGCTACGGGCCATCTATGAGGTGCTCT 
TCCGTGAGGGGGTGATGGTTGCCAAGAAGGACCGGCGACCCCGCAGCCTGCATCCCCA 
TGTGCCCGGCGTCACCATTCTACAGGTCATGCGTGCCATGGCTTCACTGAAAGCTCGG 
GGCCTGGTGCGGGAGACCTTTGCCTGGTGCCACTTCTACTGGTACCTGACCAACGAGG 
GCATTGACCACCTACGCCAGTACTTACACCTGCCACCGGAGATTGTACCTGCCTCTCT 
GCAGCGTGTGCGCCGCCCTGTCGCCATGGTGATACCTGCACGTCGTCGCTCCCCCCAT 
GTGCAGACCATGCAAGGTCCCCTAGGCTGCCCACCAAAGAGGGGGCCTCTGCCAGCTG 
AGGACCCTGCCCGTGAGGAGCGGCAGGTCTATCGCAGGAAGGAGCGTGAGGAGGGGGC 
ACCTGAAACCCCTGTGGTGTCTGCCACCACCGTGGGGACCCTGGCCAGACCAGGTCCG 
GAGCCTGCCCCAGCCACAG 
RAT 
ATGGTGGCTGGCATGCTCATGCCACTGGACCAGCTTCGGGCCATCTATGAGGTGCTCT 
TTCGTGAGGGGGTGATGGTTGCCAAGAAGGACCGGCGACCCCGAAGCCTGCATCCCCA 
TGTGCCCGGCGTCACCAATCTACAGGTCATGCGTGCCATGACCTCGCTGAAAGCTCGG 
GGCCTGGTGCGGGAGACCTTTGCCTGGTGCCACTTCTACTGGTACCTGACCAACGAGG 
GCATCGACCACCTACGCCAGTACCTACACCTGCCACCGGAGATCGTACCTGCCTCTCT 
GCAGCGTGTGCGCCGCCCTGTTGCCATGGTGATGCCTGCACGTCGTCGCTCCCCCCAT 
GTGCAGACCATGCAAGGTCCCTTAGGCTGTCCACCAAAGAGGGGCCCTCTGCCAGCTG 
AGGACCCTGCCCGGGAGGAGCGGCAGGTCTATCGCAGGAAGGAGCGTGAGGAAGGGGC 
ACCTGAAACCCCTGTGGTGTCTGCCACCATCGTGGGGACCCTGGCCAGGCCAGGCCCA 
GAGCCCACCCCAGCCACAG 
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PLEC lA 
HUMAN 
ATGTCTCAGCACCAGCTCCGCGTGCCGCAGCCCGAGGGCCTGGGCCGAAAGAGAACCA 
GCTCGGAGGACAACCTGTACCTGGCTGTGCTCAGGGCCTCTGAGGGCAAGAAAG 
MOUSE 
ATGTCTCAGCACCGGCTCCGTGTGCCCGAGCCGGAAGGCCTGGGTAGCAAGAGAACCA 
GCTCAGAGGACAACCTCTACCTGGCTGTGCTCAGAGCCTCCGAGGGCAAGAAAG 
RAT 
ATGTCTCAGCAACGGCTCCGTGTGCCCGAGCCTGAAGGCCTGGGTAGCAAGAGAACCA 
GCTCAGAGGACAACCTCTACCTGGCTGTGCTCAGGGCCTCCGAGGGCAAGAAAG 
PLEC lB 
HUMAN 
ATGGAGCCCTCGGGCAGCCTGTTTCCCTCCCTGGTGGTTGTGGGTCACGTTGTCACCC 
TGGCCGCTGTGTGGCACTGGCGCAGGGGACGTCGGTGGGCGCAGGACGAGCAAG 
MOUSE 
ATGGAGCCGTCGGGCAGCCTGTTTCCCTCCCTGGTAGTCGTGGGTCATGTTGTCACTC 
TGGCTGCCGTATGGCACTGGCGTAAGGGGCATCGGCAGGCAAAGGATGAGCAAG 
RAT 
ATGGAGCCGTCGGGCAGCCTGTTTCCCTCTCTGGTAGTCGTGGGTCATGTTGTCAGTC 
TGGCTGCTGTATGGCACTGGCGTAAGGGGCATCGGCAGGCACAGGATGAGCAAG 
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PLEC lC 
HUMAN 
ATGTCGGGTGAGGACGCTGAGGTCCGGGCAGTCTCTGAAGATGTCTCCAATGGAAGCA 
GTGGCTCGCCCAGCCCTGGGGACACACTGCCCTGGAACCTTGGGAAAACGCAGCGGAG 
CCGGCGCAGCGGGGGTGGCGCTGGGAGCAACGGGAGTGTCCTGGACCCAGCTGAGCGG 
GCGGTCATTCGCATCGCAG 
MOUSE 
ATGTCAGGGGAGGATTCTGAGGTCCGGCCAGTGGCAGTGGCTGAAGGTAGTTCCAATG 
GAAGCAGTGGCTCACCCAGCCCCGGGGACACACTGCCCTGGAACCTTGGGAAAACACA 
GAGAAGTCGGCGAAGTGGAGGTGGTTCTGTGGGCAATGGGAGCGTCTTGGACCCTGCA 
GAGCGGGCCGTCATCCGCATTGCAG 
RAT 
ATGTCAGGGGAGGACTCCGAGGTACGGCCAGTGGCAGTGGCTGAAGGTAGTTCCAATG 
GAAGCAGTGGTTCACCCAGCCCCGGGGACACACTGCCCTGGAACCTTGGGAAAACACA 
GAGAAGCCGGCGGAGTGGAGGTGGTTCTGTGGGCAATGGGAGCGTCTTGGATCCTGCA 
GAGCGGGCCGTCATCCGCATTGCAG 
PLEC lD 
HUMAN 
ATGAAGATCGTGCCCG 
MOUSE 
ATGAAGATCGTGCCCG 
RAT 
ATGAAGATCGTGCCCG 
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PLEC lE 
HUMAN 
ATGGACCCCTCGCGAGCCATCCAGAACGAGATCAGCTCCCTCAAAG 
MOUSE 
ATGGACCCCTCAAGAGCCATCCAGCACGAGATCAGCTCCCTCAAAG 
RAT 
ATGGACCCCTCGAGAGCCATCCAGCATGAAATCAGCTCCCTCAAAG 
PLEC lF 
HUMAN 
ATGGCCGGCCCGCTGCCCGACGAGCAGGACTTCATCCAGGCCTACGAGGAGGTGCGCG 
AGAAGTACAAAG 
MOUSE 
ATGGCCCATCTGCTGACGTCTGGCCCACCACCCGACGAACAGGATTTCATCCAGGCCT 
ACGAGGAGGTGCGGGAGAAGTACAAAG 
RAT 
ATGGCCCATCTGCTGACGTCCGGCCCACCACCCGACGAACAGGACTTCATCCAGGCC 
TACGAGGAGGTGCGGGAGAAGTACAAAG 
202 
PLEC lG 
HUMAN 
ATGTCGGGGGCGGGGGGCGCCTTTGCCTCGCCGAGGGAGGTCTTGCTGGAGCGGCCGT 
GCTGGCTGGACGGGGGCTGCGAGCCGGCCCGCAGGGGCTACCTCTACCAGCAGCTGTG 
CTGCGTAG 
MOUSE 
ATGGGCTGGGGCGCGGCTTCCTGGCCCACACTGGGCGGGGCGCTTGCTGCAGGGGCAG 
GTTCTCCGGGTCTGGGTATTGCGTCCGATGGGCGGGGGCGAACGTGGAAGCCAGGGCC 
TTCAGCCTTCAACACAAGCACGGCTTTCGTGTCGTCTGCGAGCAGCCCAGGGCACTCG 
GGGCTCCTGGCAATGGCAGGGACGTGGGCGGCGAAGGGAGTCTTCACTTCGCAGAGGG 
AGGTCCTGGAGCGTCCCYCGTGGCTGGATGGGGGCTGCGAGCAGGTCCGCAGGGGCTA 
CCTCTACGGGCAACTCTGTTGTGTAG 
RAT 
ATGGCAGGGACGTGGGCAGCGAAGGGCGTCTTCACTTCGCAGAGGGAGGTCCTGTTGG 
AGCGGCCCTGCTGGCTGGATGGGGGCTGTGAGCAGATTCGCAGGGGCTATCTCTACGG 
GCAACTGTGTTGTGTAG 
PLEC lK 
HUMAN 
ATGGACAGGTACAGCATGGAGGAGCTGATTCAGCTGGGCCAAG 
MOUSE 
ATGGATAGGTACAGCATGGAGGAGCTGATCCAGCTGGGCCAAG 
RAT 
ATGGATATGTACAGCATGGAGGAGCTGATCCAGCTGGGCCAAG 
PLEC lL (POSSIBLE) 
HUMAN 
ATGGATCAGGTGAGAAGCCTCTCCACAGAGGCCTGGCGAGGTCCACCCTGCTGCAGCA 
GAGCAGGTGCCTGCGTGAGGAGGGCCTCCAGAGGGCAGCGGCAGGGCTGTGGTGGGAC 
CTGCTTGTGCTCGGAGAGCACTGGCTGCTGTTGTCCAGTGCTTGGAG 
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APPENDIX II. PREDICTED AMINO ACID SEQUENCES OF PLECTIN 
ALTERNATIVELY SPLICES N-TERMINAL EXONS 
PLECTIN 1 
HUMAN 
MET V A G MET L MET P R D Q L R A I Y E V L F R E G V MET 
V A K K D R R P R S L H P H V P G V T N L Q V MET R A MET 
A S L R A R G L V R E T F A W C H F Y W Y L T N E G I A H 
L R Q Y L H L P P E I V P A S L Q R V R R P V A MET V MET 
P A R R T P H V Q A V Q G P L G S P P K R G P L P T E E Q 
R V Y R R K E L E E V S P E T P V V P A T T Q R T L A R P 
G P E P A P A T 
MOUSE 
MET V A G MET L MET P L D R L R A I Y E V L F R E G V MET 
V A K K D R R P R S L H P H V P G V T I L Q V MET R A MET 
A S L K A R G L V R E T F A W C H F Y W Y L T N E G I D H 
L R Q Y L H L P P E I V P A S L Q R V R R P V A MET V I P 
A R R R S P H V Q T MET Q G P L G C P P K R G P L P A E D 
P A R E E R Q V Y R R K E R E E G A P E T P V V S A T T V 
G T L A R P G P E P A P A T 
RAT 
MET V A G MET L MET P L D Q L R A I Y E V L F R E G V MET 
V A K K D R R P R S L H P H V P G V T N L Q V MET R A MET 
T S L K A R G L V R E T F A W C H F Y W Y L T N E G I D H 
L R Q Y L H L P P E I V P A S L Q R V R R P V A MET V MET 
P A R R R S P H V Q T MET Q G P L G C P P K R G P L P A E 
D P A R E E R Q V Y R R K E R E E G A P E T P V V S A T I 
V G T L A R P G P E P T P A T 
204 
PLECTIN lA 
HUMAN 
:MET s Q H Q L R v P Q P E G L G R K R T S S E 0 N L Y L A 
V L R A s E G K K 
MOUSE 
:MET s Q H R L R v P E P E G L G S K R T S S E 0 N L Y L A 
V L R A s E G K K 
RAT 
:MET s Q Q R L R v P E P E G L G S K R T S S E 0 N L Y L A 
V L R A S E G K K 
PLECTIN lB 
HUMAN 
:MET E p s G s L F P S L V V V G H V V T L A A V W H W R R 
G R R w A Q 0 E Q 
MOUSE 
:MET E p s G s L F P S L V V V G H V V T L A A V W H W R K 
G H R Q A K 0 E Q 
RAT 
:MET E p s G s L F P S L V V V G H V V S L A A V W H W R K 
G H R Q A Q 0 E Q 
205 
PLECTIN lC 
HUMAN 
MET s G E D A E v R A v s E D v s N G s s G s p s p G D T 
L p w N L G K T Q R s R R s G G G A G s N G s v L D p A E 
R A v I R I A 
MOUSE 
MET s G E D s E v R p v A v A E G s s N G s s G s p s p G 
D T L p w N L G K T Q R s R R s G G G s v G N G s v L D p 
A E R A v I R I A 
RAT 
MET s G E D s E v R p v A v A E G s s N G s s G s p s p G 
D T L p w N L G K T Q R s R R s G G G s v G N G s v L D p 
A E R A v I R I A 
PLECTIN lD 
HUMAN 
MET K I V P 
MOUSE 
MET K I V P 
RAT 
MET K I V P 
PLECTIN lE 
HUMAN 
MET D P S R A I Q N E I S S L K 
MOUSE 
MET D P S R A I Q H E I S S L K 
RAT 
MET D P S R A I Q H E I S S L K 
206 
PLECTIN lF 
HUMAN 
MET A G P L P D E Q D F I Q A Y E E V R E K Y K 
MOUSE 
MET A H L L T S G P P P D E Q D F I Q A Y E E V R E K Y K 
RAT 
MET A H L L T S G P P P D E Q D F I Q A Y E E V R E K Y K 
PLECTIN lG 
HUMAN 
MET S G A G G A F A S P R E V L L E R P C W L D G G C E P A R R 
G Y L Y Q Q L C C V 
MOUSE 
MET A G T W A A K G V F T S Q R E V L E R P X W L D G G C E Q V 
R R G Y L Y G Q L C C V 
RAT 
MET A G T W A A K G V F T S Q R E V L L E R P C W L D G G C E Q 
I R R G Y L Y G Q L C C V 
PLECTIN lK 
HUMAN 
MET D R Y S MET E E L I Q L G Q 
MOUSE 
MET D R Y S MET E E L I Q L G Q 
RAT 
MET D MET Y S MET E E L I Q L G Q 
PLECTIN lL (POSSIBLE) 
HUMAN 
MET D Q V R S L S T E A W R G P P C C S R A G A C V R R A S R G 
Q R Q G C G G T C L C S E S T G C C C P V 
207 
Plec-GFP F-Actin Merge 
Plec-1 
Plec-1b 
Plec-1c 
Pec-1d 
208 
Plec-GFP F-Actin Merge 
Plec-1e 
Plec-1f 
Plec-1g 
Plec-1k 
209 
Appendix III. Subcellular localisation of alternative plectin N-terminal domains. 
Representative examples of co-localisation of eGFP fluorescence and actin 
cytoskeleton (red, phalloidin staining) in SW480 cells transfected with the indicated 
constructs. Dapi staining of cell nucleus is included in the merged image (blue). 
Images are taken with Delta Vision deconvolution microscope with x 60 oil immersion 
lense. Note, co-localisation of plectin with actin at focal adhesions and stress fibers. 
Scale bars represent 20Jlm. 
210 
Abrahamsberg, C., P. Fuchs, S. Osmanagic-Myers, I. Fischer, F. Propst, A. Elbe-
Burger, and G. Wiehe. 2005. Targeted ablation of plectin isoform 1 uncovers role of 
cytolinker proteins in leukocyte recruitment. Proc Natl Acad Sci U S A. 102:18449-54. 
Agrez, M., A. Chen, R.I. Cone, R. Pytela, and D. Sheppard. 1994. The alpha v beta 6 
integrin promotes proliferation of colon carcinoma cells through a unique region of the 
beta 6 cytoplasmic domain. J Cell Bioi. 127:547-56. 
Agrez, M.V., and R.C. Bates. 1994. Colorectal cancer and the integrin family of cell 
adhesion receptors: current status and future directions. Eur J Cancer. 30A:2166-70. 
Aho, S. 2004. Many faces of periplakin: domain-specific antibodies detect the protein 
throughout the epidermis, explaining the multiple protein-protein interactions. Cell 
Tissue Res. 316:87-97. 
Aho, S., M.G. Mahoney, and J. Uitto. 1999. Plectin serves as an autoantigen m 
paraneoplastic pemphigus. J Invest Dermatol. 113:422-3. 
Aho, S., W.H. McLean, K. Li, and J. Uitto. 1998. eDNA cloning, mRNA expression, 
and chromosomal mapping ofhuman and mouse periplakin genes. Genomics. 48:242-
7. 
Alroy, J., B.U. Pauli, and R.S. Weinstein. 1981. Correlation between numbers of 
desmosomes and the aggressiveness of transitional cell carcinoma in human urinary 
bladder. Cancer. 4 7: 1 04-12. 
Amann, K.J., and T.D. Pollard. 2001. The Arp2/3 complex nucleates actin filament 
branches from the sides of pre-existing filaments. Nat Cell Bioi. 3:306-10. 
Andra, K., I. Komacker, A. Jorgl, M. Zorer, D. Spazierer, P. Fuchs, I. Fischer, and G. 
Wiehe. 2003. Plectin-isoform-specific rescue of hemidesmosomal defects in plectin (-
/-) keratinocytes. J Invest Dermatol. 120:189-97. 
Andra, K., H. Lassmann, R. Bittner, S. Shomy, R. Fassler, F. Propst, and G. Wiehe. 
1997. Targeted inactivation of plectin reveals essential function in maintaining the 
integrity of skin, muscle, and heart cytoarchitecture. Genes Dev. 11 :3143-56. 
Andra, K., B. Nikolic, M. Stoeber, D. Drenckhahn, and G. Wiehe. 1998. Not just 
scaffolding: plectin regulates actin dynamics in cultured cells. Genes Dev. 12:3442-51. 
Angst, B.D., L.A. Nilles, and K.J. Green. 1990. Desmoplakin II expression is not 
restricted to stratified epithelia. J Cell Sci. 97 ( Pt 2):24 7-57. 
Auwerx, J.H., S. Deeb, J.D. Brunzell, R. Peng, and A. Chait. 1988. Transcriptional 
activation of the lipoprotein lipase and apolipoprotein E genes accompanies 
differentiation in some human macrophage-like cell lines. Biochemistry. 27:2651-5. 
Baker, E.A., D.J. Leaper, J.P. Hayter, and A.J. Dickenson. 2006. The matrix 
metalloproteinase system in oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 
44:482-6. 
211 
Bankfalvi, A., M. Krassort, LB. Buchwalow, A. Vegh, E. Felszeghy, and J. Piffko. 
2002. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) 
during oral carcinogenesis and tumour progression. J Pathol. 198:343-51. 
Bankfalvi, A., M. Krassort, A. Vegh, E. Felszeghy, and J. Piffko. 2002. Deranged 
expression of the E-cadherin!beta-catenin complex and the epidermal growth factor 
receptor in the clinical evolution and progression of oral squamous cell carcinomas. J 
Oral Pathol Med. 31 :450-7. 
Bantounas, 1., L.A. Phylactou, and J .B. Uney. 2004. RNA interference and the use of 
small interfering RNA to study gene function in mammalian systems. J Mol 
Endocrinol. 33:545-57. 
Bakolitsa, C., D.M. Cohen, L.A. Bankston, A.A. Bobkov, G.W. Cadwell, L. Jennings, 
D.R. Critchley, S.W. Craig, and R.C. Liddington. 2004. Structural basis for vinculin 
activation at sites of cell adhesion. Nature. 430:583-6. 
Brabletz, T. 2001. [The Rudolf Virchow Prize 2001. The role of the oncoprotein beta-
catenin ni the progression ofcolorectal cancers]. Verh Dtsch Ges Pathol. 85:243-9. 
Brabletz, T., A. Jung, S. Reu, M. Porzner, F. Hlubek, L.A. Kunz-Schughart, R. 
Knuechel, and T. Kirchner. 2001. Variable beta-catenin expression in colorectal 
cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad 
Sci US A. 98:10356-61. 
Beekman, J .M., J .E. Bakema, J. van der Linden, B. Tops, M. Hinten, M. van Vugt, 
J.G. van de Winkel, and J.H. Leusen. 2004. Modulation ofFcgammaRI (CD64) ligand 
binding by blocking peptides of periplakin. J Bioi Chern. 279:33875-81. 
Berdeaux, R.L., B. Diaz, L. Kim, and G.S. Martin. 2004. Active Rho is localized to 
podosomes induced by oncogenic Src and is required for their assembly and function. J 
Cell Bioi. 166:317-23. 
Bernier, G., M. Mathieu, Y. De Repentigny, S.M. Vidal, and R. Kothary. 1996. 
Cloning and characterization of mouse ACF7, a novel member of the dystonin 
subfamily of actin binding proteins. Genomics. 38:19-29. 
Bershadsky, A.D., I.S. Tint, and T.M. Svitkina. 1987. Association of intermediate 
filaments with vinculin-containing adhesion plaques of fibroblasts. Cell Motil 
Cytoskeleton. 8:274-83. 
Bindels, S., M. Mestdagt, C. Vandewalle, N. Jacobs, L. Voiders, A. Noel, F. van Roy, 
G. Berx, J.M. Foidart, and C. Gilles. 2006. Regulation ofvimentin by SIPI in human 
epithelial breast tumor cells. Oncogene. 25:4975-85. 
Birchmeier, C., D. Meyer, and D. Riethmacher. 1995. Factors controlling growth, 
motility, and morphogenesis of normal and malignant epithelial cells. Int Rev Cytol. 
160:22 I -66. 
212 
Birchmeier, W., and C. Birchmeier. 1995. Epithelial-mesenchymal transitions m 
development and tumor progression. Exs. 74:1-15. 
Birchmeier, W., J. Hulsken, and J. Behrens. 1995. Adherens junction proteins m 
tumour progression. Cancer Surv. 24:129-40. 
Birchmeier, W., J. Hulsken, and J. Behrens. 1995. E-cadherin as an mvaswn 
suppressor. Ciba Found Symp. 189: 124-36; discussion 136-41, 174-6. 
Birkedal-Hansen, H. 1995. Matrix metalloproteinases. Adv Dent Res. 9:16. 
Birkedal-Hansen, H. 1995. Proteolytic remodeling of extracellular matrix. Curr Opin 
Cell Bioi. 7:728-35. 
Black, D.L. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev 
Biochem. 72:291-336. 
Boczonadi, V., L. Mcinroy, and A. Maatta. 2007. Cytolinker cross-talk: Periplakin N-
terminus interacts with plectin to regulate keratin organisation and epithelial migration. 
Exp Cell Res. 313:3579-91. 
Boguski, M.S. 1995. Hunting for genes m computer data bases. N Engl J Med. 
333:645-7. 
Boguski, M.S., T.M. Lowe, and C.M. Tolstoshev. 1993. dbEST--database for 
"expressed sequence tags". Nat Genet. 4:332-3. 
Boguski, M.S., and G.D. Schuler. 1995. ESTablishing a human transcript map. Nat 
Genet. 10:369-71. 
Borradori, L., P.J. Koch, C.M. Niessen, S. Erkeland, M.R. van Leusden, and A. 
Sonnenberg. 1997. The localization of bullous pemphigoid antigen 180 (BP 180) in 
hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by 
the beta4 integrin subunit. J Cell Bioi. 136:1333-47. 
Borradori, L., and A. Sonnenberg. 1996. Hemidesmosomes: roles m adhesion, 
signaling and human diseases. Curr Opin Cell Bioi. 8:647-56. 
Borradori, L., and A. Sonnenberg. 1999. Structure and function of hemidesmosomes: 
more than simple adhesion complexes. J Invest Dermatol. 112:411-8. 
Bosch, F.X., C. Andl, U. Abel, and J. Kartenbeck. 2005. E-cadherin is a selective and 
strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-
cadherin with desmosomal components. Int J Cancer. 114:779-90. 
Bosher, J.M., B.S. Hahn, R. Legouis, S. Sookhareea, R.M. Weimer, A. Gansmuller, 
A.D. Chisholm, A.M. Rose, J.L. Bessereau, and M. Labouesse. 2003. The 
Caenorhabditis elegans vab-1 0 spectraplakin isofom1s protect the epidermis against 
internal and external forces. J Cell Biol. 161:757-68. 
213 
Braga, V. 2000. Epithelial cell shape: cadherins and small GTPases. Exp Cell Res. 
261:83-90. 
Braga, V. 2000. The crossroads between cell-cell adhesion and motility. Nat Cell Bioi. 
2:E182-4. 
Braga, V.M. 2002. Cell-cell adhesion and signalling. Curr Opin Cell Bioi. 14:546-56. 
Braga, V.M., M. Betson, X. Li, and N. Lamarche-Vane. 2000. Activation of the small 
GTPase Rae is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal 
human keratinocytes. Mol Bioi Cell. 11:3703-21. 
Bremnes, R.M., R. Veve, F.R. Hirsch, and W.A. Franklin. 2002. The E-cadherin cell-
cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung 
Cancer. 36:115-24. 
Brinkley, W. 1997. Microtubules: a briefhistorical perspective. J Struct Bioi. 118:84-
6. 
Bruzzaniti, A., L. Neff, A. Sanjay, W.C. Horne, P. De Camilli, and R. Baron. 2005. 
Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and 
osteoclast activity. Mol Bioi Cell. 16:3301-13. 
Buccione, R., J.D. Orth, and M.A. McNiven. 2004. Foot and mouth: podosomes, 
invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Bioi. 5:647-57. 
Burgeson, R.E., and A.M. Christiano. 1997. The dermal-epidermal junction. Curr Opin 
Cell Bioi. 9:651-8. 
Byers, T.J., A.H. Beggs, E.M. McNally, and L.M. Kunkel. 1995. Novel actin 
crosslinker superfamily member identified by a two step degenerate PCR procedure. 
FEBS Lett. 368:500-4. 
Calderwood, D.A. 2004. Talin controls integrin activation. Biochem Soc Trans. 
32:434-7. 
Calderwood, D.A. 2004. Integrin activation. J Cell Sci. 117:657-66. 
Camargo, L.M., V. Collura, J.C. Rain, K. Mizuguchi, H. Hermjakob, S. Kerrien, T.P. 
Bonnert, P.J. Whiting, and N.J. Brandon. 2007. Disrupted in Schizophrenia 1 
Interactome: evidence for the close connectivity of risk genes and a potential synaptic 
basis for schizophrenia. Mol Psychiatry. 12:74-86. 
Caswell, P.T., and J.C. Norman. 2006. Integrin trafficking and the control of cell 
migration. Traffic. 7:14-21. 
Cavallaro, U., Schaffhauser, B., Cristofori, G. 2002. Cadherins and the tumour 
progression: is it all in a switch. Cancer lett. 25; 176(2); 123-8 
214 
Chambers, A.F., A.C. Groom, and I.C. MacDonald. 2002. Dissemination and growth 
of cancer cells in metastatic sites. Nat Rev Cancer. 2:563-72. 
Chellaiah, M.A. 2006. Regulation of podosomes by integrin alphavbeta3 and Rho 
GTPase-facilitated phosphoinositide signaling. Eur J Cell Bioi. 85:311-7. 
Chen, H.J., C.M. Lin, C.S. Lin, R. Perez-Olle, C.L. Leung, and R.K. Liem. 2006. The 
role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling 
pathway. Genes Dev. 20:1933-45. 
Choi, H.J., S. Park-Snyder, L.T. Pascoe, K.J. Green, and W.I. Weis. 2002. Structures 
of two intermediate filament-binding fragments of desmoplakin reveal a unique repeat 
motif structure. Nat Struct Bioi. 9:612-20. 
Christofori, G. 2006. New signals from the invasive front. Nature. 441:444-50. 
Chu, P.O., and L.M. Weiss. 2002. Keratin expression in human tissues and neoplasms. 
Histopathology. 40:403-39. 
Chu, Y.W., R.B. Runyan, R.G. Oshima, and M.J. Hendrix. 1993. Expression of 
complete keratin filaments in mouse L cells augments cell migration and invasion. 
Proc Natl Acad Sci US A. 90:4261-5. 
Chu, Y.W., E.A. Seftor, L.H. Romer, and M.J. Hendrix. 1996. Experimental 
coexpression of vimentin and keratin intermediate filaments in human melanoma cells 
augments motility. Am J Pathol. 148:63-9. 
Chung, W., and J.T. Campanelli. 1999. WW and EF hand domains of dystrophin-
family proteins mediate dystroglycan binding. Mol. Cell. Bioi. Res. Commun. 2; 162-
171. 
Chung, C.Y., and R.A. Firtel. 1999. PAKa, a putative PAK family member, is required 
for cytokinesis and the regulation of the cytoskeleton in Dictyostelium discoideum 
cells during chemotaxis. J Cell Bioi. 147:559-76. 
Ciocca, D.R., and S.K. Calderwood. 2005. Heat shock proteins in cancer: diagnostic, 
prognostic, predictive, and treatment implications. Cell Stress Chaperones. 10:86-103. 
Cochard, P ., and D. Paulin. 1984. Initial expression of neurofilaments and vim en tin in 
the central and peripheral nervous system of the mouse embryo in vivo. J Neurosci. 
4:2080-94. 
Cohen, D.M., B. Kutscher, H. Chen, D.B. Murphy, and S.W. Craig. 2006. A 
conformational switch in vinculin drives formation and dynamics of a talin-vinculin 
complex at focal adhesions. J Bioi Chern. 281:16006-15. 
Coopman, P .J ., D.M. Thomas, K.R. Gehlsen, and S.C. Mueller. 1996. Integrin alpha 3 
beta l participates in the phagocytosis of extracellular matrix molecules by human 
breast cancer cells. Mol Bioi Cell. 7:1789-804. 
215 
Correia, 1., D. Chu, Y.H. Chou, R.D. Goldman, and P. Matsudaira. 1999. Integrating 
the actin and vimentin cytoskeletons. adhesion-dependent formation of fimbrin-
vimentin complexes in macrophages. J Cell Bioi. 146:831-42. 
Coulombe, P.A., L. Ma, S. Yamada, and M. Wawersik. 2001. Intermediate filaments at 
a glance. J Cell Sci. 114:4345-7. 
Coulombe, P.A., and M.B. Omary. 2002. 'Hard' and 'soft' principles defining the 
structure, function and regulation of keratin intermediate filaments. Curr Opin Cell 
Bioi. 14:110-22. 
Cowin, P., T.M. Rowlands, and S.J. Hatsell. 2005. Cadherins and catenins in breast 
cancer. Curr Opin Cell Biol. 17:499-508. 
Critchley, D.R. 2004. Cytoskeletal proteins talin and vinculin in integrin-mediated 
adhesion. Biochem Soc Trans. 32:831-6. 
Culligan, K.G., A.J. Mackey, D.M. Finn, P.B. Maguire and K. Ohlendieck. 1998. Role 
of dystrophin isoforms and associated proteins in muscular dystrophy. Int. J. Mol. 
Med. 2;639-648. 
Davies, E.L., J.M. Gee, R.A. Cochrane, W.G. Jiang, A.K. Sharma, R.I. Nicholson, and 
R.E. Mansel. 1999. The immunohistochemical expression of desmoplakin and its role 
in vivo in the progression and metastasis ofbreast cancer. Eur J Cancer. 35:902-7. 
Depondt, J., A.H. Shabana, S. Florescu-Zorila, P. Gehanno, and N. Forest. 1999. 
Down-regulation of desmosomal molecules in oral and pharyngeal squamous cell 
carcinomas as a marker for tumour growth and distant metastasis. Eur J Oral Sci. 
107:183-93. 
DiColandrea, T., T. Karashima, A. Maatta, and F.M. Watt. 2000. Subcellular 
distribution of envoplakin and periplakin: insights into their role as precursors of the 
epidermal cornified envelope. J Cell Bioi. 151 :573-86. 
Drabek, K., M. van Ham, T. Stepanova, K. Draegestein, R. van Horssen, C.L. Sayas, 
A. Akhmanova, T. Ten Hagen, R. Smits, R. Fodde, F. Grosveld, and N. Galjart. 2006. 
Role of CLASP2 in microtubule stabilization and the regulation of persistent motility. 
Curr Bioi. 16:2259-64. 
Eckert, K.A., and T.A. Kunkel. 1990. High fidelity DNA synthesis by the Thermus 
aquaticus DNA polymerase. Nucleic Acids Res. 18:3739-44. 
Eckes, B., E. Colucci-Guyon, H. Smola, S. Nodder, C. Babinet, T. Krieg, and P. 
Martin. 2000. Impaired wound healing in embryonic and adult mice lacking vimentin. 
J Cell Sci. 113 ( Pt 13):2455-62. 
Eckes, B., D. Dogie, E. Colucci-Guyon, N. Wang, A. Maniotis, D. Ingber, A. 
Merckling, F. Langa, M. Aumailley, A. Delouvee, V. Koteliansky, C. Babinet, and T. 
Krieg. 1998. Impaired mechanical stability, migration and contractile capacity in 
vimentin-deticient fibroblasts. J Cell Sci. 111 ( Pt 13):1897-907. 
216 
Eger, A., A. Stockinger, G. Wiehe, and R. Foisner. 1997. Polarisation-dependent 
association of plectin with desmoplakin and the lateral submembrane skeleton in 
MDCK cells. J Cell Sci. 110 ( Pt 11):1307-16. 
Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian 
cells. Nature. 411:494-8. 
Elliott, C.E., B. Becker, S. Oehler, M.J. Castanon, R. Hauptmann, and G. Wiehe. 1997. 
P1ectin transcript diversity: identification and tissue distribution of variants with 
distinct first coding exons and rodless isoforms. Genomics. 42:115-25. 
Ellsworth, D.L., K.D. Rittenhouse, and R.L. Honeycutt. 1993. Artifactual variation in 
randomly amplified polymorphic DNA banding patterns. Biotechniques. 14:214-7. 
Engel, J., H. Fasold, F.W. Hulla, F. Waechter, and A. Wegner. 1977. The 
polymerization reaction of muscle actin. Mol Cell Biochem. 18:3-13. 
Errante, L.D., G. Wiehe, and G. Shaw. 1994. Distribution of plectin, an intermediate 
filament-associated protein, in the adult rat central nervous system. J Neurosci Res. 
37:515-28. 
Eves, R., B.A. Webb, S. Zhou, and A.S. Mak. 2006. Caldesmon is an integral 
component of podosomes in smooth muscle cells. J Cell Sci. 119:1691-702. 
Fawcett, D. W. and Porter, K. R. 1954. A study ofthe fine structure of ciliated 
epithelia. J. Morpho I. 94 pp. 221 ~281. 
Foisner, R., B. Feldman, L. Sander, G. Seifert, U. Artlieb, and G. Wiehe. 1994. A 
panel of monoclonal antibodies to rat plectin: distinction by epitope mapping and 
immunoreactivity with different tissues and cell lines. Acta Histochem. 96:421-38. 
Foisner, R., F.E. Leichtfried, H. Herrmann, J.V. Small, D. Lawson, and G. Wiehe. 
1988. Cytoskeleton-associated plectin: in situ localization, in vitro reconstitution, and 
binding to immobilized intermediate filament proteins. J Cell Bioi. I 06:723-33. 
Foisner, R., P. Traub, and G. Wiehe. 1991. Protein kinase A- and protein kinase C-
regulated interaction of plectin with lamin B and vimentin. Proc Natl Acad Sci U S A. 
88:3812-6. 
Fontao, L., S. Dirrig, K. Owaribe, M. Kedinger, and J.F. Launay. 1997. Polarized 
expression of HD 1: relationship with the cytoskeleton in cultured human colonic 
carcinoma cells. Exp Cell Res. 231:319-27. 
Fontao, L., B. Favre, S. Riou, D. Geerts, F. Jaunin, J.H. Saurat, K.J. Green, A. 
Sonnenberg, and L. Borradori. 2003. Interaction of the bullous pemphigoid antigen 1 
(BP230) and desmoplakih with intermediate filaments is mediated by distinct 
sequences within their COOH terminus. Mol Bioi Cell. 14:1978-92. 
217 
Fontao, L., D. Geerts, I. Kuikman, J. Koster, D. Kramer, and A. Sonnenberg. 2001. 
The interaction of plectin with actin: evidence for cross-linking of actin filaments by 
dimerization of the actin-binding domain of plectin. J Cell Sci. 114:2065-76. 
Fontao, L., J. Stutzmann, P. Gendry, and J.F. Launay. 1999. Regulation of the type II 
hemidesmosomal plaque assembly in intestinal epithelial cells. Exp Cell Res. 250:298-
312. 
Franke, W.W., M. Hergt, and C. Grund. 1987. Rearrangement of the vimentin 
cytoskeleton during adipose conversion: formation of an intermediate filament cage 
around lipid globules. Cell. 49:131-41. 
Franke, W.W., E. Schmid, C. Grund, H. Muller, I. Engelbrecht, R. Moll, J. Stadler, and 
E.D. Jarasch. 1981. Antibodies to high molecular weight polypeptides of desmosomes: 
specific localization of a class of junctional proteins in cells and tissue. Differentiation. 
20:217-41. 
Franke, W.W., E. Schmid, M. Osborn, and K. Weber. 1978. Different intermediate-
sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci 
us A. 75:5034-8. 
Franke, W.W., E. Schmid, D.L. Schiller, S. Winter, E.D. Jarasch, R. Moll, H. Denk, 
B.W. Jackson, and K. Illmensee. 1982. Differentiation-related patterns of expression of 
proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb 
Symp Quant Bioi. 46 Pt 1 :431-53. 
Friedl, P. 2004. Prespecification and plasticity: shifting mechanisms of cell migration. 
Curr Opin Cell Bioi. 16:14-23. 
Fuchs, E., and D.W. Cleveland. 1998. A structural scaffolding of intermediate 
filaments in health and disease. Science. 279:514-9. 
Fuchs, P., M. Zorer, G.A. Rezniczek, D. Spazierer, S. Oehler, M.J. Castanon, R. 
Hauptmann, and G. Wiehe. 1999. Unusual 5' transcript complexity of plectin isoforms: 
novel tissue-specific exons modulate actin binding activity. Hum Mol Genet. 8:2461-
72. 
Fujiwara, S., K. Kohno, A. lwamatsu, I. Naito, and H. Shinkai. 1996. Identification of 
a 450-kDa human epidermal autoantigen as a new member of the plectin family. J 
Invest Dermatol. 106:1125-30. 
Fujiwara, S., H. Shinkai, S. Takayasu, K. Owaribe, S. Tsukita, and T. Kageshita. 1992. 
A case of subepidermal blister disease associated with autoantibody against 450 kD 
protein. J Dermatol. 19:610-3. 
Fujiwara, S., N. Takeo, Y. Otani, D.A. Parry, M. Kunimatsu, R. Lu, M. Sasaki, N. 
Matsuo, M. Khaleduzzaman, and H. Yoshioka. 2001. Epiplakin, a novel member of 
the Plakin family originally identified as a 450-kDa human epidermal autoantigen. 
Structure and tissue localization. J Bioi Chern. 276:13340-7. 
218 
Furst, D.O., M. Osborn, and K. Weber. 1989. Myogenesis in the mouse embryo: 
differential onset of expression of myogenic proteins and the involvement of titin in 
myofibril assembly. J Cell Biol. 109:517-27. 
Gache, Y., S. Chavanas, J.P. Lacour, G. Wiehe, K. Owaribe, G. Meneguzzi, and J.P. 
Ortonne. 1996. Defective expression of plectin/HDl in epidermolysis bullosa simplex 
with muscular dystrophy. J Clin Invest. 97:2289-98. 
Galarneau, L., A. Loranger, S. Gilbert, and N. Marceau. 2007. Keratins modulate 
hepatic cell adhesion, size and G 1 /S transition. Exp Cell Res. 313:179-94. 
Gallant, N.D., K.E. Michael, and A.J. Garcia. 2005. Cell adhesion strengthening: 
contributions of adhesive area, integrin binding, and focal adhesion assembly. Mol 
Bioi Cell. 16:4329-40. 
Gallicano, G.I., C. Bauer, and E. Fuchs. 2001. Rescuing desmoplakin function in 
extra-embryonic ectoderm reveals the importance of this protein in embryonic heart, 
neuroepithelium, skin and vasculature. Development. 128:929-41. 
Gallicano, G.I., P. Kouklis, C. Bauer, M. Yin, V. Vasioukhin, L. Degenstein, and E. 
Fuchs. 1998. Desmoplakin is required early in development for assembly of 
desmosomes and cytoskeletallinkage. J Cell Biol. 143:2009-22. 
Garcia-Alvarez, B., A. Bobkov, A. Sonnenberg, and J.M. de Pereda. 2003. Structural 
and functional analysis of the actin binding domain of plectin suggests alternative 
mechanisms for binding to F-actin and integrin beta4. Structure. 11 :615-25. 
Garrod, D.R., and S. Fleming. 1990. Early expression of desmosomal components 
during kidney tubule morphogenesis in human and murine embryos. Development. 
108:313-21. 
Garrod, D.R., A.J. Merritt, and Z. Nie. 2002. Desmosomal adhesion: structural basis, 
molecular mechanism and regulation (Review). Mol Membr Biol. 19:81-94. 
Gavazzi, 1., M.V. Nermut, and P.C. Marchisio. 1989. Ultrastructure and gold-
immunolabelling of cell-substratum adhesions (podosomes) in RSV -transformed BHK 
cells. J Cell Sci. 94 ( Pt 1):85-99. 
Geerts, D., L. Fontao, M.G. Nievers, R.Q. Schaapveld, P.E. Purkis, G.N. Wheeler, 
E.B. Lane, I.M. Leigh, and A. Sonnenberg. 1999. Binding of integrin alpha6beta4 to 
plectin prevents plectin association with F -actin but does not interfere with 
intermediate filament binding. J Cell Biol. 14 7:417-34. 
Gilles, C., M. Palette, M. Mestdagt, B. Nawrocki-Raby, P. Ruggeri, P. Birembaut, and 
J.M. Foidart. 2003. Transactivation ofvimentin by beta-catenin in human breast cancer 
cells. Cancer Res. 63:2658-64. 
Gilles, C., M. Palette, J.M. Zahm, J.M. Tournier, L. Voiders, J.M. Foidart, and P. 
Birembaut. 1999. Vimentin contributes to human mammary epithelial cell migration. J 
Cell Sci. 112 ( Pt 24):4615-25. 
219 
Gimona, M., K. Djinovic-Carugo, W.J. Kranewitter, and S.J. Winder. 2002. Functional 
plasticity of CH domains. FEBS Lett. 513:98-106. 
Givant-Horwitz, V., B. Davidson, and R. Reich. 2005. Laminin-induced signaling in 
tumor cells. Cancer Lett. 223:1-10. 
Godse!, L.M., S.N. Hsieh, E.V. Amargo, A.E. Bass, L.T. Pascoe-McGillicuddy, A.C. 
Huen, M.E. Thorne, C.A. Gaudry, J.K. Park, K. Myung, R.D. Goldman, T.L. Chew, 
and K.J. Green. 2005. Desmoplakin assembly dynamics in four dimensions: multiple 
phases differentially regulated by intermediate filaments and actin. J Cell Bioi. 
171:1045-59. 
Goldfinger, L.E., S.B. Hopkinson, G.W. deHart, S. Collawn, J.R. Couchman, and J.C. 
Jones. 1999. The alpha3 laminin subunit, alpha6beta4 and alpha3beta1 integrin 
coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell 
Sci. 112 ( Pt 16):2615-29. 
Goldman, R.D. 1971. The role of three cytoplasmic fibers in BHK-21 cell motility. I. 
Microtubules and the effects of colchicine. J Cell Bioi. 51:752-62. 
Gong, T.W., C.G. Besirli, and M.I. Lomax. 2001. MACF1 gene structure: a hybrid of 
plectin and dystrophin. Mamm Genome. 12:852-61. 
Gonzales, M., B. Weksler, D. Tsuruta, R.D. Goldman, K.J. Yoon, S.B. Hopkinson, 
F.W. Flitney, and J.C. Jones. 2001. Structure and function of a vimentin-associated 
matrix adhesion in endothelial cells. Mol Bioi Cell. 12:85-100. 
Goto, M., H. Sumiyoshi, T. Sakai, R. Fassler, S. Ohashi, E. Adachi, H. Yoshioka, and 
S. Fujiwara. 2006. Elimination of epiplakin by gene targeting results in acceleration of 
keratinocyte migration in mice. Mol Cell Bioi. 26:548-58. 
Green, K.J., S.G. Guy, P.B. Cserhalmi-Friedman, W.H. McLean, A.M. Christiano, and 
R.M. Wagner. 1999. Analysis of the desmoplakin gene reveals striking conservation 
with other members of the plakin family of cytolinkers. Exp Dermatol. 8:462-70. 
Green, K.J., and J.C. Jones. 1996. Desmosomes and hemidesmosomes: structure and 
function ofmolecular components. Faseb J. 10:871-81. 
Green, K.J., D.A. Parry, P.M. Steinert, M.L. Virata, R.M. Wagner, B.D. Angst, and 
L.A. Nilles. 1990. Structure of the human desmoplakins. Implications for function in 
the desmosomal plaque. J Bioi Chern. 265:2603-12. 
Gregor, M., A. Zeold, S. Oehler, K.A. Marobela, P. Fuchs, G. Weigel, D.G. Hardie, 
and G. Wiehe. 2006. Plectin scaffolds recruit energy-controlling AMP-activated 
protein kinase (AMPK) in differentiated myofibres. J Cell Sci. 119: 1864-75. 
Grille, S.J., A. Bellacosa, J. Upson, A.J. Klein-Szanto, F. van Roy, W. Lee-Kwon, M. 
Donowitz, P.N. Tsichlis, and L. Larue. 2003. The protein kinase Akt induces epithelial 
mesenchymal transition and promotes enhanced motility and invasiveness of 
squamous cell carcinoma lines. Cancer Res. 63:2172-8. 
220 
Groot, K.R., L.M. Sevilla, K. Nishi, T. DiColandrea, and F.M. Watt. 2004. Kazrin, a 
novel periplakin-interacting protein associated with desmosomes and the keratinocyte 
plasma membrane. J Cell Bioi. 166:653-9. 
Gross, S.P., M. Vershinin, and G.T. Shubeita. 2007. Cargo transport: two motors are 
sometimes better than one. Curr Biol. 17:R478-86. 
Gu, L.H., and P.A. Coulombe. 2007. Keratin function in skin epithelia: a broadening 
palette with surprising shades. Curr Opin Cell Bioi. 19:13-23. 
Gu, L.H., and P.A. Coulombe. 2007. Keratin expression provides novel insight into the 
morphogenesis and function of the companion layer in hair follicles. J Invest 
Dermatol. 127:1061-73. 
Guo, L., L. Degenstein, J. Dowling, Q.C. Yu, R. Wollmann, B. Perman, and E. Fuchs. 
1995. Gene targeting of BPAG 1: abnormalities in mechanical strength and cell 
migration in stratified epithelia and neurologic degeneration. Cell. 81:233-43. 
Guo, W., and F.G. Giancotti. 2004. Integrin signalling during tumour progression. Nat 
Rev Mol Cell Bioi. 5:816-26. 
Guttman, J.A., D.J. Mulholland, and A.W. Vogl. 1999. Plectin is concentrated at 
intercellular junctions and at the nuclear surface in morphologically differentiated rat 
Sertoli cells. Anat Rec. 254:418-28. 
Hayot, C., 0. Debeir, P. Van Ham, M. Van Damme, R. Kiss, and C. Decaestecker. 
2006. Characterization of the activities of actin-affecting drugs on tumor cell 
migration. Toxicol Appl Pharmacal. 211 :30-40. 
Helfand, B.T., L. Chang, and R.D. Goldman. 2004. Intermediate filaments are 
dynamic and motile elements of cellular architecture. J Cell Sci. 117:133-41. 
Hendrix, M.J., E.A. Seftor, Y.W. Chu, R.E. Seftor, R.B. Nagle, K.M. McDaniel, S.P. 
Leong, K.H. Yohem, A.M. Leibovitz, F.L. Meyskens, Jr., and et al. 1992. 
Coexpression of vimentin and keratins by human melanoma tumor cells: correlation 
with invasive and metastatic potential. J Natl Cancer Inst. 84:165-74. 
Hendrix, M.J., E.A. Seftor, Y.W. Chu, K.T. Trevor, and R.E. Seftor. 1996. Role of 
intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 
15:507-25. 
Hendrychova, J., M. Vitova, K. Bisova, G. Wiehe, and V. Zachleder. 2002. Plectin-
like proteins are present in cells of Chlamydomonas eugametos (Volvocales). Folia 
Microbial (Praha). 47:535-9. 
Herrmann, H., Fourquet, B., Franke, W.W. 1989. Expression of intermediate filament 
proteins during development of xenopus laevis. I. eDNA clones encoding different 
forms of vimentin. Development l 05:279-298. 
221 
Herrmann, H., and U. Aebi. 2000. Intermediate filaments and their associates: multi-
talented structural elements specifying cytoarchitecture and cytodynamics. Curr Opin 
Cell Bioi. 12:79-90. 
Herrmann, H., and G. Wiehe. 1987. Plectin and IFAP-300K are homologous proteins 
binding to microtubule-associated proteins 1 and 2 and to the 240-kilodalton subunit of 
spectrin. J Bioi Chern. 262:1320-5. 
Hesse, M., T.M. Magin, and K. Weber. 2001. Genes for intermediate filament proteins 
and the draft sequence of the human genome: novel keratin genes and a surprisingly 
high number of pseudogenes related to keratin genes 8 and 18. J Cell Sci. 114:2569-
75. 
Hieda, Y., Y. Nishizawa, J. Uematsu, and K. Owaribe. 1992. Identification of a new 
hemidesmosomal protein, HD1: a major, high molecular mass component of isolated 
hemidesmosomes. J Cell Bioi. 116:1497-506. 
Hijikata, T., T. Murakami, M. Imamura, N. Fujimaki, and H. Ishikawa. 1999. Plectin is 
a linker of intermediate filaments to Z-discs in skeletal muscle fibers. J Cell Sci. 112 ( 
Pt 6):867-76. 
Hijikata, T., T. Murakami, H. Ishikawa, and H. Yorifuji. 2003. Plectin tethers desmin 
intermediate filaments onto subsarcolemmal dense plaques containing dystrophin and 
vinculin. Histochem Cell Bioi. 119:1 09-23. 
Homan, S.M., R. Martinez, A. Benware, and S.E. LaFlamme. 2002. Regulation of the 
association of alpha 6 beta 4 with vimentin intermediate filaments in endothelial cells. 
Exp Cell Res. 281:107-14. 
Hopkinson, S.B., and J.C. Jones. 2000. TheN terminus of the transmembrane protein 
BP 180 interacts with the N-terminal domain of BP230, thereby mediating keratin 
cytoskeleton anchorage to the cell surface at the site of the hemidesmosome. Mol Bioi 
Cell. 11:277-86. 
Hynes, R.O. 2002. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 
8:918-21. 
Impola, U., V.J. Uitto, J. Hietanen, L. Hakkinen, L. Zhang, H. Larjava, K. Isaka, and 
U. Saarialho-Kere. 2004. Differential expression of matrilysin-1 (MMP-7), 92 kD 
gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous 
cell cancer. J Pathol. 202:14-22. 
Inada, H., H. Togashi, Y. Nakamura, K. Kaibuchi, K. Nagata, and M. Inagaki. 1999. 
Balance between activities of Rho kinase and type 1 protein phosphatase modulates 
turnover of phosphorylation and dynamics of desminlvimentin filaments. J Bioi Chern. 
274:34932-9. 
Inagaki, N., H. Goto, M. Ogawara, Y. Nishi, S. Ando, and M. Inagaki. 1997. Spatial 
patterns of Ca2+ signals define intracellular distribution of a signaling by 
Ca2+/Calmodulin-dependent protein kinase II. J Bioi Chern. 272:25195-9. 
222 
Ivaska, J., H.M. Pallari, J. Nevo, and J.E. Eriksson. 2007. Novel functions ofvimentin 
in cell adhesion, migration, and signaling. Exp Cell Res. 313:2050-62. 
lvaska, J., H. Reunanen, J. Westermarck, L. Koivisto, V.M. Kahari, and J. Heino. 
1999. Integrin alpha2beta1 mediates isoform-specific activation of p38 and 
upregulation of collagen gene transcription by a mechanism involving the alpha2 
cytoplasmic tail. J Cell Bioi. 147:401-16. 
lvaska, J., K. Vuoriluoto, T. Huovinen, I. Izawa, M. Inagaki, and P.J. Parker. 2005. 
PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and 
motility. Embo J. 24:3834-45. 
Izawa, 1., and M. Inagaki. 2006. Regulatory mechanisms and functions of intermediate 
filaments: a study using site- and phosphorylation state-specific antibodies. Cancer Sci. 
97:167-74. 
Jacinto, A., and L. Wolpert. 2001. Filopodia. Curr Bioi. 11 :R634. 
Jefferson, J.J., C. Ciatto, L. Shapiro, and R.K. Liem. 2007. Structural analysis of the 
plakin domain of bullous pemphigoid antigen 1 (BP AG 1) suggests that plakins are 
members of the spectrin superfamily. J Mol Bioi. 366:244-57. 
Jefferson, J.J., C.L. Leung, and R.K. Liem. 2004. Plakins: goliaths that link cell 
junctions and the cytoskeleton. Nat Rev Mol Cell Bioi. 5:542-53. 
Jefferson, J.J., C.L. Leung, and R.K. Liem. 2006. Dissecting the sequence specific 
functions of alternative N-terminal isoforms of mouse bullous pemphigoid antigen 1. 
Exp Cell Res. 312:2712-25. 
Jiang, W.G. 1996. E-cadherin and its associated protein catenins, cancer invasion and 
metastasis. Br J Surg. 83:437-46. 
Jones, J .C., and R.D. Goldman. 1985. Intermediate filaments and the initiation of 
desmosome assembly. J Cell Bioi. 101:506-17. 
Jones, J.C., and K.J. Green. 1991. Intermediate filament-plasma membrane 
interactions. Curr Opin Cell Bioi. 3:127-32. 
Jones, J.C., S.B. Hopkinson, and L.E. Goldfinger. 1998. Structure and assembly of 
hemidesmosomes. Bioessays. 20:488-94. 
Jones, J.C., M.A. Kurpakus, H.M. Cooper, and V. Quaranta. 1991. A function for the 
integrin alpha 6 beta 4 in the hemidesmosome. Cell Regul. 2:427-38. 
Kalendar R. 2007. FastPCR: a PCR primer and probe design and repeat sequence 
searching software with additional tools for the manipulation and analysis of DNA and 
protein. ( www. biocenter.helsinki. fi/bi/programs/fastpcr.htm) 
Kalinin, A., L.N. Marekov, and P.M. Steinert. 2001. Assembly of the epidermal 
cornified cell envelope. J Cell Sci. 114:3069-70. 
223 
Kartenbeck, J., U. Haselmann, and N. Gassier. 2005. Synthesis of junctional proteins 
in metastasizing colon cancer cells. Eur J Cell Bioi. 84:417-30. 
Kazerounian, S., and S. Aho. 2003. Characterization of periphilin, a widespread, 
highly insoluble nuclear protein and potential constituent of the keratinocyte cornified 
envelope. J Bioi Chern. 278:36707-17. 
Kazerounian, S., J. Uitto, and S. Aho. 2002. Unique role for the periplakin tail in 
intermediate filament association: specific binding to keratin 8 and vimentin. Exp 
Dermatol. 11:428-38. 
Kiosses, W.B., R.H. Daniels, C. Otey, G.M. Bokoch, and M.A. Schwartz. 1999. A role 
for p21-activated kinase in endothelial cell migration. J Cell Bioi. 147:831-44. 
Kirchner, J., Z. Kam, G. Tzur, A.D. Bershadsky, and B. Geiger. 2003. Live-cell 
monitoring of tyrosine phosphorylation in focal adhesions following microtubule 
disruption. J Cell Sci. 116:975-86. 
Kodama, A., I. Karakesisoglou, E. Wong, A. Vaezi, and E. Fuchs. 2003. ACF7: an 
essential integrator of microtubule dynamics. Cell. 115:343-54. 
Kokkinos, M.l., R. Wafai, M.K. Wong, D.F. Newgreen, E.W. Thompson, and M. 
Waltham. 2007. Vimentin and epithelial-mesenchymal transition in human breast 
cancer--observations in vitro and in vivo. Cells Tissues Organs. 185:191-203. 
Koretz, K., S. Bruderlein, C. Henne, T. Fietz, M. Laque, and P. Moller. 1994. 
Comparative evaluation of integrin alpha- and beta-chain expression in colorectal 
carcinoma cell lines and in their tumours of origin. Virchows Arch. 425:229-36. 
Koster, J., S. van Wilpe, I. Kuikman, S.H. Litjens, and A. Sonnenberg. 2004. Role of 
binding of plectin to the integrin beta4 subunit in the assembly of hemidesmosomes. 
Mol Bioi Cell. 15:1211-23. 
Kowalczyk, A.P., P. Navarro, E. Dejana, E.A. Bornslaeger, K.J. Green, D.S. Kopp, 
and J.E. Borgwardt. 1998. VE-cadherin and desmoplakin are assembled into dermal 
microvascular endothelial intercellular junctions: a pivotal role for plakoglobin in the 
recruitment of desmoplakin to intercellular junctions. J Cell Sci. Ill ( Pt 20):3045-57. 
Kowalczyk, A.P., T.S. Stappenbeck, D.A. Parry, H.L. Palka, M.L. Virata, E.A. 
Bornslaeger, L.A. Nilles, and K.J. Green. 1994. Structure and function of desmosomal 
transmembrane core and plaque molecules. Biophys Chern. 50:97-112. 
Kreis, S., H.J. Schonfeld, C. Melchior, B. Steiner, and N. Kieffer. 2005. The 
intermediate filament protein vimentin binds specifically to a recombinant integrin 
alpha2/betal cytoplasmic tail complex and co-localizes with native alpha2/betal m 
endothelial cell focal adhesions. Exp Cell Res. 305: 110-21. 
Kron, S.J., D.G. Drubin, D. Botstein, and J.A. Spudich. 1992. Yeast actin filaments 
display ATP-dependent sliding movement over surfaces coated with rabbit muscle 
myosin. Proc Natl Acad Sci U S A. 89:4466-70. 
224 
Ku, N.O., J. Liao, and M.B. Omary. 1998. Phosphorylation of human keratin 18 serine 
33 regulates binding to 14-3-3 proteins. Embo J. 17:1892-906. 
Ku, N.O., S.A. Michie, R.M. Soetikno, E.Z. Resurreccion, R.L. Broome, and M.B. 
Omary. 1998. Mutation of a major keratin phosphorylation site predisposes to 
hepatotoxic injury in transgenic mice. J Cell Bioi. 143:2023-32. 
Kurose, K., 0. Mori, H. Hachisuka, H. Shimizu, K. Owaribe, and T. Hashimoto. 2000. 
Cultured keratinocytes from plectin/HD 1-deficient epidermolysis bullosa simplex 
showed altered ability of adhesion to the matrix. J Dermatol Sci. 24:184-9. 
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head 
ofbacteriophage T4. Nature. 227:680-5. 
Lane, E.B., B.L. Hogan, M. Kurkinen, and J.l. Garrels. 1983. Co-expression of 
vimentin and cytokeratins in parietal endoderm cells of early mouse embryo. Nature. 
303:701-4. 
Le Borgne, R., A. Alconada, U. Bauer, and B. Hoflack. 1998. The mammalian AP-3 
adaptor-like complex mediates the intracellular transport of lysosomal membrane 
glycoproteins. J Bioi Chern. 273:29451-61. 
Lechler, T., and E. Fuchs. 2007. Desmoplakin: an unexpected regulator of microtubule 
organization in the epidermis. J Cell Bioi. 176:147-54. 
Lee, J.M., S. Dedhar, R. Kalluri, and E.W. Thompson. 2006. The epithelial-
mesenchymal transition: new insights in signaling, development, and disease. J Cell 
Bioi. 172:973-81. 
Lemieux, P., S. Oesterreich, J.A. Lawrence, P.S. Steeg, S.G. Hilsenbeck, J.M. Harvey, 
and S.A. Fuqua. 1997. The small heat shock protein hsp27 increases invasiveness but 
decreases motility of breast cancer cells. Invasion Metastasis. 17:113-23. 
Lesniewicz, K., J. Luscher-Firzlaff, E. Poreba, P. Fuchs, G. Walsemann, G. Wiehe, 
and B. Luscher. 2005. Overlap of the gene encoding the novel poly(ADP-ribose) 
polymerase Parp 10 with the plectin 1 gene and common use of ex on sequences. 
Genomics. 86:38-46. 
Leung, C.L., K.J. Green, and R.K. Liem. 2002. Plakins: a family of versatile cytolinker 
proteins. Trends Cell Bioi. 12:37-45. 
Leung, C.L., R.K. Liem, D.A. Parry, and K.J. Green. 2001. The plakin family. J Cell 
Sci. 114:3409-10. 
Leung, C.L., D. Sun, M. Zheng, D.R. Knowles, and R.K. Liem. 1999. Microtubule 
actin cross-linking factor (MACF): a hybrid of dystonin and dystrophin that can 
interact with the actin and microtubule cytoskeletons. J Cell Bioi. 147:1275-86. 
225 
Li, K., G.J. Guidice, K. Tarnai, H.C. Do, D. Sawamura, L.A. Diaz, and J. Uitto. 1992. 
Cloning of partial eDNA for mouse 180-kDa bullous pemphigoid antigen (BP AG2), a 
highly conserved collagenous protein of the cutaneous basement membrane zone. J 
Invest Dermatol. 99:258-63. 
Lie, A.A., R. Schroder, I. Blumcke, T.M. Magin, O.D. Wiestler, and C.E. Elger. 1998. 
Plectin in the human central nervous system: predominant expression at pialglia and 
endothelia!glia interfaces. Acta Neuropathol (Berl). 96:215-21. 
Lin, C.M., H.J. Chen, C.L. Leung, D.A. Parry, and R.K. Liem. 2005. Microtubule actin 
crosslinking factor 1 b: a novel plakin that localizes to the Golgi complex. J Cell Sci. 
118:3727-38. 
Linder, S. 2007. The matrix corroded: podosomes and invadopodia in extracellular 
matrix degradation. Trends Cell Bioi. 17: 1 07-1 7. 
Linder, S., and M. Aepfelbacher. 2003. Podosomes: adhesion hot-spots of invasive 
cells. Trends Cell Bioi. 13:376-85. 
Linder, S., D. Nelson, M. Weiss, and M. Aepfelbacher. 1999. Wiskott-Aldrich 
syndrome protein regulates podosomes in primary human macrophages. Proc Natl 
Acad Sci US A. 96:9648-53. 
Litjens, S.H., J .M. de Pereda, and A. Sonnenberg. 2006. Current insights into the 
formation and breakdown ofhemidesmosomes. Trends Cell Bioi. 16:376-83. 
Litjens, S.H., J. Koster, I. Kuikman, S. van Wilpe, J.M. de Pereda, and A. Sonnenberg. 
2003. Specificity of binding of the plectin actin-binding domain to beta4 integrin. Mol 
Bioi Cell. 14:4039-50. 
Litjens, S.H., K. Wilhelmsen, J.M. de Pereda, A. Perrakis, and A. Sonnenberg. 2005. 
Modeling and experimental validation of the binary complex of the plectin actin-
binding domain and the first pair of fibronectin type III (FNIII) domains of the beta4 
integrin. J Bioi Chern. 280:22270-7. 
Liu, C.G., C. Maercker, M.J. Castanon, R. Hauptmann, and G. Wiehe. 1996. Human 
plectin: organization of the gene, sequence analysis, and chromosome localization 
(8q24). Proc Natl Acad Sci US A. 93:4278-83. 
Long, H.A., V. Boczonadi, L. Mcinroy, M. Goldberg, and A. Maatta. 2006. 
Periplakin-dependent re-organisation of keratin cytoskeleton and loss of collective 
migration in keratin-8-downregulated epithelial sheets. J Cell Sci. 119:5147-59. 
Loranger, A., S. Gilbert, J.S. Brouard, T.M. Magin, and N. Marceau. 2006. Keratin 8 
modulation of desmoplakin deposition at desmosomes in hepatocytes. Exp Cell Res. 
312:4108-19. 
Lorenz, M., H. Yamaguchi, Y. Wang, R.H. Singer, and J. Condeelis. 2004. Imaging 
sites ofN-wasp activity in lamellipodia and invadopodia of carcinoma cells. Curr Bioi. 
14:697-703. 
226 
Lotz, M.M., I. Rabinovitz, and A.M. Mercurio. 2000. Intestinal restitution: progression 
of actin cytoskeleton rearrangements and integrin function in a model of epithelial 
wound healing. Am 1 Pathol. 156:985-96. 
Lunter, P.C., and G. Wiehe. 2002. Direct binding ofplectin to Fer kinase and negative 
regulation of its catalytic activity. Biochem Biophys Res Commun. 296:904-10. 
Lyons, A.J., and J. Jones. 2007. Cell adhesion molecules, the extracellular matrix and 
oral squamous carcinoma. Int 1 Oral Maxillofac Surg. 36:671-9. 
Maatta, A., T. DiColandrea, K. Groot, and F.M. Watt. 2001. Gene targeting of 
envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified 
envelope. Mol Cell Biol. 21:7047-53. 
Maatta, A., C.J. Hutchison, and M.D. Watson. 2004. Spectraplakins and nesprins, giant 
spectrin repeat proteins participating in the organization of the cytoskeleton and the 
nuclear envelope. Symp Soc Exp Biol:265-77. 
Machesky, L.M., and Gould, K.L. 1999. The Arp2/3 complex: a multifunctional actin 
organizer. Curr. Opin. Cell Bioi. 11: 117-121 Magin, T.M., P. 
Mandelkow, E., and E.M. Mandelkow. 1995. Microtubules and microtubule-associated 
proteins. Curr Opin Cell Biol. 7:72-81. 
Manton, 1., and Clarke, R. 1952. An electron microscopy study of the spermatozoid of 
sphagnum. J. Exp. Bot. 3 pp. 265-275. 
Mercurio, A.M., I. Rabinovitz, and L.M. Shaw. 2001. The alpha 6 beta 4 integrin and 
epithelial cell migration. Curr Opin Cell Biol. 13:541-5. 
Mareel, M., K. Vleminckx, S. Vermeulen, M. Bracke, and F. Van Roy. 1992. E-
cadherin expression: a counterbalance for cancer cell invasion. Bull Cancer. 79:347-
55. 
Mareel, M., K. Vleminckx, S. Vermeulen, G. Yan, M. Bracke, and F. van Roy. 1994. 
Downregulation in vivo of the invasion-suppressor molecule E-cadherin in 
experimental and clinical cancer. Princess Takamatsu Symp. 24:63-80. 
Mareel, M.M., and R. Crombez. 1992. Biology of cancer invasion and metastasis. Acta 
Otorhinolaryngol Belg. 46:107-15. 
Marekov, L.N ., and P.M. Steinert. 1998. Cerami des are bound to structural proteins of 
the human foreskin epidermal cornified cell envelope. 1 Bioi Chern. 273:17763-70. 
Marinkovich, M.P., G.P. Lunstrum, D.R. Keene, and R.E. Burgeson. 1992. The 
dermal-epidermal junction of human skin contains a novel laminin variant. 1 Cell Bioi. 
119:695-703. 
227 
Martys, J.L., C.L. Ho, R.K. Liem, and G.G. Gundersen. 1999. Intermediate filaments 
in motion: observations of intermediate filaments in cells using green fluorescent 
protein-vimentin. Mol Bioi Cell. 10:1289-95. 
Mcinroy, L., and A. Maatta. 2007. Down-regulation of vimentin expression inhibits 
carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 
Mcintosh, J.R., E.L. Grishchuk, and R.R. West. 2002. Chromosome-microtubule 
interactions during mitosis. Annu Rev Cell Dev Bioi. 18:193-219. 
McLean, W.H., L. Pulkkinen, F.J. Smith, E.L. Rugg, E.B. Lane, F. Bullrich, R.E. 
Burgeson, S. Amano, D.L. Hudson, K. Owaribe, J.A. McGrath, J.R. McMillan, R.A. 
Eady, I.M. Leigh, A.M. Christiano, and J. Uitto. 1996. Loss of plectin causes 
epidermolysis bullosa with muscular dystrophy: eDNA cloning and genomic 
organization. Genes Dev. 10:1724-35. 
Mejillano, M.R., S. Kojima, D.A. Applewhite, F.B. Gertler, T.M. Svitkina, and G.G. 
Borisy. 2004. Lamellipodial versus filopodia} mode of the actin nanomachinery: 
pivotal role ofthe filament barbed end. Cell. 118:363-73. 
Mese, G., Richard, G. and White, T. 2007. Gap junctions: basic structure and function. 
J Invest Dermatol 127:25162524/ 
Minard, M.E., L.M. Ellis, and G.E. Gallick. 2006. Tiam1 regulates cell adhesion, 
migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 23:301-13. 
Mitchison, T., and M. Kirschner. 1984. Dynamic instability of microtubule growth. 
Nature. 312:237-42. 
Mizutani, K., H. Miki, H. He, H. Maruta, and T. Takenawa. 2002. Essential role of 
neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of 
extracellular matrix in src-transformed fibroblasts. Cancer Res. 62:669-74. 
Morino, M., T. Tsuzuki, Y. Ishikawa, T. Shirakami, M. Yoshimura, Y. Kiyosuke, K. 
Matsunaga, C. Y oshikumi, and N. Saijo. 1997. Specific expression of HSP27 in human 
tumor cell lines in vitro. In Vivo. 11: 179-84. 
Mullins, R.D., Heuser, J.A., and Pollard, T.D. 1998. The interaction of Arp2/3 
complex with actin: nucleation, high affinity pointed end capping, and formation of 
branching networks of filaments. Proc. Nat!. A cad. Sci. USA. 95:6181-6186 
Ngan, C.Y., H. Yamamoto, I. Seshimo, T. Tsujino, M. Man-i, J.I. Ikeda, K. Konishi, I. 
Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, and M. Monden. 2007. Quantitative 
evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 
96:986-92. 
Niessen, C.M., F. Hogervorst, L.H. Jaspars, A.A. de Melker, G.O. Delwel, E.H. 
Hulsman, I. Kuikman, and A. Sonnenberg. 1994. The alpha 6 beta 4 integrin is a 
receptor for both laminin and kalinin. Exp Cell Res. 211:360-7. 
228 
Niessen, C.M., E.H. Hulsman, L.C. Oomen, I. Kuikman, and A. Sonnenberg. 1997. A 
minimal region on the integrin beta4 subunit that is critical to its localization in 
hemidesmosomes regulates the distribution of HD lip lectin in COS-7 cells. J Cell Sci. 
110 ( Pt 15): 1705-16. 
Nikolic, B., E. Mac Nulty, B. Mir, and G. Wiehe. 1996. Basic amino acid residue 
cluster within nuclear targeting sequence motif is essential for cytoplasmic plectin-
vimentin network junctions. J Cell Biol. 134:1455-67. 
Nishizawa, M., I. Izawa, A. Inoko, Y. Hayashi, K. Nagata, T. Yokoyama, J. Usukura, 
and M. Inagaki. 2005. Identification of trichoplein, a novel keratin filament-binding 
protein. J Cell Sci. 118:1081-90. 
Nishizawa, Y., J. Uematsu, and K. Owaribe. 1993. HD4, a 180 kDa bullous 
pemphigoid antigen, is a major transmembrane glycoprotein of the hemidesmosome. J 
Biochem (Tokyo). 113:493-501. 
Norgett, E.E., S.J. Hatsell, L. Carvajal-Huerta, J.C. Cabezas, J. Common, P.E. Purkis, 
N. Whittock, I.M. Leigh, H.P. Stevens, and D.P. Kelsell. 2000. Recessive mutation in 
desmoplakin disrupts desmoplakin-intermediate filament interactions and causes 
dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet. 9:2761-6. 
Ochoa, G.C., V.I. Slepnev, L. Neff, N. Ringstad, K. Takei, L. Daniell, W. Kim, H. 
Cao, M. McNiven, R. Baron, and P. De Camilli. 2000. A functional link between 
dynamin and the actin cytoskeleton at podosomes. J Cell Biol. 150:3 77-89. 
O'Keefe, E.J ., H.P. Erickson, and V. Bennett. 1989. Desmoplakin I and desmoplakin 
II. Purification and characterization. J Bioi Chern. 264:8310-8. 
Okuda, T., S. Matsuda, S. Nakatsugawa, Y. lchigotani, N. Iwahashi, M. Takahashi, T. 
Ishigaki, and M. Hamaguchi. 1999. Molecular cloning of macrophin, a human 
homologue of Drosophila kakapo with a close structural similarity to plectin and 
dystrophin. Biochem Biophys Res Commun. 264:568-74. 
Okumura M, Uematsu J, Hirako Y, Nishizawa Y, Shimizu H, Kido N, Owaribe K. 
1999. Identification of the hemidesmosomal 500 kDa protein (HD 1) as plectin. J 
Biochem (Tokyo). Dec;126(6):1144-50. 
Orian-Rousseau, V., D. Aberdam, L. Fontao, L. Chevalier, G. Meneguzzi, M. 
Kedinger, and P. Simon-Assmann. 1996. Developmental expression of laminin-5 and 
HD 1 in the intestine: epithelial to mesenchymal shift for the laminin gamma-2 chain 
subunit deposition. Dev Dyn. 206:12-23. 
Oshima, R.G. 2007. Intermediate filaments: a historical perspective. Exp Cell Res. 
313:1981-94. 
Osiak, A.E., G. Zenner, and S. Linder. 2005. Subconfluent endothelial cells form 
podosomes downstream of cytokine and RhoGTPase signaling. Exp Cell Res. 
307:342-53. 
229 
Osmanagic-Myers, S., M. Gregor, G. Walko, G. Burgstaller, S. Reipert, and G. Wiehe. 
2006. Plectin-controlled keratin cytoarchitecture affects MAP kinases involved in 
cellular stress response and migration. J Cell Biol. 174:557-68. 
Osmanagic-Myers, S., and G. Wiehe. 2004. Plectin-RACKl (receptor for activated C 
kinase 1) scaffolding: a novel mechanism to regulate protein kinase C activity. J Biol 
Chern. 279:18701-10. 
O'Toole, E.A. 2001. Extracellular matrix and keratinocyte migration. Clinical and 
experimental dermatology. 26:525-530. 
O'Toole, E.A., Marinkovich, M.P., Warren, K., Hoeftler, K., Furthmayr, H., Woodley, 
D.T. 1997. Laminin-5 inhibits human keratinocyte migration. Exp. Cell Res. 233:330-
339. 
Owaribe K., Y. Nishizawa, and W. W. Franke. 1991. Isolation and characterization of 
hemidesmosomes from bovine corneal epithelial cells. Exp. Cell Res. 192:622-630. 
Pankov, R., E. Cukierman, B.Z. Katz, K. Matsumoto, D.C. Lin, S. Lin, C. Hahn, and 
K.M. Yamada. 2000. Integrin dynamics and matrix assembly: tensin-dependent 
translocation of alpha(5)beta(l) integrins promotes early fibronectin fibrillogenesis. J 
Cell Biol. 148:1075-90. 
Perez-Moreno, M., C. Jamora, and E. Fuchs. 2003. Sticky business: orchestrating 
cellular signals at adherensjunctions. Cell. 112:535-48. 
Pfendner, E., F. Rouan, and J. Uitto. 2005. Progress in epidermolysis bullosa: the 
phenotypic spectrum ofplectin mutations. Exp Dermatol. 14:241-9. 
Prout, M., Z. Damania, J. Soong, D. Fristrom, and J.W. Fristrom. 1997. Autosomal 
mutations affecting adhesion between wing surfaces in Drosophila melanogaster. 
Genetics. 146:275-85. 
Pytela, R., and G. Wiehe. 1980. High molecular weight polypeptides (270,000-
340,000) from cultured cells are related to hog brain microtubule-associated proteins 
but copurify with intermediate filaments. Proc Natl Acad Sci U SA. 77:4808-12. 
Rabinovitz, 1., A. Toker, and A.M. Mercurio. 1999. Protein kinase C-dependent 
mobilization of the alpha6beta4 integrin from hemidesmosomes and its association 
with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J 
Cell Biol. 146:1147-60. 
Rash, J.E., J.W. Shay, and J.J. Biesele. 1970. Preliminary biochemical investigations 
ofthe intermediate filaments. J Ultrastruct Res. 33:399-407. 
Raymond, K., M. Kreft, J.Y. Song, H. Janssen, and A. Sonnenberg. 2007. Dual Role of 
{alpha}6{beta}4 Integrin in Epidermal Tumor Growth: Tumor-suppressive Versus 
Tumor-promoting Function. Mol Bioi Cell. 
230 
Reimann, J., W.S. Kunz, S. Vielhaber, K. Kappes-Horn, and R. Schroder. 2003. 
Mitochondrial dysfunction in myofibrillar myopathy. Neuropathol Appl Neurobiol. 
29:45-51. 
Reipert, S., F. Steinbock, I. Fischer, R.E. Bittner, A. Zeold, and G. Wiehe. 1999. 
Association of mitochondria with plectin and desmin intermediate filaments in striated 
muscle. Exp Cell Res. 252:479-91. 
Rezniczek, G.A., C. Abrahamsberg, P. Fuchs, D. Spazierer, and G. Wiehe. 2003. 
Plectin 5'-transcript diversity: short alternative sequences determine stability of gene 
products, initiation of translation and subcellular localization of isoforms. Hum Mol 
Genet. 12:3181-94. 
Rezniczek, G.A., J.M. de Pereda, S. Reipert, and G. Wiehe. 1998. Linking integrin 
alpha6beta4-based cell adhesion to the intermediate filament cytoskeleton: direct 
interaction between the beta4 subunit and plectin at multiple molecular sites. J Cell 
Bioi. 141 :209-25. 
Rezniczek, G.A., L. Janda, and G. Wiehe. 2004. Plectin. Methods Cell Bioi. 78:721-
55. 
Roper, K., and N.H. Brown. 2003. Maintaining epithelial integrity: a function for 
gigantic spectraplakin isoforms in adherens junctions. J Cell Biol. 162:1305-15. 
Roth, A.L., and D.K. Berg. 2003. Large clusters of alpha7-containing nicotinic 
acetylcholine receptors on chick spinal cord neurons. J Comp Neural. 465:195-204. 
Rouan, F., L. Pulkkinen, G. Meneguzzi, S. Laforgia, P. Hyde, D.U. Kim, G. Richard, 
and J. Uitto. 2000. Epidermolysis bullosa: novel and de novo premature termination 
codon and deletion mutations in the plectin gene predict late-onset muscular 
dystrophy. J Invest Dermatol. 114:381-7. 
Ruhrberg, C., Hajibagheri, M.A., Simon, M., Dooley, T.P., Watt, F.M. 1996. 
Envoplakin a novel precursor of the cornified envelope that has homologu to 
desmoplakin. J Cell Bioi 134(3):715-29. 
Ruhrberg, C., Hajibagheri, M.A., Parry, D.A., Watt, F.M., Periplakin a novel 
component of cornified envelopes and desmosomes that belongs to the plakin family 
and forms complexes with envoplakin J Cell Biol 29: 139(7) 1835-49. 
Ruhrberg, C., and F.M. Watt. 1997. The plakin family: versatile orgamzers of 
cytoskeletal architecture. Curr Opin Genet Dev. 7:392-7. 
Sabeh, F., I. Ota, K. Holmbeck, H. Birkedal-Hansen, P. Soloway, M. Balbin, C. 
Lopez-Otin, S. Shapiro;M. Inada, S. Krane, E. Allen, D. Chung, and S.J. Weiss. 2004. 
Tumor cell traffic through the extracellular matrix is controlled by the membrane-
anchored collagenase MT1-MMP. J Cell Bioi. 167:769-81. 
231 
Sahai, E. and Marshall C.J. 2003. Differing modes of tumour cell invasion have 
distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell 
Biol. Aug 5(8):690-2. 
Sahai, E. 2005. Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 15:87-96. 
Sanchez-Aparicio, P., A.M. Martinez de Velasco, C.M. Niessen, L. Borradori, I. 
Kuikman, E.H. Hulsman, R. Fassler, K. Owaribe, and A. Sonnenberg. 1997. The 
subcellular distribution of the high molecular mass protein, HD 1, is determined by the 
cytoplasmic domain of the integrin beta 4 subunit. J Cell Sci. 110 ( Pt 2): 169-78. 
Sawin, K.E., and S.A. Endow. 1993. Meiosis, mitosis and microtubule motors. 
Bioessays. 15:399-407. 
Schaapveld, R.Q., L. Borradori, D. Geerts, M.R. van Leusden, I. Kuikman, M.G. 
Nievers, C.M. Niessen, R.D. Steenbergen, P.J. Snijders, and A. Sonnenberg. 1998. 
Hemidesmosome formation is initiated by the beta4 integrin subunit, requires complex 
formation of beta4 and HD 1 /plectin, and involves a direct interaction between beta4 
and the bullous pemphigoid antigen 180. J Cell Biol. 142:271-84. 
Schaapveld, R. Q., Herrmann, H., Schultess, J., Markl, J., 2001. Vimentin and desmin 
of a cartilaginous fish, the shark Scyliorhinus stellaris: sequence, expression patterns 
and in vitro assembly. Eur. J. Cell Biol. 80:692-702 
Schmelz, M., R. Moll, C. Kuhn, and W.W. Franke. 1994. Complexus adhaerentes, a 
new group of desmoplakin-containing junctions in endothelial cells: II. Different types 
of lymphatic vessels. Differentiation. 57:97-117. 
Schmidt, A., and M.N. Hall. 1998. Signaling to the actin cytoskeleton. Annu Rev Cell 
Dev Biol. 14:305-38. 
Schmidt, A., and S. Jager. 2005. Plakophilins--hard work in the desmosome, recreation 
in the nucleus? Eur J Cell Biol. 84:189-204. 
Schroder, R., B. Goudeau, M.C. Simon, D. Fischer, T. Eggermann, C.S. Clemen, Z. Li, 
J. Reimann, Z. Xue, S. Rudnik-Schonebom, K. Zerres, P.F. van der Yen, D.O. Furst, 
W.S. Kunz, and P. Vicart. 2003. On noxious desmin: functional effects of a novel 
heterozygous desmin insertion mutation on the extrasarcomeric desmin cytoskeleton 
and mitochondria. Hum Mol Genet. 12:657-69. 
Schroder, R., W.S. Kunz, F. Rouan, E. Pfendner, K. Tolksdorf, K. Kappes-Hom, M. 
Altenschmidt-Mehring, R. Knoblich, P.F. van der Yen, J. Reimann, D.O. Furst, I. 
Blumcke, S. Vielhaber, D. Zillikens, S. Eming, T. Klockgether, J. Uitto, G. Wiehe, and 
A. Rolfs. 2002. Disorganization of the desmin cytoskeleton and mitochondrial 
dysfunction in plectin-related epidermolysis bullosa simplex with muscular dystrophy. 
J Neuropathol Exp Neurol. 61:520-30. 
232 
Schroder, R., I. Warlo, H. Hernnann, P.F. van der Ven, C. Klasen, I. Blumcke, R.R. 
Mundegar, D.O. Furst, H.H. Goebel, and T.M. Magin. 1999. Immunogold EM reveals 
a close association of plectin and the desmin cytoskeleton in human skeletal muscle. 
Eur J Cell Biol. 78:288-95. 
Schweizer, J., P.E. Bowden, P.A. Coulombe, L. Langbein, E.B. Lane, T.M. Magin, L. 
Maltais, M.B. Omary, D.A. Parry, M.A. Rogers, and M.W. Wright. 2006. New 
consensus nomenclature for mammalian keratins. J Cell Biol. 174:169-74. 
Schwende, H., E. Fitzke, P. Ambs, and P. Dieter. 1996. Differences in the state of 
differentiation ofTHP-1 cells induced by phorbol ester and 1 ,25-dihydroxyvitamin D3. 
J Leukoc Biol. 59:555-61. 
Seals, D.F., E.F. Azucena, Jr., I. Pass, L. Tesfay, R. Gordon, M. Woodrow, J.H. Resau, 
and S.A. Courtneidge. 2005. The adaptor protein Tks5/Fish is required for podosome 
formation and function, and for the protease-driven invasion of cancer cells. Cancer 
Cell. 7:155-65. 
Seifert, G.J., D. Lawson, and G. Wiehe. 1992. Immunolocalization of the intermediate 
filament-associated protein plectin at focal contacts and actin stress fibers. Eur J Cell 
Biol. 59:138-47. 
Sevcik, J., L. Urbanikova, J. Kost'an, L. Janda, and G. Wiehe. 2004. Actin-binding 
domain of mouse plectin. Crystal structure and binding to vimentin. Eur J Biochem. 
271:1873-84. 
Simon, M., and H. Green. 1984. Participation of membrane-associated proteins in the 
formation of the cross-linked envelope ofthe keratinocyte. Cell. 36:827-34. 
Simon-Assmann, P., B. Duclos, V. Orian-Rousseau, C. Arnold, C. Mathelin, E. 
Engvall, and M. Kedinger. 1994. Differential expression of laminin isoforms and alpha 
6-beta 4 integrin subunits in the developing human and mouse intestine. Dev Dyn. 
201:71-85. 
Simon-Assmann, P., C. Leberquier, N. Molto, T. Uezato, F. Bouziges, and M. 
Kedinger. 1994. Adhesive properties and integrin expression profiles of two colonic 
cancer populations differing by their spreading on laminin. J Cell Sci. 107 ( Pt 3):577-
87. 
Singh, S., S. Sadacharan, S. Su, A. Belldegrun, S. Persad, and G. Singh. 2003. 
Overexpression of vimentin: role in the invasive phenotype in an androgen-
independent model of prostate cancer. Cancer Res. 63:2306-11. 
Sjoblom, T., S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber, D. Mandelker, 
R.J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S.D. 
Markowitz, 1. Willis, D. Dawson, J.K. Willson, A.F. Gazdar, J. Hartigan, L. Wu, C. 
Liu, G. Parmigiani, B.H. Park, K.E. Bachman, N. Papadopoulos, B. Vogelstein, K.W. 
Kinzler, and V.E. Velculescu. 2006. The consensus coding sequences of human breast 
and colorectal cancers. Science. 314:268-74. 
233 
Skerrow, C.J., and A.G. Matoltsy. 1974. Isolation of epidermal desmosomes. J Cell 
Bioi. 63:515-23. 
Skerrow, C.J., and A.G. Matoltsy. 1974. Chemical characterization of isolated 
epidermal desmosomes. J Cell Bioi. 63:524-30. 
Small, J.V. 1995. Getting the actin filaments straight: nucleation-release or 
treadmilling? Trends Cell Bioi. 5:52-5. 
Small, J.V., M. Herzog, and K. Anderson. 1995. Actin filament organization in the fish 
keratocyte lamellipodium. J Cell Bioi. 129:1275-86. 
Smith, F.J., Eady, R.A., Leigh, I.M., McMillian, J.R., Rugg, E.L., Kelsell, D.P., 
Bryant, S.P., Spurr, N.K., Geddes, J.F., Kirtschig, G., Milana, G., deBono, A.G., 
Wiehe, G., Pulkkinen, L., Uitto, J., McLean. W.H., Lane., E.B., 1996. Plectin 
definciency results in muscular dystrophy with epidermolosis bullosa. Nat Genet. 
13:450-457 
Sonnenberg, A., J. Calafat, H. Janssen, H. Daams, L.M. van der Raaij-Helmer, R. 
Falcioni, S.J. Kennel, J.D. Aplin, J. Baker, M. Loizidou, and et al. 1991. Integrin alpha 
6/beta 4 complex is located in hemidesmosomes, suggesting a major role in epidermal 
cell-basement membrane adhesion. J Cell Bioi. 113:907-17. 
Sonnenberg, A., and R.K. Liem. 2007. Plakins in development and disease. Exp Cell 
Res. 313:2189-203. 
Sonnenberg, A., A.M. Rojas, and J.M. de Pereda. 2007. The structure of a tandem pair 
of spectrin repeats of plectin reveals a modular organization of the plakin domain. J 
Mol Bioi. 368:1379-91. 
Spazierer, D., P. Fuchs, V. Proll, L. Janda, S. Oehler, I. Fischer, R. Hauptmann, and G. 
Wiehe. 2003. Epiplakin gene analysis in mouse reveals a single exon encoding a 725-
kDa protein with expression restricted to epithelial tissues. J Bioi Chern. 278:31657-
66. 
Spazierer, D., P. Fuchs, S. Reipert, I. Fischer, M. Schmuth, H. Lassmann, and G. 
Wiehe. 2006. Epiplakin is dispensable for skin barrier function and for integrity of 
keratin network cytoarchitecture in simple and stratified epithelia. Mol Cell Bioi. 
26:559-68. 
Spinardi, L., Y.L. Ren, R. Sanders, and F.G. Giancotti. 1993. The beta 4 subunit 
cytoplasmic domain mediates the interaction of alpha 6 beta 4 integrin with the 
cytoskeleton ofhemidesmosomes. Mol Bioi Cell. 4:871-84. 
Spinardi, L., J. Rietdorf, L. Nitsch, M. Bono, C. Tacchetti, M. Way, and P.C. 
Marchisio. 2004. A dynamic podosome-like structure of epithelial cells. Exp Cell Res. 
295:360-74. 
234 
Stanley, J.R., P. Hawley-Nelson, S.H. Yuspa, E.M. Shevach, and S.l. Katz. 1981. 
Characterization of bullous pemphigoid antigen: a unique basement membrane protein 
of stratified squamous epithelia. Cell. 24:897-903. 
Stanley, J.R., T. Tanaka, S. Mueller, V. Klaus-Kovtun, and D. Roop. 1988. Isolation of 
complementary DNA for bullous pemphigoid antigen by use of patients' 
autoantibodies. J Clin Invest. 82:1864-70. 
Stappenbeck, T.S., J.A. Lamb, C.M. Corcoran, and K.J. Green. 1994. Phosphorylation 
of the desmoplakin COOH terminus negatively regulates its interaction with keratin 
intermediate filament networks. J Bioi Chern. 269:29351-4. 
Stegh, A.H., H. Herrmann, S. Lampe!, D. Weisenberger, K. Andra, M. Seper, G. 
Wiehe, P.H. Krammer, and M.E. Peter. 2000. Identification of the cytolinker plectin as 
a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor 
receptor-mediated apoptosis. Mol Cell Bioi. 20:5665-79. 
Steinboeck, F., and D. Kristufek. 2005. Identification of the cytolinker protein plectin 
in neuronal cells - expression of a rodless isoform in neurons of the rat supenor 
cervical ganglion. Cell Mol N eurobiol. 25: 1151-69. 
Sterk, L.M., C.A. Geuijen, L.C. Oomen, J. Calafat, H. Janssen, and A. Sonnenberg. 
2000. The tetraspan molecule CD 151, a novel constituent of hemidesmosomes, 
associates with the integrin alpha6beta4 and may regulate the spatial organization of 
hemidesmosomes. J Cell Bioi. 149:969-82. 
Stossel, T.P. 1993. On the crawling of animal cells. Science. 260:1086-94. 
Strada!, T., W. Kranewitter, S.J. Winder, and M. Gimona. 1998. CH domains revisited. 
FEBS Lett. 431:134-7. 
Strelkov, S.V., H. Herrmann, and U. Aebi. 2003. Molecular architecture of 
intermediate filaments. Bioessays. 25:243-51. 
Sun, D., C.L. Leung, and R.K. Liem. 2001. Characterization of the microtubule 
binding domain of microtubule actin crosslinking factor (MACF): identification of a 
novel group of microtubule associated proteins. J Cell Sci. 114:161-172. 
Sun, Y., J. Zhang, S.K. Kraeft, D. Auclair, M.S. Chang, Y. Liu, R. Sutherland, R. 
Salgia, J.D. Griffin, L.H. Ferland, and L.B. Chen. 1999. Molecular cloning and 
characterization of human trabeculin-alpha, a giant protein defining a new family of 
actin-binding proteins. J Bioi Chern. 274:33522-30. 
Suzuki, S., Z.S. Huang, and H. Tanihara. 1990. Cloning of an integrin beta subunit 
exhibiting high homology with integrin beta 3 subunit. Proc Natl Acad Sci U S A. 
87:5354-8. 
Suzuki, S., and Y. Naitoh. 1990. Amino acid sequence of a novel integrin beta 4 
subunit and primary expression ofthe mRNA in epithelial cells. Embo J. 9:757-63. 
235 
Svitkina, T.M., and G.G. Borisy. 1999. Arp2/3 complex and actin depolymerizing 
factor/cofilin in dendritic organization and treadmilling of actin filament array in 
lamellipodia. J Cell Biol. 145:1009-26. 
Svitkina, T.M., A.B. Verkhovsky, and G.G. Borisy. 1996. Plectin sidearms mediate 
interaction of intermediate filaments with microtubules and other components of the 
cytoskeleton. J Cell Biol. 135:991-1007. 
Szent-Gyorgyi, A.G. 2004. The early history of the biochemistry of muscle 
contraction. J Gen Physiol. 123:631-41. 
Takeichi, M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. 
Science. 251:1451-5. 
Tatin, F., C. Varon, E. Genot, and V. Moreau. 2006. A signalling cascade involving 
PKC, Src and Cdc42 regulates podosome assembly in cultured endothelial cells in 
response to phorbol ester. J Cell Sci. 119:769-81. 
Tennenbaum, T., A.K. Weiner, A.J. Belanger, A.B. Glick, H. Hennings, and S.H. 
Yuspa. 1993. The suprabasal expression of alpha 6 beta 4 integrin is associated with a 
high risk for malignant progression in mouse skin carcinogenesis. Cancer Res. 
53:4803-10. 
Tian, R., M. Gregor, G. Wiehe, and J.E. Goldman. 2006. Plectin regulates the 
organization of glial fibrillary acidic protein in Alexander disease. Am J Pathol. 
168:888-97. 
Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins 
from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 
Proc Natl Acad Sci U S A. 76:4350-4. 
Tsuboi, S. 2007. Requirement for a complex of Wiskott-Aldrich syndrome protein 
(WASP) with WASP interacting protein in podosome formation in macrophages. J 
Immunol. 178:2987-95. 
Tsuruta, D., and J.C. Jones. 2003. The vimentin cytoskeleton regulates focal contact 
size and adhesion of endothelial cells subjected to shear stress. J Cell Sci. 116:4977-
84. 
Tucker, J. 1992. The microtubule-organizing center. Bioessays. 14:861-7. 
Uematsu, J., Y. Nishizawa, A. Sonnenberg, and K. Owaribe. 1994. Demonstration of 
type II hemidesmosomes in a mammary gland epithelial cell line, BMGE-H. J 
Biochem (Tokyo). 115:469-76. 
Uitto, J ., and L. Pulkkinen. 1996. Molecular complexity of the cutaneous basement 
membrane zone. Mol Biol Rep. 23:35-46. 
Uitto, J., G. Richard, and J.A. McGrath. 2007. Diseases of epidermal keratins and their 
linker proteins. Exp Cell Res. 313:1995-2009. 
236 
Valster, A., N.L. Tran, M. Nakada, M.E. Berens, A.Y. Chan, and M. Symons. 2005. 
Cell migration and invasion assays. Methods. 3 7:208-15. 
van den Heuvel, A.P., A.M. de Vries-Smits, P.C. van Weeren, P.F. Dijkers, K.M. de 
Bruyn, J.A. Riedl, and B.M. Burgering. 2002. Binding of protein kinase B to the plakin 
family member periplakin. J Cell Sci. 115:3957-66. 
Van Waes, C. 1995. Cell adhesion and regulatory molecules involved m tumor 
formation, hemostasis, and wound healing. Head Neck. 17: 140-7. 
Van Waes, C., D.M. Surh, Z. Chen, M. Kirby, J.S. Rhim, R. Brager, R.B. Sessions, J. 
Poore, G.T. Wolf, and T.E. Carey. 1995. Increase in suprabasilar integrin adhesion 
molecule expression in human epidermal neoplasms accompanies increased 
proliferation occurring with immortalization and tumor progression. Cancer Res. 
55:5434-44. 
Vasiliev, J.M. 2004. Cytoskeletal mechanisms responsible for invasive migration of 
neoplastic cells. Int J Dev Bioi. 48:425-39. 
Vasiliev, J.M., T. Omelchenko, I.M. Gelfand, H.H. Feder, and E.M. Bonder. 2004. 
Rho overexpression leads to mitosis-associated detachment of cells from epithelial 
sheets: a link to the mechanism of cancer dissemination. Proc Natl Acad Sci U S A. 
Vasioukhin, V., C. Bauer, L. Degenstein, B. Wise, and E. Fuchs. 2001. 
Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-
catenin in skin. Cell. 104:605-17. 
Vikstrom, K.L., G.G. Borisy, and R.D. Goldman. 1989. Dynamic aspects of 
intermediate filament networks in BHK-21 cells. Proc Natl Acad Sci U S A. 86:549-
53. 
Vita, G., M.C. Monici, K. Owaribe, and C. Messina. 2003. Expression of plectin in 
muscle fibers with cytoarchitectural abnormalities. Neuromuscul Disord. 13:485-92. 
Vijayaraj, and R.E. Leube. 2007. Structural and regulatory functions of keratins. Exp 
Cell Res. 313:2021-32. 
101:12526-30. 
Walsh, E.P., and N.H. Brown. 1998. A screen to identify Drosophila genes required 
for integrin-mediated adhesion. Genetics. 150:791-805. 
Waterman-Starer, C.M., and E.D. Salmon. 1997. Actomyosin-based retrograde flow of 
microtubules in the lamella of migrating epithelial cells influences microtubule 
dynamic instability and turnover and is associated with microtubule breakage and 
treadmilling. J Cell Bioi. 139:417-34. 
Watennan-Storer, C.M., and E.D. Salmon. 1997. Microtubule dynamics: treadmilling 
comes around again. Curr Bioi. 7:R369-72. 
237 
Webb, B.A., R. Eves, and A.S. Mak. 2006. Cortactin regulates podosome formation: 
roles of the protein interaction domains. Exp Cell Res. 312:760-9. 
Webb, D.J., J.T. Parsons, and A.F. Horwitz. 2002. Adhesion assembly, disassembly 
and turnover in migrating cells -- over and over and over again. Nat Cell Bioi. 4:E97-
100. 
Weed, S.A., Karginov, A.V., Schafer, D.A., Weaver, A.M., Kinley, A.W., Cooper, 
J.A. and Parsons, J.T. 2000. Cortactin localization to sites of actin assembly in 
lamellipodia requires interactions with F-actin and the Arp2/3 complex. J Cell Bioi. 
2;151(1):29-40. 
Weiss, P., and W. Ferris. 1954. Electronmicrograms of larval amphibian epidermis. 
Exp Cell Res. 6:546-9. 
Weiss, P., and W. Ferris. 1954. Electron-Microscopic Study of the Texture of the 
Basement Membrane of Larval Amphibian Skin. Proc Natl Acad Sci U S A. 40:528-
40. 
Wiehe, G. 1998. Role of plectin in cytoskeleton organization and dynamics. J Cell Sci. 
111 ( Pt 17):2477-86. 
Wiehe, G., and M.A. Baker. 1982. Cytoplasmic network arrays demonstrated by 
immunolocalization using antibodies to a high molecular weight protein present in 
cytoskeletal preparations from cultured cells. Exp Cell Res. 138:15-29. 
Wiehe, G., D. Gromov, A. Donovan, M.J. Castanon, and E. Fuchs. 1993. Expression 
of plectin mutant eDNA in cultured cells indicates a role of COOH-terminal domain in 
intermediate filament association. J Cell Bioi. 121 :607-19. 
Wiehe, G., R. Krepler, U. Artlieb, R. Pytela, and W. Aberer. 1984. Identification of 
plectin in different human cell types and immunolocalization at epithelial basal cell 
surface membranes. Exp Cell Res. 155:43-9. 
Wiehe, G., R. Krepler, U. Artlieb, R. Pytela, and H. Denk. 1983. Occurrence and 
immunolocalization ofplectin in tissues. J Cell Bioi. 97:887-901. 
Wicki, A., and G. Christofori. 2007. The potential role of podoplanin m tumour 
invasion. Br J Cancer. 96:1-5. 
Wicki, A., F. Lehembre, N. Wick, B. Hantusch, D. Kerjaschki, and G. Christofori. 
2006. Tumor invasion in the absence of epithelial-mesenchymal transition: 
podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 9:261-72. 
Wijnhoven, B.P., W.N. Dinjens, and M. Pignatelli. 2000. E-cadherin-catenin cell-cell 
adhesion complex and human cancer. Br J Surg. 87:992-1005. 
238 
Wilhelmsen, K., S.H. Litjens, I. Kuikman, N. Tshimbalanga, H. Janssen, I. van den 
Bout, K. Raymond, and A. Sonnenberg. 2005. Nesprin-3, a novel outer nuclear 
membrane protein, associates with the cytoskeletal linker protein plectin. J Cell Bioi. 
171:799-810. 
Williams, J.F. 1989. Optimization strategies for the polymerase chain reaction. 
Biotechniques. 7:762-9. 
Winder, S.J., L. Hemmings, S.J. Bolton, S.K. Maciver, J.M. Tinsley, K.E. Davies, 
D.R. Critchley, and J. Kendrick-Jones. 1995. Calmodulin regulation of utrophin actin 
binding. Biochem Soc Trans. 23:397S. 
S.J. Winder, T.J. Gibson and J. Kendrick-Jones. 1995. Dystrophin and utrophin: the 
missing links!. FEBS Lett. 369;27-33 
Winsor, B., and E. Schiebel. 1997. Review: an overview of the Saccharomyces 
cerevisiae microtubule and microfilament cytoskeleton. Yeast. 13:399-434. 
Wolf, K., I. Mazo, H. Leung, K. Engelke, U.H. von Andrian, E.I. Deryugina, A.Y. 
Strongin, E.B. Brocker, and P. Friedl. 2003. Compensation mechanism in tumor cell 
migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. 
J Cell Bioi. 160:267-77. 
Wong, M.K., and A.I. Gotlieb. 1988. The reorganization of microfilaments, 
centrosomes, and microtubules during in vitro small wound reendothelialization. J Cell 
Bioi. 107:1777-83. 
Wozniak, M.A., K. Modzelewska, L. Kwong, and P.J. Keely. 2004. Focal adhesion 
regulation of cell behavior. Biochim Biophys Acta. 1692:103-19. 
Wright, M.D., S.M. Geary, S. Fitter, G.W. Moseley, L.M. Lau, K.C. Sheng, V. 
Apostolopoulos, E.G. Stanley, D.E. Jackson, and L.K. Ashman. 2004. Characterization 
of mice lacking the tetraspanin superfamily member CD 151. Mol Cell Bioi. 24:5978-
88. 
Xie, Z., W. Su, Z. Guo, H. Pang, S.R. Post, and M.C. Gong. 2006. Up-regulation of 
CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular 
smooth muscle cells. Cardiovasc Res. 69:491-501. 
Yamada, K.M., and S. Miyamoto. 1995. Integrin transmembrane signaling and 
cytoskeletal control. Curr Opin Cell Bioi. 7:681-9. 
Yamaguchi, H., M. Lorenz, S. Kempiak, C. Sarmiento, S. Coniglio, M. Symons, J. 
Segall, R. Eddy, H. Miki, T. Takenawa, and J. Condeelis. 2005. Molecular 
mechanisms of invadopodium formation: the role of the N-W ASP-Arp2/3 complex 
pathway and cofilin. J Cell Bioi. 168:441-52. 
Yang, Y., C. Bauer, G. Strasser, R. Wollman, J.P. Julien, and E. Fuchs. 1999. 
Integrators of the cytoskeleton that stabilize microtubules. Cell. 98:229-38. 
239 
Yarrow, 1.C., Z.E. Perlman, N.J. Westwood, and T.J. Mitchison. 2004. A high-
throughput cell migration assay using scratch wound healing, a comparison of image-
based readout methods. BMC Biotechnol. 4:21. 
Yoon, M., R.D. Moir, V. Prahlad, and R.D. Goldman. 1998. Motile properties of 
vimentin intermediate filament networks in living cells. 1 Cell Biol. 143:147-57. 
Young, K.G., M. Pool, and R. Kothary. 2003. Bpag1 localization to actin filaments and 
to the nucleus is regulated by its N-terminus. 1 Cell Sci. 116:4543-55. 
Zamir, E., and B. Geiger. 2001. Molecular complexity and dynamics of cell-matrix 
adhesions. 1 Cell Sci. 114:3583-90. 
Zemig, G., and G. Wiehe. 1985. Morphological integrity of single adult cardiac 
myocytes isolated by collagenase treatment: immunolocalization of tubulin, 
microtubule-associated proteins 1 and 2, plectin, vimentin, and vinculin. Eur 1 Cell 
Biol. 38:113-22. 
Zhang, T., P. Haws, and Q. Wu. 2004. Multiple variable first exons: a mechanism for 
cell- and tissue-specific gene regulation. Genome Res. 14:79-89. 
Zhou, X., A. Stuart, L.E. Dettin, G. Rodriguez, B. Hoel, and G.I. Gallicano. 2004. 
Desmoplakin is required for microvascular tube formation in culture. 1 Cell Sci. 
117:3129-40. 
Ziegler, W.H., R.C. Liddington, and D.R. Critchley. 2006. The structure and regulation 
of vinculin. Trends Cell Biol. 16:453-60. 
240 0"" ' ' "-" ' . 2 ' 
' 
